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Summary
The metabolism of paracetamol has been studied in man following a 
therapeutic dose, in neonates who received the drug via breast milk, 
in patients with rheumatoid a rth ritis  and hyperthyroidism, in the 
presence of salicylamide and after overdose. The finding of 
acid-labile prearomatic species in urine has led to the suggestion 
that these metabolites might arise from an epoxide.
The metabolism of aspirin in man was investigated in normal 
volunteers a fter a therapeutic dose, in patients with rheumatoid 
a rth ritis  and after overdose.
An age effect was noted in the metabolism of paracetamol and aspirin 
in normal volunteers. The urinary metabolic profile of both 
paracetamol and aspirin in rheumotoid patients was different from 
that of normal volunteers. Recoveries of paracetamol and its  
metabolites in neonatal urine was different from normal volunteers. 
Predosing with salicylamide affected both the AUC and the urinary 
metabolic profile  of paracetamol. Administration of L-methionine 
and/or ^acetyl cysteine to paracetamol poisoned patients appeared 
to replete both sulphate and glutathione stores. Aspirin overdosed 
patients showed a lower recovery of salicyluric acid in urine than 
normals.
The metabolism of paracetamol in mice and guinea pigs has been 
investigated in single and repeated doses in the presence of enzyme 
inducing agents and metabolic competing agents. The metabolism of 
paracetamol in the presence of L-methionine in rabbits has also been 
studied. Pretreatment with inducing agents, concurrent treatment 
with competing agents and repeated dosing were found to a lte r the 
metabolism of paracetamol when compared with a single dose of 
paracetamol alone. A large dose of paracetamol administered to 
rabbits showed a different metabolic profile  from a small dose of 
paracetamol and from the large dose given concurrently with 
L-methionine.
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Abstract
1.1. The metabolism of paracetamol has been studied in man
following a therapeutic dose, in neonates who received the 
drug via the breast milk, in patients with rheumatoid 
a rth ritis  and thyroid disease, in normal volunteers in the 
presence of salicylamide and after overdose.
l . i i  After a therapeutic dose of paracetamol administered to
normal volunteers, the percentages of excreted material 
recovered as paracetamol cysteine were found to decrease 
and as paracetamol glucuronide were found to increase with 
increasing age.
l . i i i  After indirect administration of paracetamol in breast
milk, neonates excreted larger proportions of unchanged 
paracetamol and lesser proportions of paracetamol sulphate 
than normal volunteers.
l . i v  Patients with rheumatoid a rth ritis  who took varying amounts
of paracetamol excreted greater amounts of paracetamol 
glucuronide and lower amounts of unchanged paracetamol and 
paracetamol sulphate than did control subjects.
l .v  The seven hyperthyroid patients showed a metabolic profile
similar to subjects in the control study.
l .v i  In volunteers pre-dosed with salicylamide, the percentage
recovery of paracetamol as sulphate in 24 hour urine was 
lower than when paracetamol was given alone. I t  was also 
found that the area under the serum paracetamol 
concentration time curve was greater when salicylamide was 
taken than when paracetamol was taken alone.
l . v i i  After overdose, i t  was found that excretion of the sulphate
and glutathione conjugates of paracetamol was lower than 
after a therapeutic dose. After administration of ^-acetyl 
cysteine and/or L-methionine to these patients, i t  is 
suggested that repletion of both sulphate and glutathione 
stores may occur.
n
1 .v ii i  The finding of pre-aromatic species in urine which were 
converted to 3-hydroxy paracetamol and paracetamol cysteine 
plus mercapturic acid on incubation with acid, has led to 
the suggestion that these metabolites might arise from an 
epoxide. Thus i t  has been proposed that 4-hydroxy-2,3- 
dihydroacetanilide-2-3-oxide is like ly  to be an hepatotoxic 
metabolite of paracetamol in man.
2. The metabolism of paracetamol in mice and guinea pigs has
also been investigated in the presence of enzyme inducing 
agents and metabolic competing agents and in single and 
repeated doses. The metabolism of paracetamol in the 
presence of L-methionine in rabbits has been studied.
2 .i Phenobarbitone, phenylbutazone and rifampicin were found to
increase the recoveries of the cysteine and mercapturic 
acid metabolites in mice and guinea pigs indicating an 
increase in paracetamol oxidation.
2 .Ü  Repeated dosing with paracetamol lOOmg/kg twice daily in
guinea pigs resulted in a significantly lower recovery of 
paracetamol glucuronide and a greater recovery of unchanged 
paracetamol than did a single dose of paracetamol (p<0.05). 
Mice showed a decreased percentage recovery of paracetamol 
glucuronide with time after repeated doses of paracetamol 
lOOmg/kg twice daily accompanied by an increased recovery 
of unchanged paracetamol. Percentage recoveries of the 
glutathione conjugates of paracetamol decreased with time 
up to 168 hours but then increased dramatically. Marked 
differences between single and repeated doses in mice were 
also observed.
2 . i i i  L-ascorbic acid, salicylamide and a-tocopherol given
concurrently with paracetamol lOOmg/kg increased recoveries 
of paracetamol glucuronide and decreased paracetamol 
excreted unchanged in guinea pigs.
m
In mice, a-tocopherol increased the percentage recoveries 
of paracetamol glucuronide and paracetamol cysteine and 
mercapturic acid and decreased the recovery of unchanged 
paracetamol. L-ascorbic acid and salicylamide did not 
a lte r the metabolic profile  of paracetamol in mice.
2 .iv  Paracetamol 400mg/kg administered to rabbits caused a 
decrease in the percentage recoveries of paracetamol 
cysteine and mercapturic acid metabolites in urine compared 
with paracetamol lOOmg/kg. L-methionine 400mg/kg 
administered with paracetamol 400mg/kg resulted in an 
increase in paracetamol cysteine and mercapturic acid 
recoveries but these percentages were s t i l l  not as high as 
those found after paracetamol lOOmg/kg.
3. The metabolism of aspirin in man was investigated in normal
volunteers after a therapeutic dose, in patients with 
rheumatoid a rth ritis  and after overdose.
3 .i After a 600mg dose of aspirin, the percentage dose of
aspirin excreted was found to decrease with increasing age 
and the percentage recoveries of salicylic  acid and the 
sal icy1 glucuronides were also found to vary with age. 
Percentage recovery of salicylic  acid in 0 - 8 hour urine 
was positively correlated with urinary pH.
3 .Ü  In patients with rheumatoid a rth ritis  who took varying
amounts of aspirin the percentage recovery of salicyluric  
acid was greater and the recoveries of unchanged salicylate  
and sal icy1 glucuronides were lower than after a 
therapeutic dose of aspirin in normal volunteers.
3 . i i i  In overdose patients, the major metabolite recovered
in it ia l ly  was salicylic  acid. The rate of excretion of 
each metabolite with time was found to vary markedly 
between individuals and i t  is suggested that maximal 
excretion rates of salicyluric acid and the sal icy1 
glucuronides are not reached at such doses of aspirin as 
was previously thought.
Glossary o f Abbreviations
ASA - acetyl salicylic acid
GA - gentisic acid
HPLC- high performance liquid chromatography
P - paracetamol
PC - paracetamol cysteine
PG - paracetamol glucuronide
PM - paracetamol mercapturic acid
PS - paracetamol sulphate
SA - salicylic  acid
SG - salicyl glucuronides
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1.1.1 Analgesics - their history and use
Almost everyone at some time experiences minor or major pain. The 
most ancient pain-relieving substance, opium, which was originally 
smoked or drunk, relieves most types and degrees of pain but is 
characterized by significant tolerance, physical dependence and 
social abuse. Today, morphine is used mainly for the re lie f of 
severe pain, for example in cancer, postoperative pain or trauma.
The re lie f  of pain by the opioids is selective to the extent that 
other senses (touch, vibration, vision and hearing) are not affected 
but the level at which pain is perceived is raised and euphoria is 
induced so that the sufferer is more inclined to ignore the pain.
The serious limitations of morphine and other narcotic analgesics 
stimulated the search for potent analgesics that would not lead to 
compulsive drug use.
This led to the discovery of the antipyretic, non-narcotic, mild 
analgesics such as aspirin and paracetamol which provide re lie f of 
moderate pain and are not associated with appreciable tolerance or 
physical dependence.
1.1.2. History of aspirin and paracetamol
The Reverend Edward Stone of Chipping Norton f irs t  described the 
efficacy of willow bark in a le tte r  to the President of the Royal 
Society, Lord Macclesfield, dated 25th April 1763. This began:
"My Lord,
Among the many useful discoveries which this age has made, 
there are few which better deserve the attention of the public than 
what I am going to lay before your Lordship. There is a bark of an 
English tree which I have found by experience to be a powerful 
astringent, and very efficacious in curing aguish (rheumatism) and
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intermitting disorders (bouts of fever)'* (taken from Fairley, 1978). 
Following publication of this le tte r , willow bark was frequently 
prescribed for fevers but usually as a substitute for the expensive 
and scarce Peruvian bark (Cinchona). An English pharmacist called 
White reported in 1798 "Since the introduction of this bark into 
practice in the Bath City Infirmary and Dispensary, as a substitute 
for the Cinchona, not less than 20 pounds a year have been saved to 
the Charity" (Fairley, 1978).
Salicylic acid was f ir s t  synthesised chemically by Lowig in 1835 and 
its  use as an anti-inflammatory and analgesic in rheumatic fever was 
reported by MacLagan in 1876. Unfortunately salicylic  acid was 
found to be too great an ir r ita n t  to the mouth, gullet and stomach 
to be of great use except in the most painful cases. In 1853 Yon 
Gerhardt made a small amount of acetyl sa licylic  acid but the 
synthesis was so expensive and time consuming that i t  was not put 
into production. Forty years la te r, Felix Hoffmann became 
interested because his father had a rth ritis  and benefited from 
salicylic  acid but could not tolerate its  effect on his stomach. 
Hoffman studied Gerhard's acétylation process and modified i t  so 
that the synthesis was practicable. Hoffman and a colleague,
Dreser, both of whom worked for Bayer, established that salicylic  
acid was released from acetyl sa licylic  acid. Dreser and Hoffman 
decided to call the drug aspirin, the 'a' stood for acetyl, the 
'sp ir' for the spiraea plant family (otherwise known as meadowsweet 
from which the salicylic  acid was obtained) and the 'in ' for good 
measure (Fairley, 1978). In 1899 aspirin was marketed by Bayer.
Dr. T.B. Begg of the Medical Research Council's Clinical 
Chemotherapy Research Unit wrote that "From 1876 until the present 
time, sodium salicylate and from 1899, acetyl salicylic  acid 
have been the mainstay of the chemotherapy of acute rheumatism" 
(taken from Fairley, 1978).
Some years before aspirin came into general use in medicine, 
derivatives of phenyl and aniline (compounds derived from the 
benzene fraction of coal tar) were found to have an antipyretic 
action and the f ir s t  of these compounds, acetanilide was introduced 
into medicine by accident when a pharmacist mistakenly dispensed 
acetanilide in place of naphthalene. Unfortunately acetanilide was 
found to cause cyanosis. Baron Joseph Von Mering searching for less 
toxic alternatives to acetanilide observed that acetanilide was 
converted in the body to para-aminophenol and (from derivatives of 
para-aminophenol) discovered phenacetin and paracetamol (which is 
actually the form in which phenacetin is excreted from the body). 
Phenacetin which had about the same analgesic potency as aspirin, 
was found however to be capable of causing severe renal necrosis and 
the sale of phenacetin was banned except when on prescription from 
1st September 1974. Von Mering dismissed paracetamol as being too 
toxic and i t  did not really  become popular until 1949 when i t  was 
recognized as the major active metabolite of both acetanilide and 
phanacetin (Brodie and Axelrod, 1949). Five years la te r, the drug 
was marketed in Britain under the trade-name Panadol, produced by 
Bayer Products Ltd whose German parent-company had originally  
patented aspirin (Fairley, 1978). Panadol became very popular in 
Britain at a time when aspirin's ir r ita n t  effect on the 
gastrointestinal tract was being publicized in the newspapers and is 
even now used as an alternative to aspirin. Paracetamol was 
included in the British Pharmacopea from 1963 and became widely used 
for many minor painful and febrile  conditions.













Aspirin and paracetamol as antipyretics and analgesics may be 
considered to be equipotent (Yaffe, 1981; Cooper, 1981) and both are 
often formulated with other drugs such as opiates, vasoconstrictors, 
anti-emetics, CNS stimulants etc. F irs t reports of hepatic necrosis 
from overdose of paracetamol were published in 1966 (Davidson and 
Eastham, 1966; Thomson and Prescott, 1966). Despite their reported 
si de-effects, since 1949 aspirin and paracetamol have been the two 
most commonly used drugs in the re lie f  of mild to moderate pain.
1 .1 .3 . Modes of action and uses of paracetamol and aspirin
The mechanisms of the inflammatory process are complex; contenders 
as mediators of inflammation so far include histamine (but not in 
the inflammation seen in rheumatoid a r th r it is ) , 5-hydroxy 
tryptamine, complement and more recently the prostaglandins. 
Prostaglandins when injected into the skin cause erythema and 
increased vascular permeability leading to oedema and hyperalgesia. 
I t  is thought that prostaglandins may act as modulators capable of 
increasing or decreasing the response to pain. Prostaglandin 
is in addition a strong pyrogen when injected into the in terio r  
hypothalamus or cerebral ventricles and this effect is not blocked 
by antipyretic agents. Prostaglandins are also thought to be 
involved in the adhesion of platelets to blood vessel walls and 
there appear to be two d ifferent mechanisms for the metabolism of 
arichidonic acid (a precursor of the prostaglandins) in platelets  
and in the vessel w all. In platelets i t  is assumed that thromboxane 
Ag is formed which enhances aggregation and has a vasoconstrictor/ 
effect. In contrast, in vessel walls the same intermediate product 
gives rise to prostacyclin which has an anti-aggregant and 
vasodilator effect.
Aspirin and paracetamol have analgesic and antipyretic effects and 
both are effective in relieving pain of moderate intensity including 
headache, myalgia, arthralgia and dysmenorrhea. Severe pain and 
that originating in the viscera are not alleviated by these drugs.
The analgesia caused by aspirin is considered to be due to both a 
central and a peripheral action. Ferreira and Vane (1974) suggested 
that salicylates act by inhibiting prostaglandin synthesis which 
occurs in inflamed tissues and thus may prevent sensitisation of 
pain receptors to chemicals such as bradykinin or histamine or to 
mechanical stimulation. These authors showed that paracetamol had 
almost the same potency as aspirin in inhibition of prostaglandin 
synthesis in the brain but found that paracetamol was much less 
effective than aspirin as an inhibitor of peripheral prostaglandin 
synthetase. Further to this McDonald-Gibson and Collier (1979) 
found that paracetamol in low concentrations (0.07 - 1.98miyi) 
stimulated prostaglandin production in bull seminal vesicle 
homogenates perhaps by acting as a co-factor of cyclo-oxygenase. 
Higher concentrations (6.61m!V0 significantly depressed prostaglandin 
production. In addition these workers found that mixtures of 
paracetamol and acetyl salcylic acid exhibited more inhibitory 
potency than either drug alone. They concluded that this might be 
due to the action of paracetamol as a phenolic cofactor which 
increases the susceptibility of prostaglandin cyclo-oxygenase to 
acetyl sa licy lic  acid. This raises the possibility that mixtures of 
paracetamol and aspirin may be more effective than each drug 
separately.
Aspirin is an e ffic ie n t anti-inflammatory agent and is therefore of 
particular use in conditions in which inflammation plays a dominant 
role - notably rheumatoid a rth r it is . Aspirin may be especially 
effective as an analgesic therefore in inflamed tissues where 
prostaglandin synthesis is leading to pain. M ills (1974) suggested 
that the markedly d ifferent sensitivity of central and peripheral 
prostaglandin synthetases to paracetamol may partly explain its  weak 
anti-inflammatory actions in c lin ical doses. More recently an 
anti-inflammatory effect of paracetamol has been reported and i t  may 
reduce pain and swelling in inflammatory conditions other than 
a rth ritis  sometimes more effectively than aspirin (Cooper, 1981 and 
Skjelbred, Albuma and Lokken, 1977).
Aspirin lowers body temperature in febrile  patients but not in 
patients with normal temperatures. This effect also appears to 
involve inhibition of prostaglandins of a PGE-like nature in the 
brain and this effect is inhibited by salicylates which suggests 
that PGE may be an endogenous pyrogen. Paracetamol has been shown 
to inh ib it the action of endogenous pyrogens on the hypothalamic 
heat-regulating centres (Milton, 1976) and its  antipyretic effect 
may stem from a direct action on these centres resulting in 
dissipation of heat.
The possible role of aspirin as an antithrombotic agent has recently 
evoked much interest (Aspirin Myocadial Infarction Study Group
(1980), Barnett, 1978 and Persantine Aspirin Reinfarction Study 
Research Group, 1980). Since platelets are involved in thrombus 
formation i t  may be possible, by using a suitable dose of aspirin, 
selectively to inh ib it the synthesis of thromboxane but not 
prostacyclin and thus prevent p late let aggregation. Clinical tr ia ls  
are in progress to ascertain the value of aspirin in the prevention 
of mortality after myocardial infarction and preliminary reports 
suggest that aspirin may be of benefit although the evidence is not 
clear-cut (Loew, 1977; Editoria l, Lancet, 1979, 1356; Elwood 1980 
and Aspirin Abstracts Nos. 4 and 5).
In summary, aspirin has an important place in the treatment of pain 
of most types, of fever and of inflammation of many causes including 
that encountered in the rheumatic diseases. Paracetamol has similar 
analgesic and antipyretic effects to those of aspirin but may 
possess only a weak anti-inflammatory action. Therefore i t  is used 
in mild to moderate pain which is not of visceral origin and which 
is not accompanied by significant inflammation. Paracetamol as yet 
appears to have no place as an antithrombotic agent.
1.1.4. Toxicity of aspirin and paracetamol
Aspirin and paracetamol were in use long before the current system 
of legislation for the introduction of new medicines in the United 
Kingdom was in operation, but their wide consumption, duration of 
use and ava ilab ility  without prescription indicates that these drugs 
are considered to be safe in normal clin ical doses.
1.1 .4 .1 . Toxicity in chronic use
Moderate doses of aspirin taken over a period of time have long been 
associated with occult and overt gastrointestinal bleeding and 
gastric ulcer (see Silvoso, Ivey, Butt et a l, 1979). However 
recently Rees and Turnberg (1980) concluded that although acute 
exposure of the gastric mucosa results in increased blood-1oss, 
abnormal mucosal function and short lasting morphological damage, 
there was l i t t l e  evidence that low dose aspirin consumption results 
in either peptic ulcer or acute gastrointestinal bleeding. Frequent 
or heavy consumption of the analgesic seems to be associated with 
gastric ulcer and acute gastrointestinal bleeding but this may 
re flec t a tendency for aspirin ingestion in response to pain from 
peptic ulcer causing gastrointestinal bleeding. Support for this 
hypothesis has been given by Piper, McIntosh, A rio tti, Fenton and 
MacLennan (1981) who found a strong positive correlation between 
heavy aspirin consumption (re lative  risk of 17.3) or heavy 
paracetamol consumption (re lative  risk of 24.4) with chronic gastric 
ulcer where relative risk is the ratio  of the risk amongst that 
exposed to that amongst the unexposed. Unlike aspirin, paracetamol 
does not cause gastric mucosal injury (Loebl, Craig, Culic, Ridolfo, 
Falk and Schmid, 1977), Ivey, Silvoso and Krause, (1978). However 
Langman, Edmond and Hardy (1979) found paracetamol consumption to be 
greater than aspirin consumption in 190 patients with upper 
gastrointestinal bleeding. This suggests that a causal relationship 
between aspirin intake and gastrointestinal bleeding may not 
necessarily exist.
Aspirin may also cause stomach upset including dyspepsia, heartburn, 
nausea and vomiting. I t  may also prolong the duration of pregnancy 
i f  taken regularly during the second and third trimester. Its  role 
as a causative agent in Reye's syndrome has yet to be evaluated.
Aspirin and paracetamol have also been associated with 
nephrotoxicity. However paracetamol has to be given in extremely 
large doses to
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experimental animals (except Gunn rats) to produce renal papillary 
necrosis and there have been few reports on paracetamol-induced 
nephropathy (Prescott, 1982). Aspirin has been shown to produce 
experimental renal necrosis, (Molland, 1978) and possible renal 
function impairment and analgesic nephropathy in man (Lee, 1979).
In a recent study however, carried out by AKyol, Thomson and Kerr
(1981) in 15 patients who had taken no other known nephrotoxin but 
aspirin over a mean of 16 years, no evidence of analgesic 
nephropathy was found. Thus while longterm analgesic abusers do 
develop a nephropathy, a causal relationship is d if f ic u lt  to prove 
for any specific analgesic. There may be an association between 
uroepithelial tumours and analgesic nephropathy and although 
phenacetin seems to be a common lin k , tumours have also been 
reported in patients taking salicylates without phenacetin 
(Prescott, 1982).
Aspirin may have adverse effects on the live r but these usually 
occur in association with diseases such as rheumatic fever, 
juvenile rheumatoid a rth ritis  and systemic lupus erythematosus when 
aspirin is taken in large doses over a long period. There have been 
only a few reports of hepatotoxicity arising as a result of chronic 
ingestion of paracetamol (for example see Zimmerman, 1981 and 
Johnson and Tolman, 1977) despite its  effect on the liv e r in acute 
overdose.
1 .1 .4 .2 . Toxicity in acute overdose
High doses of aspirin cause tinnitus, deafness, nausea, abdominal 
pain, respiratory alkalosis (more common in adults), metabolic 
acidosis (may occur in children) and hepatotoxicity. Acute overdose 
with paracetamol is manifest as liv e r  necrosis and, more recently 
recognised, nephrotoxicity (Cobden, Record, Wood and Kerr 1982). 
After severe paracetamol poisoning peak disturbance of hepatic 
function occurs 4 - 6  days after overdose and may be followed by 
frank liv e r  fa ilure and hepatic encephalopathy (Meredith and 
Goulding, 1980).
The toxicity of aspirin is related both to metabolic and 
pharmacokinetic factors and paracetamol toxicity is thought to arise 
from its  mode of metabolism. A b rie f description of the ways in 
which drug biotranformation contributes towards overall elimination 
of a drug from the body and some of the factors influencing drug 
metabolism therefore follows.
1.2. Drug Metabolism
Termination of a drug's biological effect requires that i t  be 
removed from its  site of action by metabolism and excretion. Since 
the products of metabolic transformations are usually more polar 
than their parent compounds and therefore more readily eliminated, 
i t  follows that the metabolism of a drug or xenobiotic may affect 
not only its  duration of action but also its  tox ic ity .
Williams (1972) summarised the possible fate of a drug in the body 
as follows:
a drug can undergo an enzyme catalyzed transformation 
a drug can undergo a spontaneous reaction when given certain 
physical conditions such as pH e.g. thalidomide 
a drug can be excreted unchanged.
Most drugs undergo the f ir s t  of these and enzymes that catalyse 
these metabolic changes are located mainly in the endoplasmic 
reticulum of the liv e r . These enzymes vary in nature and amount 
from species to species and variation in the duration of action of 
drugs between species may be explained by these differences (Brodie, 
1956). Some extra-hepatic tissues (e.g. lung and kidney) are also 
capable of drug metabolism but these tend to be less active per unit 
weight than liv e r .
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I t  is conventional to consider drug metabolism in two phases. Phase 
I reactions include oxidation, reduction and hydrolytic reactions 
which allow polar groups (e.g. OH, COOH, NHg and SH) to be 
introduced into the molecule. Phase I I  reactions are conjugation 
(synthetic) reactions which involve the addition of polar groups to 
the molecule.
oxidation.
Phase I reduction, or Phase I I
Drug _________ hydrolysis __________  conjugation
products products
enzymes enzymes
Phase I reactions can lead to inactivation of the drug (e.g. 
oxidation of pentobarbitone), they can convert an inactive drug to 
an active drug (e.g. prontosil > sulphanilamide) or they may convert 
a pharmacologically active drug to an active metabolite (e.g. 
phenylbutazone > oxyphenbutazone). Phase I I  reactions generally 
result in termination of the activ ity  of a drug. Some drugs which 
already possess a suitable (e.g. hydroxyl) group may only undergo a 
Phase I I  reaction. Phase I I  reactions give rise to very polar 
molecules which are rapidly excreted from the body (for example 
salicylic  acid > salicyluric acid, paracetamol > paracetamol 
glucuronide + paracetamol sulphate) and involve the conjugation with
an endogenous molecule (e.g. glucuronic acid, glycine, cysteine,
methionine and sulphate) with the drug or its  Phase I metabolite. A
source of energy is also needed for the conjugation and this is
usually supplied through adenosine triphosphate.
Some factors which may affect the rate of metabolism of drugs are 
1isted in Table 1.1.
n
Table 1.1




other drugs or foreign compounds
route of administration
age season
chronic administration d iet
sex (mainly in rats) gut flora
stress al t i  tu de
temperature 
time of day
b ilia ry  excretion and enterohepatic circulation
disease
These factors particularly a lte r the activ ities  of microsomal 
drug-metabolising enzymes; the conjugation reactions are generally 
influenced to a lesser extent. As indicated in Table 1.1. ac tiv ity  
of microsomal drug-oxidsing enzymes may be altered by pathological 
states such as liv e r or kidney disease, hormonal disturbances, 
tumour bearing states and adjuvant a rth ritis  (for a review see Kato,
1977). Examples of the effect of disease states on drug metabolism 
include the prolongation of hexobarbitone sleeping time in jaundiced 
rabbits (McLuen and Fouts, 1960) and the prolongation of the 
sleeping time of several barbiturates in rats with adjuvant induced 
a rth rit is  (Querauviller, Chalchat, Brovilhet and Delberre, 1968).
The kinetics of several common drugs have been reported to be 
altered in non-neoplastic liv e r disease. Half l i f e  was reported to 
be increased of diazepam (Klotz, Antonin, Brugel and Bieck, 1976); 
hexobarbitone (Breimer, Z illy  and Richter, 1975); paracetamol
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(Prescott, Wright, Roscoe and Brown, 1971); lignocaine (Thomson,
Mel mon, Richardson et a l, 1973) and propranolol (Branch, Morgan, 
James and Read, 1976).
Chronic administration of a drug can decrease the pharmacological 
activ ity  of another drug by stimulating its  metabolic inactivation 
and thus reducing its  concentration at its  site of action. This 
effect seems to be produced by an increase in the amounts of drug 
metabolising enzymes (and in particular cytochrome P-450) and is 
referred to as enzyme induction. This term has been used 
specifically to describe a process which increases the rate of 
synthesis of an enzyme or decreases its  rate of degradation (or 
both) relative to its  rate of synthesis in the uninduced organism.
A number of drugs cause an increase in hepatic drug metabolising 
enzymes. These include polycyclic aromatic hydrocarbons such as 
3,4-benzpyrene and 3-methyl cholanthrene which show considerable 
specific ity, the barbiturates which are relatively non specific, 
rifampicin, phenylbutazone and ethyl alcohol. Many environmental 
chemicals can stimulate enzyme activ ity  and effects of these must be 
allowed for in the design of experiments involving enzyme induction.
Factors which influence concentrations of drug metabolising enzymes 
may a lte r drug to x ic ity . Pretreatment of rats with enzyme inducers 
decreases the acute toxicity  of strychnine, pentobarbitone and 
meprobamate because these drugs are converted rapidly to less active 
metabolites by microsomal enzymes (Conney, 1971). Prescott, 
Critchley, Balali-Mood and Pentland (1981) concluded that although 
the half l i f e  of paracetamol was decreased in patients taking an ti­
convulsants or rifampicin there did not appear to be increased 
conversion of paracetamol to its  toxic intermediate metabolite.
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1.3. Drug Elimination
Most drugs are excreted through the kidneys and drugs can be handled 
by the kidneys in three ways;
i )  the majority of drugs are eliminated mainly by glomerular 
f ilt ra t io n  and a ll drugs of low molecular weight and a ll water 
soluble drugs are rapidly cleared by this fa ir ly  non-selective 
process. The rate of glomerular f iltra t io n  depends upon the 
a v a ilab ility  of the drug in an unbound form in the plasma and 
the rate at which the drug is converted to polar products by 
bi otransformati on.
i i )  lip id  soluble drugs and metabolites which have entered the 
renal tubule by glomerular f ilt ra t io n  diffuse back into the 
plasma by passive diffusion following a concentration 
gradient. This prolongs the duration of action of such 
drugs. The rate of reabsorption depends upon the lip id  
solub ility  of the drug but as most drugs are weak 
electrolytes, they may be present partly in the lip id  soluble 
non-ionized form at physiological pH. The pH of urine can 
therefore affect the degree of ionisation of weak electrolytes 
and hence tubular reabsorption. This forms the basis of 
forced alkaline or, (less commonly) forced acidic diuresis for 
the treatment of poisoned patients.
i i i )  Drugs, which are strong bases or acids are eliminated by a 
process of active secretion into kidney tubules.
Organic anions and cations are handled by separate active transport 
mechanisms which are energy dependent and blocked by metabolic 
inhibitors. The anionic group has been studied in detail and can be 
saturated at high concentrations. Each acid has its  characteristic 
maximum tubular excretion rate (Tm). The various anionic compounds 
compete for secretion, for example probenecid blocks the otherwise 
rapid excretion of pen icillin  thereby prolonging its  duration of 
action.
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Organic cations are excreted by a different energy dependent pathway 
for which they compete and which is exclusive to cations.
1.4. Disposition and metabolism of paracetamol and aspirin
A more detailed description of the absorption, distribution, 
excretion and in particular the metabolism of paracetamol and 
aspirin follows.
1.4 .1 . Paracetamol
1 .4 .1 .1 . Absorption, distribution and excretion
Paracetamol is rapidly absorbed from the gastrointestinal tract and 
Hunt and Dunford in 1979 found that peak plasma concentrations occur 
from half to one hour a fter ingestion. They also found that gastric 
emptying time was a major variable in determining the rate but not 
the extent of paracetamol absorption. This study showed in addition 
that the mean plasma elimination half l i f e  was three hours (range 
2.52 - 3.62h). Distribution of paracetamol is re lative ly  uniform in 
most body fluids. Gazzard, Ford-Hutchinson, Smith and Williams 
(1973) found no plasma protein binding of paracetamol at plasma 
concentrations below 60ng/ml but at 280ng/ml, 15 - 21% was bound in 
humans and pigs. Hunt and Dunford (1977) found that prolongation of 
mean plasma half l i f e  in patients with severe liv e r  disease was 
related to reduced plasma albumin although this could result from 
the liv e r  disease per se. Following metabolism paracetamol is 
mainly eliminated by the kidneys and only a small percentage (about 
5%) is excreted unchanged in urine.
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1.4.1.2 Metabolism
The biochemical mechanism of the hepatotoxicity of paracetamol was 
f i r s t  suggested by Mitchell, Jollow, Potter, Davis, G ille tte  and 
Brodie in 1973. Studies on the mechanism of paracetamol-induced 
liv e r  damage in laboratory animals showed that paracetamol is 
converted in the body to a chemically reactive arylating agent that 
covalently binds to v ita l hepatocellular macromolecules. In 
addition a direct relationship was demonstrated between the
formation of a paracetamol glutathione conjugate, arylation of/
hepatic macromolecules and hepatic damage after paracetamol 
i ngestion.
The major urinary metabolites of paracetamol are the glucuronic acid 
and sulphate conjugates which combine with paracetamol at the 4 
position forming the non-toxic glucuronide and ethereal sulphate 
derivatives. In addition paracetamol is oxidised by the cytochrome 
P-450-dependent drug-metabolising enzyme(s) to a reactive 
intermediate. This intermediate is preferentially conjugated with 
hepatic glutathione and after further metabolism is excreted in the 
urine as paracetamol cysteine and paracetamol mercapturic acid. The 
mercapturate conjugate of paracetamol was f ir s t  identified by 
Mitchell and Jollow in 1974 after conjugates of paracetamol 
containing divalent sulphur were found in urine. Hepatic 
glutathione however is limited and once i t  is depleted covalent 
binding to hepatocytes may occur.
The present understanding of the relationship between the metabolism 
ofparacetamol and its  hepatotoxicity is summarised in the scheme 
overleaf (Fig 1 .1 ).
1.4.1.3 Paracetamol poisoning
Paracetamol in normal therapeutic doses is one of the safest mild 
analgesics. Serious toxicity with paracetamol was f ir s t  recognised 
in 1966 when fatal hepatic necrosis after overdosage was reported 
(Davidson and Eastham, 1966 and Thomson and Prescott, 1966). I t  was 
already known that paracetamol could produce centrilobular hepatic
16



































these reactions are thought 
to occur prim arily in the 
kidney (Jones, Stead, Moldeus 
and Orrenius, 1978).
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necrosis in animals (Eder, 1964, Boyd and Bereczky, 1966). 
Paracetamol, as a result of its  free ava ilab ility  is now commonly 
taken in overdose for suicide purposes and there is a steady 
increase in the number of paracetamol-poisoned patients admitted to 
poisoning treatment centres throughout Britain.
Current rheumatological textbooks recommend doses of paracetamol of 
up to 6 g per day when used in the treatment of pain in rheumatoid 
a rth r it is . Fernandez and Fernandez-Brito (1977) reported a case in 
which 5.85g of paracetamol taken as a single dose caused liv e r  
damage. Another case report described the development of liv e r  
fibrosis which was attributed to ingestion of 2.7g paracetamol per 
day for one week followed by a week at a lower dose level (Olsson,
1978). An earlie r case history reported chronic aggressive 
hepatitis in a female patient who ingested 2.925g of paracetamol per 
day for a year (Johnson and Tolman, 1977). One case of moderately 
severe liv e r necrosis after 4g per day for approximately one year 
was reported by Bonkowsky, Mudge and McMurtry (1978).
Notwithstanding these reports the dose regimen quoted in Martindale 
(Extra Pharmacopea) is 0.5 - Ig every 3 - 4  hours with a maximum of 
4g per day. A one-day survey conducted at the Royal National 
Hospital for Rheumatic Diseases in Bath showed that some patients 
ingested as much as 8 g paracetamol per day (Dr A St.J. Dixon 
personal communication). The possibility, is thus raised that some 
patients with painful diseases such as rheumatoid a rth rit is  may be 
unknowingly creating the potential for toxicity by longterm use of 
large doses of paracetamol.
In the f ir s t  few days after acute paracetamol overdose there are few 
symptoms. In the f ir s t  twenty four hours nausea, vomiting, anorexia 
and abdominal pain occur which may last for up to a week. Liver 
injury is usually evident on the second day with elevation of serum 
bilirub in , transaminase and lactate dehydrogenase concentrations and 
prolonged prothrombin time. In serious cases, encephalopathy, coma 
and death may ensue. Transient azotemia often occurs and in some 
patients renal fa ilure dominates. A recent report suggests that
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acute renal fa ilure may occur in the absence of liv e r fa ilure and 
may become evident one week after ingestion compared with two to 
four days for the live r damage (Cobden et a l, 1982), The 
centrilobular necrosis which is seen on liv e r  biopsy is reversible 
over the following months in non-fatal cases (Woodbury and Fingl,
1975).
Prescott, Sutherland, Park, Smith and Proudfoot (1976) suggested 
that the earliest evidence of liv e r  damage is prolongation of the 
plasma half-time of paracetamol. They showed that a paracetamol 
half-time greater than four hours indicates the occurrence of 
hepatic necrosis and above twelve hours indicates that hepatic coma 
may be expected. The admission plasma paracetamol concentration has 
also been used to estimate the severity of intoxication and liv e r  
damage is lik e ly  to be severe above the upper lin e , mild between the 
lines and c lin ic a lly  insignificant below the lower lin e .
450
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1.4.1.4 Paracetamol poisoning and spec ific  therapy
The basis of the specific therapy employed in paracetamol poisoning 
stems from work by Mitchell, Jollow, Potter, G ille tte  and Brodie 
(1973) who demonstrated that glutathione had a crucial role in the 
metabolism of paracetamol. They found that pretreatment with 
diethyl maleate depleted hepatic glutathione and potentiated 
paracetamol-induced hepatic necrosis while pretreatment with 
cysteine (a precursor of glutathione) prevented the hepatotoxicity. 
Paracetamol caused a dose-dependent depletion of hepatic glutathione 
which was enhanced by treatments that potentiated hepatic damage and 
which was prevented by treatments that protected against the liv e r  
necrosis. Thus the treatment of paracetamol poisoning is directed 
towards removal of the active metabolite (which is responsible for 
the hepatotoxicity) by either the provision of sulphydryl groups or 
by administration of compounds which may act as glutathione 
precursors. Compounds such as cysteamine, methionine and N-acetyl 
cysteine which contain thiol groups should be given within 1 2  hours 
of paracetamol ingestion because they may precipitate hepatic coma 
i f  given after this time. These antidotes were f ir s t  found to be 
effective by Prescott and co-workers (Prescott, Swainson, Forrest, 
Newton, Wright and Mathew, 1974; Prescott, Sutherland, Park, Smith 
and Proudfoot, 1976; Prescott, 1977); glutathione its e lf  is thought 
to be poor in penetrating cell membranes (see Black, 1980).
Although Strolin-Benedetti, Malnoe, Schneider, Lam, Krebor and Smith 
(1975) found that glutathione given intravenously can protect mice 
against the hepatotoxicity of a large dose of paracetamol, Gazzard, 
Hughes, Portmann, Dordoni and Williams (1974) found intravenous 
glutathione to have no protective effect in rats.
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1.4.2 Aspirin (acetylsalicylic acid)
1.4.2.1 Absorption, Distribution, Kinetics and Metabolism
Acetyl s iic y lic  acid is absorbed from the stomach and from the small 
intestine. As i t  is an anionic drug which is unionized at low pH 
and has a pK̂  of 3.5, the acidic environment of the stomach (about 
pH 1.4) would be expected to favour absorption. In fact most of an 
oral dose of aspirin is probably absorbed from the upper small 
intestine which has a vastly greater surface area than does the 
stomach. There is l i t t l e  difference between rates of absorption of 
unbuffered aspirin, buffered aspirin and aspirin solution (although 
aspirin absorption appears to be greatly affected by the fasting 
state absorption being much slower after a heavy meal, Davison, 
1971). When non-dissociated acetyl sa licy lic  acid molecules in the 
gastric lumen enter mucosal cells , the higher pH renders acetyl 
salicylate more ionized and less lip id  suluble thus favouring 
accumulation in epithelial ce lls . High acetyl salicylic  acid 
concentrations in superficial cells has been advanced as an 
explanation for the mucosal cell loss and also gastric damage due to 
aspirin (Wood, 1963).
Aspirin taken by mouth is mainly absorbed unchanged but some 
salicylic  acid enters the portal circulation. Aspirin has a plasma 
half l i f e  of about fifteen minutes due to its  rapid Conversion to 
salicylic  acid by hydrolases in liv e r  and plasma. At clinical 
concentrations some 50 - 90  ̂ of salicylic  acid is bound to plasma 
proteins, mainly albumin (Reynolds and C luff, 1960) while aspirin is 
bound to only a very limited extent.
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Stafford (1963) suggested however that in some pathological states 
plasma proteins may be quantitatively and qualitatively altered and 
this may result in higher concentrations of salicylate in the 
plasma; hypoalbumenaemia may occur in rheumatoid a rth ritis  (Reynolds 
and C luff, 1960).
The usual therapeutic dose of aspirin is 600mg orally every 6  hours 
this gives rise to peak plasma free salicylate concentration of less 
than 60ng/ml. In a rth ritic  conditions for which up to lOg per day 
is indicated, peak plasma levels may reach 200 - 300wg/ml (Davison, 
1971) and these concentrations are often associated with symptoms of 
toxic ity  such as tinnitus, anaemia and gastric disturbances. In low 
doses elimination of salicylate follows f ir s t  order kinetics but at 
higher therapeutic doses and in overdose saturation of the 
elimination process occurs due to the limited capacity of two major 
elimination pathways (salicyluric acid and salicyl phenolic 
glucuronide). The plasma half l i f e  of salicylic  acid is 4 - 6  hours 
in low doses. After high doses the time for plasma concentration to 
fa ll by half may be prolonged to over 15 hours (Levy, Tsuchiya and 
Amsel, 1972)
Salicylate biotransformation takes place mainly in the microsomal 
system and mitochondria of the liv e r . The three main metabolites of 
salicylate are salicyluric acid (the glycine conjugate), the ether 
or phenolic glucuronide and the ester or acyl glucuronide. About 5% 
is oxidised to gentisic acid (2,5-dihydroxy benzoic acid) and to
2 ,3-dihydroxy benzoic acid and 2,3,5-dihydroxy benzoic acid. These 
are a ll found in urine but only a small proportion of these 
hydroxyl ated metabolites ( 1 % of total salicylate) has been found in 
plasma (Waodbury and Fingl, 1975).
The main metabolic pathways of aspirin are outlined in Fig.
1 . 2 .Excretion of sa licylic  acid and its  metabolic products is mainly 
by the kidneys, only traces are found in sweat, b ile and faeces. 
Urinary pH can profoundly a lte r the proportion excreted as free 
salicylate. The rate of urinary excretion of free salicylate is 
also influenced by the glomerular
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Fig. 1.2 Metabolism of aspirin
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f ilt ra t io n  rate, the rate of proximal tubular secretion of 
salicylate and the rate of urine flow. Competition for the tubular 
transport system may also occur with anionic substances such as 
probenacid, p-aminobenzoic acid, p-aminohippuric acid and 
acetazolamide (Milne, 1963).
Dose dependent elimination of salicyluric acid was f ir s t  noted by 
Levy (1965). He found that a fter a 0.25g dose of aspirin overall 
elimination of salicylate and its  metabolites followed first-order  
kinetics but with doses of Ig or more of aspirin administered to 
four subjects the formation of salicyluric acid, which accounts for 
80 - 90% of the total metabolites of sa licylic  acid, tended towards 
zero-order kinetics. Levy, Tsuchiya and Amsel (1972) suggested that 
the liv e r  was lim ited in its  a b ility  to form these conjugates from 
urinary excretion rate data in man.
1.4.2.2 Aspirin poisoning and therapy
Toxicity associated with chronic ingestion of acetyl salicylic  acid 
described in Section 1.2.3 includes gastrointestinal bleeding and 
kidney and liv e r damage. Occult bleeding from the gut occurs in 
most people taking aspirin regularly due to painless gastric 
haemorrhage. Aspirin is probably also a cause of major 
gastrointestinal haemorrhage although this view was questioned 
recently when i t  was found by Langman (1977) that some patients who 
presented with bleeding were taking analgesics other than aspirin. 
Aspirin also causes renal irr ita tio n  shown by increased urinary 
excretion of renal tubular cells and studies by Prescott (1965) 
showed that in therapeutic doses aspirin produced much larger 
amounts of renal tubular cells in urine than did paracetamol or 
phenacetin. Prescott and Ansari (1969) found that in rats a delayed 
rise in tubular cell excretion was accompanied by proximal tubular 
necrosis. Like phenacetin and paracetamol i t  is now thought that 
aspirin may be converted in the body to a highly reactive alkylating  
agent which binds covalently to tubular cell proteins causing 
necrosis.
. ' -fT (M itchell, McMurtry, Statham and Nelson
(1977). Again the formation of the reactive intermediate is via
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cytochrome P450. More recently aspirin has been implicated as 
causing hepatotoxicity (Prescott, 1980) but this was usually minor 
compared with other manifestations of salicylate poisoning. Aspirin 
is rapidly metabolised to salicylic  acid and Levy and Yaffe (1968) 
have found that some individuals may be slow metabolisers of 
salicylate so that accumulation to toxic levels may occur with a 
dose regimen which would normally be safe. Some pathological 
conditions (for example Gilberts disease) are manifestos a 
deficiency in the a b ility  to conjugate with glucuronic acid, and 
give rise to high levels of salicylate in the body.
The effects of overdose of aspirin include tinnitus, deafness, 
nausea, vomiting, respiratory alkalosis, and metabolic acidosis. 
Doses of 500mg/kg salicylate or more are potentially lethal while 
doses in excess of 300mg/kg may result in prolonged and severe 
effects (Temple, 1981).
Treatment of salicylate poisoning is directed towards minimizing 
absorption, correcting acid-base disturbances, hastening elimination 
of absorbed salicylate and preventing complications. Forced 
alkaline diuresis has been used successfully in salicylate poisoning 
but is often complicated by hypokalaema. Lawson, Proudfoot, Brown 
et al (1969) advocated a forced 'cocktail' diuresis which included a 
supplement of potassium chloride in addition to sodium bicarbonate, 
laevulose and saline. More recently Balali-Mood, Critchley, 
Proudfoot and Prescott (1982) reported that sodium bicarbonate given 
alone was more effective than either forced alkaline diuresis or 
forced diuresis alone in decreasing plasma salicylate concentrations 
and in increasing renal clearance and excretion of salicylate.
1.5 Scope of the Project and Background to the Study
Aspirin and paracetamol are commonly used drugs both of which have 
the potential for toxicity  during chronic treatment and after 
overdosage.
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Both drugs are extensively metabolised and i t  is possible to 
identify the major metabolites from each and hence follow their 
metabolism in situations which may be of c lin ical significance. The 
following studies were therefore undertaken:
a) Metabolism in normal volunteers (aspirin and paracetamol)
b) Metabolism in disease states (rheumatoid patients - aspirin
and paracetamol; thyroid patients - paracetamol only)
c) Metabolism of paracetamol in the presence of other drugs 
(salicy 1 amide in man; phenobarbitone, phenylbutazone, 
rifampicin, L-ascorbic acid, salicylamide and a-tocopherol in 
mice and guinea pigs).
d) Metabolism of aspirin and paracetamol after overdose in man.
e) Metabolism of paracetamol a fter specific therapy for high
doses of paracetamol in rabbits.
f )  Chronic dosing with paracetamol in mice and guinea pigs.
A one-day survey of patients in the Royal National Hospital for 
Rheumatic Diseases (RNHRD) in Bath revealed that paracetamol is at 
least as popular as aspirin as the basic prescribed and 
self-administered drug for control of pain in rheumatoid a rth rit is . 
I t  also showed that concurrent treatment with combinations of 
paracetamol with other drugs which could affect the metabolism of 
paracetamol (for example inducing and metabolic competing agents) is 
common. Patients were found to be taking paracetamol with one or 
more other drug such as aspirin, immunosuppressives (e.g. 
azathioprine), penicillamine, gold, steroids, phenylbutazone and 
indomethacin (Dixon, Personal communication, 1978). This apparently 
is  usual throughout Great Britain (see Editorial, BMJ, 8  March 
1980). Access to patients at the RNHRD has enabled the study of 
possible alterations in metabolism which might be attributable to 
the disease state, to effects of chronic administration of aspirin 
and paracetamol, or to drug-drug interactions. In order to study 
the effects of chronic administration of paracetamol on its  
metabolism mice and guinea pigs were treated chronically with 
paracetamol and the urinary metabolic profile  was assessed.
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Salicylate and paracetamol poisoning remain a major c lin ical problem 
involving accidental ingestion in children and intentional overdose 
in adults. Consumption of paracetamol in Great Britain increased in 
the mid 1960s because i t  had fewer adverse effects at the 
recommended doses than aspirin and this increased therapeutic use of 
paracetamol was accompanied by an increase in the number of patients 
taking paracetamol for deliberate self-poisoning (Koch - Weser,
1976). Poisoned patients in the Bath area are mainly treated in the 
Clinical Pharmacology Unit (CPU) at the Royal United Hospital and 
this Unit has provided an excellent fa c ility  to study the metabolism 
of aspirin and paracetamol in such cases. A survey of patients 
admitted to the CPU over the period June 1979 - January 1981 was 
carried out to determine the drugs taken most frequently in overdose 
and i t  was found that the third and fourth mostpopular drugs taken 
in overdose admitted to the CPU are salicylates (accounting for 
16.43% of total admissions) and paracetamol (accounting for 11.80%).
The a v a ilab ility  of the CPU has enabled samples to be taken from 
patients a fter accidental or deliberate self-poisoning with aspirin 
or paracetamol so that the metabolism of these two drugs after high 
doses and also the effects of specific and non-specific antidotes 
may be ascertained. In addition, a control study from a wide 
age-range of human volunteers has allowed the establishment of a 
control metabolic profile  after therapeutic doses of aspirin and 
paracetamol.
Inducing agents may affect the toxicity of paracetamol by increasing 
the formation of the reactive intermediate (Mitchell e t a l,  1973).
As there is such a large number of environmental agents known to 
induce drug-metabolising enzymes as well as the possibility of 
induction by the practice of polypharmacy the effects of three 
agents (phenobarbitone, rifampicin (an antib iotic) and 
phenylbutazone (commonly used in rheumatoid a rth ritis ) on the 
metabolism of paracetamol have been studied in animals.
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In addition, effects of agents which may compete with paracetamol 
for available conjugating substrates have been examined in animals 
and man. Agents which conjugate with sulphate such as salicylamide 
or L-ascorbic acid may decrease sulphate a va ilab ility  to the extent 
that a higher proportion of a given dose of paracetamol may be 
oxidised to the reactive metabolite.
Antipyrine metabolism was found by Crooks, Medley, Macnee and 
Stevenson (1973) to be increased in hyperthyroid patients and to be 
subnormal in hypothyroid patients. I t  is possible that accelerated 
metabolism in hyperthyroidism may enhance the toxicity of 
paracetamol by amplifying the rate of formation of the potentially  
hepatotoxic intermediate of paracetamol. The metabolism of 
paracetamol was therefore studied in a small group of patients with 
thyroid disease.
Finally after identification of two of the minor metabolites of 
paracetamol found in urine as 2- and 3-hydroxy paracetamol, i t  has 
been possible to show that considerable amounts of these metabolites 
and the cysteine and mercapturic acid metabolites of paracetamol in 
urine arise from acid-labile pre-aromatic unaromatized derivatives. 
These results give rise to the hypothesis that the pathways of 0- 
and S-substitution are linked and arise as a consequence of 
nucleophilic attack on an epoxide ring. Thus i t  is proposed that 
4-hydroxy-2 ,3 -dihydroacetani1i de 2,3-oxide is a like ly  intermediate 











i)  acetanilide, (N-phenyl acetamide), CHg CONH CgHg,
MP = 114-115*C, MW = 135.17, (BDH Chemicals Ltd),
i i )  o-anisic acid, (o-methoxy benzoic acid), O-CHgOCg
Ĥ COgH, MP = 98-100°C, MW = 152.15, (Aldrich Chemical 
Co. L td .).
i i i )  aspirin, (acetyl sa licylic  acid), 2 -(CH2 C0 2 ) CgĤ
COgH, MP = 138-140*C, MW = 180.2, (Evans Medical Ltd),
iv) gentisic acid, (2,5-dihydroxybenzoic acid), sodium sa lt,
(OHj-CgH.COONa, MP = 205°C, MW = 176.1, (Sigma 
(chemical Co.)
v) 2 -hydro%y paracetamol, (2 , 4-dihydroxy (^-phenyl acetamide),
2 , 4 - ( 0 H)2 CH2 C0 NHCgĤ , MW = 261, (S tirling  Winthrop 
R&D*).
v i) paracetamol B.P., (4-acetamidophenol), CĤ  CONH CgĤ
OH, MP = 169-172*C, MW = 151, (obtained from the Pharmacy, 
Royal United Hospital, Bath),
v ii)  paracetamol cysteine, (3-[(l-acetamido-4-hydroxy
phenyl)thio]alanine), 1, 3, 4-NH COCHg CgHg S CH2  
CH (NHg,) COOH (OH), MP = 192-193*0, MW = 270, (S tirling  
Winthrop R&D*).
v i i i )  paracetamol glucuronide, (4-hydroxy N-phenyl acetamide
4-glucuronide), p-CHg CONH Cg Ĥ  OCg Hg Og, MW 
= 327, (S tirling  Winthrop R&D*).
ix) paracetamol meta sulphate, (3 ,4-dihydroxy 3-sulphate
^-phenyl acetamide),3 , 4 - ( 0 H)2 CH2 C0 NHCgĤ 4 - 0 S0 2 H,
MW = 261, (S tirling  Winthrop R&D*).
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x) paracetamol mercapturic acid, (1-acetamido-4-hydroxy phenyl 
mercapturic acid), 1, 3, 4 -HNCOCH2  Cg SCHg CH 
(NH C0 CH3 )C0 0 H(0 H),MW = 312, (S tirling  Winthrop R&D*).
xi) paracetamol sulphate, (4 -hydroxy N-phenyl acetamide-4
-sulphate), p-CHgCONHCgĤ OSÔ HJHW = 230, (S tirling  
Winthrop R&D*).
x ii)  sa licylic  acid, (2 -hydroxy benzoic acid), HO CgĤ  COOH,
MP = 157-162*C MW = 138.13, (BDH Chemicals Ltd).
x i i i )  salicyluric acid, (0-hydro)^ hippuric acid), HO CgĤ CONH
CHgCOgH, MP = 167-169*0, MW = 195.2, (Sigma Chemical
Co. )
*These compounds were kindly donated by Dr R S Andrews of S tirling
Winthrop R&D.
b) Solvents
HPLC grade solvents were used throughout without further 
purification and a ll were obtained from Fisons. 
i ) acetonitrile , (methyl cyanide), CĤ CN, MP = -48*0, MW =
41.05.
i i )  isopropanol, (CH l̂g CHOH, MP = -89.5*0, MW = 60.1.
i i i )  methanol, CH3 OH, MP = -98*0, MW = 32.04.
c) Other Chemicals
i )  acetic acid (g la c ia l), CH3 COOH, MW = 60.05, (BDH
Chemicals Ltd).
i i )  formic acid, (98%), HCOOH, MW = 46.03, (BDH Chemicals Ltd),
i i i )  ketodase (g-glucuronidase) buffered in acetate to pH 5.0,
each ml contained 5,000 Fishman Units, (General 
Diagnostics).
iv) perchloric acid (60%), HClO ,̂ MW = 100.46, (Fisons).
v) potassium dihydrogen orthophosphate, KHgPÔ , MP =
252.6*0, MW = 136.09, (BDH Chemicals Ltd).
v i) sodium lauryl sulphate, n -CH3 (CH2 )|̂ Q0 S0 3 Na, MW =
288.38, (BDH Chemicals Ltd).
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v il)  sulfatase. Type H-2 (from Helix pomatia) also containing 
g-glucuronidase, (Sigma Chemical Co.).
v i i i )  tetrabutyl ammonium phosphate (TBAP, ion pairing agent) was
the g if t  of Dr C Riley, University of Bath.
All compounds used were of analytical grade purity or better where 
possible.
d) Drugs
i )  L-ascorbic acid (vitamin C), COC(OH)C(OH)OCH CH (OH)
CĤ OH, MP =190-192*0, MW = 176.1, (Sigma Chemical Co.)
i i )  soluble aspirin B.P. tablets, each tablet contained 300mg,
used for human studies, (obtained from the Pharmacy, Royal 
United Hospital, Bath),
i i i )  L-methionine B.P. (obtained from the Pharmacy, Royal
United Hospital, Bath),
iv) paracetamol B.P. tablets, each tablet contained SOOmg, used
for human studies, (obtained from the Pharmacy, Royal 
United Hospital, Bath),
v) phenobarbitone sodium (5-ethyl 5-phenyl barbituric acid),
CsHsCẑ sCfCOlNHOCNCONA MP = 174-178*0, MW = 284.2,
(BDH Chemicals Ltd),
vi) phenylbutazone tablets, BP, (4-butyl-1 , 2-diphenyl-
pyrazolidine-3, 5-dione), MP = 105*0, MW = 308.4, each 
tablet contained lOOmg phenybutazone, (obtained from the 
dispensary. School of Pharmacy, University of Bath),
v ii)  rifampicin capsules, BP, (5,6,9,17,19,21 - hexahydroxy-
23-methoxy-2,4,12,16,18,20,22 - heptamethyl 8 - [N-(4-methyl 
-1-piperazinyl) formimidoyl]-2,7-(epoxypentadeca [1,11,13] 
trienimino) naphtho [2 ,1-6] furan - l,ll(2H )-d ione  
21-acetate), Ĉ gHggN̂ Ô g, MW = 822.96, each capsule 
contained 150mg rifampicin (Ciba).
v i i i )  salicylamide B.P., Cg Ĥ  (OHlCONHg, mp = 140*0, MW =
137.14, was the g if t  of A Davis, Beecham Pharmaceuticals.
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Ix) DL-a-tocopherol acetate, (vitamin E), 5,7,8-trimethyl 
tocol, CggHgo Og, MP = 2.5-3.5*C, MW = 430.69, was 
the g if t  of Dr R Ehsanullah of Roche Products Limited.
Preparation of salicylamide solution:- 25ml 20% NaOH was made up 
using NaOH B.P. and s te rile  water. Ig salicylamide powder was 
weighed into each of 1 2  disposable plastic beakers and s terile  water 
was added and slurried. 1.45ml 20% NaOH was added in drops with 
constant stirring  to each beaker making sure that the pH a t no time 
exceeded 10.5. This resulted in an equimolar solution of 
salicylamide with sodium hydroxide. Each beaker was them made up to 
a final volume of 200ml which included 5m1 concentrated water of 
aniseed B.P.
2.2 Animals
The experimental animals used were male CFLP mice weighing between 
10 and 45g; male Dunkin Hartely guinea pigs weighing from 280-600g 
and female New Zealand white rabbits weighing from 2.8 to 4.6kg.
Guinea pigs and rabbits were housed in individual metabolism cages 
(Associated Crates Limited) and mice were placed in groups of four 
in metabolism cages (North Kent Plastic) which allowed the separate 
collection of urine and faeces. During each experiment water was 
allowed ad libitum but (except for the chronic studies) food was 
restricted for 24 hours while urine was being collected. The normal 
diet of the animals was FDI for rabbits and guinea pigs and CRM for 
mice. They were maintained on a constant light-dark cycle (14h 
lig h t - 05.00-19.00 and lOh darkness - 19.00-05.00). All 
experiments were carried out in the animal house which was 
maintained at an ambient temperature of 24°C.
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2.3 Human volunteers and patients
Human volunteers who were aged from 13 to 80 were healthy and 
ambulatory and gave their informed consent. The younger volunteers 
were hospital and laboratory workers or their children while the 
older volunteers (aged over 60 years) were contacted through local 
general practitioners. Studies of drug overdose were carried out on 
self-poisoned patients who had been admitted to the Clinical 
Pharmacology Unit, a t the Royal United Hospital, Bath. In-patients 
in the Royal National Hospital for Rheumatic Diseases, Bath and 
out-patients with thyroid disorders who were attending the Medical 
Out Patients Department at the Royal United Hospital, Bath were also 
studied. A record was made of a ll drugs currently or regularly 
taken by volunteers and patients
2.4 Administration of compounds to animals and humans
a) Animal Studies
Guniea pigs, mice and rabbits received paracetamol in various 
doses either dissolved in propylene glycol (guinea pigs only) or 
as a saturated suspension in 0.9% saline (guinea pigs, mice and 
rabbits). Intraperitoneal injections were made unless otherwise 
stated.
Phenobarbitone was made up as a stock solution of lOOmg/ml or 
lOmg.ml in saline for guinea pigs and mice resepctively. Both 
species were pretreated with lOOmg/kg phenobarbitone i.p . for 4 
days and 7 days before administration of 150mg/kg paracetamol 
i .p . at the start of the las t day. Phenylbutazone tablets were 
ground up using a pestle and mortar and then suspensions of 
lOOmg/ml and lOmg/ml were made in 0.9% saline. Guinea pigs and 
mice were pretreated with lOOmg/kg phenylbutazone i.p . for 4 
days followed by lOOmg/kg paracetamol i .p . on the final day.
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Rifampicin was given to the same two species at a dose of 80mg/kg 
i .p . and was made up as a 40mg/ml solution in M-saline adjusted with 
50ul 2N NaOH to achieve solution. Guinea pigs were treated with 
this solution but i t  was diluted to 8 mg/ml for mouse studies. After 
5 day pretreatment with rifampicin, paracetamol 150mg/kg i .p . was 
administered on the 5th day. After the administration of 
paracetamol, animals were housed in metabolic cages as previously 
described and 24 hour urine was collected.
L-ascorbic acid and salicylamide were both made up as lOmg/ml and 
lOOmg/ml solutions in N-saline which were administered to mice and 
guinea-pigs respectively, a-tocopherol was obtained in ampoules of 
2 0 0 mg/ml and this solution was used as such for guinea pig studies 
but was diluted to lOmg/ml for mouse work. These three metabolic 
competing agents were administered i .p . concurrently with lOOmg/kg 
paracetamol i .p .  and animals placed in metabolic cages while 24 hour 
urine was collected.
Paracetamol was administered orally to rabbits as a solution of 
lOOmg/ml or 200mg/ml N-saline. L-methionine was made up as a 
standard solution of 200mg/ml in N-saline and was administered by 
mouth just prior to paracetamol. After being dosed with paracetamol 
rabbits were housed in metabolic cages for the collection of 24 hour 
urine. Blood (approximately 3ml) was taken every 45 minutes from an 
ear vein after the application of xylene to the ear, to d ilate the 
blood vessels of the pinna. Blood samples were collected up until 
315 minutes in each experiment.
In each experiment, urine was collected from metabolic cages in 




Each subject took paracetamol, Ig , (2 x 0.5g tablets) or soluble 
aspirin BP, 600mg (2 x 300mg tablets in 50ml of water) after fasting 
overnight and emptying the bladder. Salicylamide was administered 
as its  sodium sa lt as described above. Each subject collected 
his/her own urine samples (0-8h and 8-24h collection periods) in 
acidified urine bottles.
2.5 Storage of biological samples
All samples were maintained at -20*C until required for analysis. 
Urine was collected in 21 plastic bottles which contained 10ml,
1 N HCl so that the final pH of the urine was approximately 2 and 
aliquots of approximately 20ml urine were taken. Serum samples were 
stored in unheparinized tubes.
2.6 Treatment of urine and serum
a) Preparation of urine for HPLC
For animal and human studies, 1ml urine was added to 1ml of the 
internal standard solution (lOOwg/ml acetanilide in d is tille d  water 
for paracetamol studies, 500ug/ml o-anisic acid in acetonitrile  for 
aspirin studies) and made up to 10ml with d is tille d  water. For 
human overdose studies and repeated studies in animals, dilution of 
urine was often necessary but the same concentrations of the 
internal standards were used throughout. Urine solutions were 
analysed by HPLC after pre-injection f iltra t io n  (f ilte rs  by 
Millipore (UK) Ltd, London).
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b) Preparation of serum for HPLC
Serum was obtained by centrifuging clotted blood at 1310.4g for 15 
minutes. The procedure described in the following flow diagram was 
then carried out. There is no dilution factor because the internal 
standard (acetanilide) was treated identically to paracetamol and 
its  metabolites.
1 ml serum + 1 ml 
(lOOug/ml) acetanilide + 
1ml 15% perchloric acid 
were whirlimixed and 
centrifuged at 1783.6g 
for 1 0  minutes to 
precipitate proteins.
2 ml of supernatant were 
removed and added to 1 ml 
KH2 PO4  to 
precipitate the 
perchlorate. This was 
whirlimixed and 
centrifuged at 1783.6g 
for 1 0  minutes.
The supernatant was 
respun at 2329.6g for 15 
minutes and the 
supernatant analysed by 
HPLC after pre-injection 
f ilt ra t io n .
c) Calibration curves for parent drug and metabolites were 
constructed in urine and plasma as described above with the 
exception that no acid was added to the standard solutions made
I
up in blank) urine 1 ml blank urine was used in calibration  
curves made up in urine. See section 2.8.b.
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2.7 High performance liquid chromatography
a) Generalised Scheme
( i)  ( i i )  (iv) ( i i i )






i)  Laboratory Data Control (LDC) Constametric I I I  Metering 
Pump (Jones Chromatography, Llanbradach) which is a 
constant flow pump providing a pulsationless flow using 
dual recepirocating pistons.
i i )  precolumn (5cm long, 5mm internal diameter, ^/4 inch 
external diameter) containing Hypersil CDS.
i i i )  Rheodyne value, model 7125 which was a syringe-loading
sample injection value f itte d  with a 20nl loop. An 
interchangeable Supraevaglass micromatic syringe was used 
f it te d  with a luer 33# needle.
iv) chromatography column consisted of a 24cm long, 5mm
internal diameter, ^/4 inch external diameter stainless 
steel tube packed with octadecyl s ilica  (APEX, Jones 
Chromatography, Llanbradach). The column end f itt in g  
comprised a low dead-volume Swagelok connection with a 
V l 6  inch outlet which was connected to the detector by
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microbore ptfe tubing (internal diameter 0.15mm). Low dead 
volume V l 6  inch stainless steel tubing (internal diamter 
0.15mm) was used to connect the injection value to the top 
of the column. All other connections were made of 
stainless steel tubing and standard Swagelok fittin g s  (HETP 
Ltd).
v) detector used was an LDC model Spectromonitor I I I
spectrophotometer (Jones Chromatography, Llandradach) 
providing wavelength coverage in the uv spectrum from 
190-350nm. This provided an output signal of lOmv which 
corresponded to fu ll scale for recording absorbance.
vi) chromatographs were produced on a JJ model CR 550
potentiometric chart recorder (JJ Lloyd Instruments Ltd).
All equipment was operated at ambient temperature throughout.
b) Degassing mobile phases
This was achieved by refluxing for 10 minutes, by sparging with 
helium for 5 minutes or ultrasonication for 10 minutes. The helium 
method was the most successful.
c) Internal standards
Internal standards were chosen which did not interfere  
chromatographically with analytes. Stock solutions were lOOwg/ml 
acetanilide in d is tille d  water and 500ug/ml o-anisic acid in 
acetonitrile for the assay for paracetamol and its  metabolites and 
aspirin and its  metabolites respectively.
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d) Resolution of peaks
Resolution (R^) is a measure of how well two analytes are
separated and
Rg = differences in retention times (min) 
mean peak (base) width (min)
Rg <0.08 partial resolution, some overlap 
Rg <1 . 0 0  normal criterion , small overlap 
Rg <2 . 0 0  excellent separation, no overlap unless peak 
ta i 1 .
In this system i t  was ensured that R̂  >0.08 for a ll peaks.
e) Experimental conditions
i ) Analysis of paracetamol and its  metabolites
(Modified from the method of Adriaenssens and Prescott, 1978).
Mobile phase: 97.5% 0.08M KHgPÔ  (10.89g /l), 2.5%
isopropanol, 0.075% TBAP (0.5M, 150ul/200ml) and 
0.1% (v/v) formic acid (200ul/200ml); pH = 3.0.
flow: 1.5ml/min.
UV wavelength: 254 nm.
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Ratio Kl X max (nm)
Paracetamol glucuronide 3 min 20s 0 . 8 6 242
Paracetamol cysteine 4 min 50s 1.47 200, 242, 294
Paracetamol 6  min 43s 3.15 242
Paracetamol sulphate 13 min 58s 7.82 240
Paracetamol mercapturate 16 min 30s 9.21 241, 296
Acetanilide (internal standard) 23 min 35s 13.59 273
i i ) Analysis of 2-OH paracetamol and 3-OH paracetamol
Mobile phase: 97.5% 50mM sodium lauryl sulphate, 2.5% isopropanol,
0.1% formic acid, pH = 3.0.
flow: 0.5ml/min until 2-OH and 3-OH paracetamol eluted and
then flow was increased to 3.0ml/min to elute the 
internal standard (acetanilide).
UV wavelength: 254nm.
2-OH paracetamol and 3-OH paracetamol eluted with retention times of 7 
min 30s and 7 min 55s respectively. Acetanilide was eluted at 15 min. 
The standard solution of 3-OH paracetamol was obtained by incubating 
paracetamol metasulphate with sulfatase at pH 5 overnight.
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i i i )  Analysis o f asp irin  and i t s  metabolites
Mobile Phase: 35% methanol, 64% d is tille d  water, 1% glacial acetic
acid; pH = 3.0.
flow: 1 . 0  ml/min
UV wavelength: 250 nm





Ratio Ki X max (nm)
Salicyluric acid 7 min 35s 1.85 237, 297
O-anisic acid (internal 
Standard) 1 0  min 6 s 2.83 292, 235
Acetyl sa licylic  acid 1 1  min 17s 3.45 224, 295
Salicylic acid 17 min 20s 5.71 230, 295
f ) Determination of salicyl glucuronides
As standards were not available, the salicyl glucuronides were quantified 
using a specific enzyme hydrolase (g-glucuronidase). Urine was adjusted 
to pH5 with dilute acetic acid. 0.5ml Ketodase was added 
(e-glucuronidase containing 5,000 Fishman Units per ml) and whirlimixed 
for 30s, stoppered and incubated overnight at 37*C. Analysis for 
salicylic  acid was then carried out as above. The amount of salicyl 
glucuronides present was taken to be the difference in salicylic  acid 
measured before and after e-glucuronidase treatment.
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2.8 Estimation o f paracetamol and asp irin  by HPLC - standard curves
a) Linearity of Response
Calibration curves were constructed by determining the peak height ratios 
of four to seven standard solutions containing a range of solute 
concentrations and a constant concentration of the relevant internal 
standard. Each solution was injected onto the HPLC in duplicate, the 
mean was taken and fitte d  to the following equation using linear 
regression.
y = mx + c
where y is the peak height ra tio , x is the concentration of solute and m 
and c are regression coefficients. The constancy of the calibration  
curve was checked throughout the period of the experiments and no change 
was found.
b) Standard curves for paracetamol and aspirin and their metabolites
Calibration curves were constructed for paracetamol and its  metabolites 
in plasma and urine and for aspirin and two of its  metabolites in urine. 
Figs 2.1, 2.2 and 2.3 show graphically the calibration curves for 
paracetamol in urine in the range l-40ug/ml, paracetamol in plasma in the 
range 0.25-10ng/ml and salicylic  acid in urine in the range 25-150wg/ml. 
The correlation coefficient r , the slope m and the intercept c are given 
on each graph. Calibration curves for metabolites of paracetamol and 
aspirin are not shown graphically but values for r , m and c are given 
below.
42
Fig. 2.1 Calibration curve for paracetcHtDl in urine
peak ht 20. 
ratio
r * 0.9964 




Fig. 2.2 Calibration curve for paracetamol in plasma
peak ht 2.0 
ratio
r = 0.9834 










r = 0.9978 
m = 0.004 
c =-0.01I
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i )  Paracetamol metabolites In urine
r m c n
Range 
( wg/ml)
paracetamol 0.9964 0.482 -0.40 6 1-40
paracetamol glucuronide 0.9996 0.086 0.37 7 10-880
paracetamol sulphate 0.9858 0 . 0 2 0 0.18 6 1 0 - 1 0 0
paracetamol cysteine 0.9966 0.407 - 0 . 6 8 6 2.5-40
paracetamol mercapturic aicd 0.9989 0.075 0 . 0 1 5 2.5-40
i i )  Minor metabolites of paracetamol in urine
r m c n
Range 
( pg/ml)
2 - hydroxy paracetamol 0.9989 0.184 0.218 5 2.5-4.0
3-hydroxy paracetamol 0.9982 0 . 1 1 1 -0.069 5 3.2-38.6
i i i )  Paracetamol metabolites in plasma
r m c n
Range 
( wg/ml)
paracetamol 0.9834 0.185 - 0 . 1 1 5 0.25-lC
paracetamol glucuronide 1 . 0 0 0 0 0.032 0.03 3 10-50
paracetamol sulphate 1 . 0 0 0 0 0.009 - 0 . 0 2 3 10-50
paracetamol cysteine 0.9993 0 . 1 1 0 0 . 1 2 3 10-50
paracetamol mercapturic acid 0.9954 0.026 -0.09 3 10-50
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iv ) Aspirin  metabolites in urine
Range
r m e n  (ng/ml)
acetyl salicylic  acid 0.9677 0.009 -0.14 4 25-100
salicyluric acid 0.9970 0.036 -0.23 5 25-150
salicylic  acid 0.9978 0.004 -0.01 5 25-150
c) Concentration determination
Peak height ratios of parent drug and metabolites were determined in 
serum and urine samples and concentrations were calculated using the 
equation
= /! - c
m
Where x- is the unknown concentration to be determined, ŷ  is the 
observed peak height ratio and c and m are regression coefficients 
calculated from the calibration curves.
2.9 Statistical Evaluation and Treatment of Results
Results were expressed as means and standard errors of the mean (SEN). 
The significance of the difference between means was taken as p<0.05 
using Student's two-tailed t -te s t. Regression and correlation 
coefficients were calculated using the statis tica l package Genstat.
In a ll of the studies in which concentrations of paracetamol and its  
metabolites or aspirin and its  metabolites were measured in urine or 
plasma, the weight of each metabolite recovered was converted to the 
weight of paracetamol or aspirin from which i t  had originated as
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described below*. Since there was considerable variation in total 
urinary recovery of paracetamol and aspirin and their metabolites between 
individuals in each collection period, direct comparisons of each 
treatment with control values yielded l i t t l e  information. Therefore, 
throughout this work results have been expressed either as percentage 
dose excreted or as percentage recovery of paracetamol or aspirin and 
their metabolites for studies in man and animals.
Percentage dose of paracetamol and aspirin excreted has been expressed in 
terms of the administered dose of paracetamol or aspirin as follows:
% dose of paracetamol excreted: P + PG* + PS* + PC* + PM* (mg) x 100
l,ÙOÛmg
% dose of aspirin excreted: ASA* + GA* + SA* + SUA* + SG (mg) x 100
460.2mg*
The percentage recovery in each urine collection period was also 
determined. For paracetamol, for example, the total weight of P + PG + 
PS + PC + PM was calculated and the fractional contribution of 
paracetamol and of individual metabolites was expressed as a percentage 
of this total i .e .
% recovery of paracetamol = paracetamol or metabolite* (mg) x 1 0 0
PG' +" pGy +--ps* + P C * + PM (mg)
correspondingly for aspirin
% recovery of aspirin = SA or SUA* or SG (mg) x 100
ASA* + GA* + SA* + SÜA* + SG* (mg)
47
These procedures were adopted because they express the metabolic 
disposition of paracetamol or aspirin in terms of their principal 
biotransformation products.
*Corrected for molecular weight with respect to paracetamol or to 
salicylic  acid. Correction factors are given in Appendix 1.
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Chapter 3
Paracet^oi Results In Man 
3.1 Control Study 
Introduction
In order to study the effects of different clinical situations and 
treatments on the metabolism of | paracetamol, i t  was necessary to 
examine the urinary metabolic profile  ofj paracetamol in a control 
group of normal subjects.
Drug metabolism is known to vary with age (Crooks, O'Malley and 
Stevenson, 1976). Thus i t  was important to structure the control 
group so that a wide age range was studied and 8 - 1 0  normal 
volunteers per decade of age were collected where possible. Many 
previous studies of drug metabolism with age have only compared 
young and old age groups and have measured drug half l i f e .  The 
present study a) measures metabolites and b) takes a spectrum of 
age. I t  thus constitutes one of the f ir s t  detailed examinations of 
drug metabolism with age.
Procedures
Human volunteers under 60yrs of age were hospital and laboratory 
workers or their children; those aged over 60 years were contacted 
through local general practitioners. Each volunteer was asked to 
record smoking habits and was questioned about other drugs taken. 
Paracetamol, Ig (or 500mg for those under ISyrs) was taken by each 
subject (23 males, 26 females) early in the morning after emptying 
the bladder and fasting overnight. All urine passed in the 
subsequent 8  hours (0 - 8 hour collection) and in the period 8 - 2 4  
hours after dosing ( 8  - 24hour collection) was collected in separate 
acidified polypropylene urine bottles. Urine was analysed by HPLC 
for the four major metabolites of paracetamol (that is , paracetamol 
glucuronide (PG), paracetamol sulphate (PS), paracetamol cysteine 




In this and subsequent studies in which paracetamol and its  
metabolites were quantified in urine, the amount of each metabolite 
was converted to the weight of paracetamol from which i t  had 
originated (conversion factors used appear in Appendix 1 ). The 
total recovery of paracetamol in each collection period was 
calculated from the sum of the metabolites, thus converted, and of 
unchanged paracetamol. The recovery of individual metabolites or of 
unchanged paracetamol was then expressed as a percentage of the 
to ta l.
Table 3.1.1 shows the percentage of the dose which was recovered in 
each collection period.
Table 3.1.1 Percentage of paracetamol and its  metabolites recovered 
in urine following administration of l.Og or 0.5g by mouth to 
healthy volunteees in a single dose (means * SEM)
Percentage dose excreted 
Collection period Mean SEM
0 - 8 h 49.21 3.31
8  - 24h 27.37 2.45
0 - 24h 76.59 4.53
No correlation was found between the percentage dose excreted and 
the age of the volunteers in either collection period or over the 
whole 24 hour period. Quantities of paracetamol and its  metabolites 
expressed in mg (converted to parent paracetamol as described above) 
and the percentage recovery of each metabolite in each urine 
collection period for each volunteer are given in Appendix 2 and 3 
respectively.
Table 3.1.2 shows means of the percentage total recovered amounts of 
paracetamol excreted unchanged and each of its  four metabolites in 
the collection periods.
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The amount recovered as paracetamol sulphate was significantly lower 
in the second ( 8  - 24h) urine collection period than the f ir s t  (0 - 
8 h) period (p<0.002). The decrease in the recovery of paracetamol 
sulphate in the second collection was accompanied by a significant 
increase in the percentage recovered as paracetamol cysteine plus 
paracetamol mercapturic acid (p<0.001). Recoveries of PM and PC 
individually were greater in the second than in the f ir s t  collection 
period (p<0.01). These results are plotted in Fig. 3 .1 .1 .
Table 3.1.3 shows the excretion of paracetamol and its  metabolites 
in each urine collection period. Results are presented for 
convenience in cohorts of ten years of age and are illustrated  in 
Figs. 3.1 .2 , 3.1.3 and 3.1.4.
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Fig. 3.1.1.
Percentage recovery of paracetanol and its metabolites in 
urine following administration of l.Og or O.Sg by mouth to 
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Inspection of Figs. 3 .1.2, 3.1.3 and 3.1.4 does not reveal an
obvious relation of individual metabolites with age. Therefore the
ratio of Phase I I  to Phase I metabolites was calculated, that is , 
the ratio of conjugated to oxidised plus conjugated metabolites or 
(PG + PS)/(PC + PM). Fig. 3 .1 .5 . shows that there was a clear 
relationship between this ratio  and age. However i t  can be seen 
that the scatter increases with age. S ta tis tica lly  in order to 
calculate a mathematical relationship, i t  is important that this 
scatter is approximately the same at a ll ages. Therefore the 
natural logarithm of the ratio  was calculated in order to minimize 
scatter in the higher age groups. Loĝ  ratio for each urine 
collection period is plotted against age in Figs. 3 .1 .6 , 3.1.7 and 
3.1.8 . I t  can be seen that the scatter is now similar at a ll ages 
and that the ratios in 0 - 8 h and 0 - 24h urine collections are 
significantly related to age while ratios in the 8  - 24h period do 
not reach significance. For the whole 24 hour period the following 
regression equation was obtained:
log^ [(PG + PS)/(PC + PM)] = 1.902 + 0.0093 (age)
The regression coefficient 0.0093 is more than Z h  times its  standard 
error of ± 0.0034 and thus is highly significantly different from 
zero (p<0.01). I t  is apparent from the equation that the ratio (PG 
+ PS)/(PC + PM) increases by just under 1% per year of age. The 
line for this equation is given in Fig. 3.1.8 as a fu ll lin e . A 
slightly closer relationship is given when natural logarithms of 
both the ratio and age are taken, giving
log^ [(PG + PS)/(PC + PM)] = 0.746 + 0.423 log^ (age).
The regression coefficient 0.423 is now more than 3 times its  
standard error of ± 0.134 and is significantly different from zero 
(p<0.01). This equation is shown as the dashed line in Fig 3 .1 .8 .
I t  can be seen that i t  accommodates the low values of log^ [(PG + 
PS)/(PC + PM)] in the two children and also brings out the fact that 






















































In order to examine the relationship of log^ [(PG + PS)/(PC + PM)] 
to lo 9 g age in more deta il, the recovery of the individual 
metabolites over the 0 - 24h collection period was considered 
separately. The natural logarithm of the amount of paracetamol 
glucuronide excreted was positively correlated with age (r  = +0.356, 
p<0.05) and the relationship may be expressed by the equation:
log^ PG% = 0.152 X log^ age - 1.225
The regression coefficient 0.152 has a standard error of = 0.058 and 
is  significantly different from zero (<0.02). In the 0 - 2 4  hour 
urine collection percentage recovery of paracetamol cysteine plus 
mercapturic acid was negatively correlated with age (r  = - 0.374, 
p<0 . 0 1 ) and the relationship is expressed by the equation:
log^ (PC + PM)% = - 0.355 x log^ age + 3.43.
The regression coefficient (-0.355) has a standard error of ± 0.121 
and is significantly different from zero (p<0.01). Recovery of 
paracetamol cysteine was negatively correlated with age (r = -0.486, 
p<0.01) in the 0 - 2 4  hour urine collection and the relationship may 
be expressed by the equation:
log PC%= -0.715 X log age + 0.663
The regression coefficient (-0.715) has a standard error of ± 0.188 
and is significantly different from zero (p<0.001). Correlations 
between paracetamol mercapturic acid and paracetamol sulphate and 
log^ of age were poor.
When the individual metabolites were examined in relation to age in 
the 0 - 8  hour and 8 - 2 4  hour collection periods, percentage 
recoveries of (PC + PM) and PC decreased significantly with age in 
the f ir s t  8  hours of collection (p<0 . 0 2  and p<0 . 0 0 1  respectively).
In the 8 - 2 4  hour collection period (PC + PM) and PC decreased with 
age at a similar rate to
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that of the f ir s t  8  hour period but the scatter was so much greater 
that statis tica l significance was not attained. Percentage recovery 
of PG was not related to age in the 0 - 8  hour period but increased 
with age in the 8  - 24 urine collection period (p<0.05).
In summary, the decrease in percentage recoveries of(PC + PM)and PC 
with age in the f ir s t  8  hours and the increase with age of the 
percentage recovery of PG in the 8 - 2 4  hour period served to 
increase the ratio of Phase I I  in the 0 - 8  hour period. Figs. 3.1.9
Phase I
3.1.10 and 3.1.11 show percentage recovery of paracetamol 
glucuronide plotted against age. For c la rity , percentage recoveries 
of metabolites are plotted against age without transformation so 
that the scatter of results can be seen. Fig. 3.1.12 shows the 
percentage recovery of paracetamol cysteine plus paracetamol 
mercapturic acid plotted against age and Fig. 3.1.13 shows the 
relation of paracetamol cysteine alone with age. Finally a ll the 
analyses were repeated excluding the ten volunteers under the age of 
30. This is because, as has been already described, the trend with 
age is in general less marked in the older volunteers and its  
overall significance may have been disproportionally affected by 
values found in the younger volunteers.
In volunteers aged over 30 years the following findings were made: 
the percentage recovery of paracetamol glucuronide increased with 
age but not now to a s ta tis tic a lly  significant extent, the 
percentage recovery of paracetamol sulphate was unrelated to age; 
the percentage recovery of paracetamol cysteine decreased with age 
but not to a s ta tis tic a lly  significant extent and the percentage 
recovery of paracetamol mercapturic acid was unrelated to age. The 
ratio Phase I I/Phase I metabolites s t i l l  increased with age but not 
to a s ta tis tic a lly  significant extent.
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Fig. 3.1.9.
Percentage recovery of paracetamol glucuronide from healthy 
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Fig. 3.1.12 Percentage recovery of paracetamol cysteine plus 
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Fig. 3.1.13.Percentage recovery of paracetamol cysteine frcm healthy 
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Thus the changes in metabolic pattern with age are slight and only 
reach s tatis tica l significance when results from the under 30s are 
i Deluded.
There were also significant correlations between recoveries of 
individual metabolites. PG was significantly negatively correlated 
with PS (p<0.001), PC (p<0.01), PM (p<0.05) and PC + PM (p<0.001) in 
both urine collection periods and over the whole 24 hours. PS was 
negatively correlated with unchanged paracetamol in each period 
(p<0.05).
These results are plotted in Figs. 3.1.14, 3.1.15, 3.1.16, 3.1.17, 
3.1.18, 3.1.19 and 3.1.20.
In order to compare the metabolism of paracetamol in normal 
volunteers a fter a therapeutic Ig dose with the metabolism of 
paracetamol under conditions such as disease or overdose two further 
ratios were calculated; namely (PG + PS)/(PC + PM) and PG/PS. The 
ratios PG/PS and (PG + PS)/(PC + PM) were chosen for the following 
reasons: because the amount of paracetamol ingested has to be fa ir ly  
large before glucuronic acid is depleted or glucuronyl transferase 
activ ity  is saturated the ratio  PG/PS reflects the recovery of 
paracetamol sulphate i .e .  i f  PG/PS increases this suggests a 
decrease in recovery of paracetamol sulphate and vice versa. The 
ratio  (PG + PS)/(PC + PM) increases when either paracetamol sulphate 
recovery increases (which would be obvious from the PG/PS ratio ) or 
when (PC + PM) fa lls . The ratio  (PG + PS)/(PC + PM) decreases 
either when paracetamol sulphate recovery decreases (which shows up 
in the PG/PS ratio) or when (PC + PM) recoveries increase.
Therefore the two ratios summarise the metabolic patterns of 
paracetamol sulphate and paracetamol cysteine plus mercapturic 
acid. Mean values of this ratio  in each collection period are given 
in Table 3 .1 .4 .
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Fig. 3.1.14 Percentage recovery of paracetamol glucuronide and 
paracetamol sulphate after administration of 
paracetamol Ig by mouth to healthy volunteers
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Fig. 3.1.15 Percentage recovery of paracetamol glucuronide and 
paracetamol sulphate after administration of 
paracetamol Ig by mouth to healthy volunteers
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Fig. 3.1.16. _Percentage recovery of paracetamol glucuronide and paracetamol 
sLdfbate after administration of paracetamol l.Og l:y mouth to 
healthy volunteers
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Fig. 3.1.17. Percentage recovery as paracetamol cysteine plotted against 
percentage recovery as paracetamol glucuronide
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Fig. 3.1.18. Percentage recovery as paracetamol mercapturic acid plotted 
against percentage recovery of paracetamol glucuronide
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.Fig. 3.1.19. .
Percentage recovery as paracetamol cysteine plus paracetamol 
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Fig, 3.1.20 Percentage recovery of paracetamol sulphate plotted against 
percentage recovery of unchanged paracetamol
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Table 3.1.4 PG/PS and (PG+PS)/(PC+PM) ratios in each collection
(PG+PS)/(PC+PM) PG/PS
0 - 8 h 14.84 ± 1.14 1.80 ± 0.19
8  - 24h 10.09 ± 0.97 3.64 ± 0.72
0 - 24h 11.29 ± 0.82 1.83 ±  0.13
Table 3.1.4 shows that the ratio (PG + PS)/(PC + PM) was 
significantly lower in the 8  -  24h period than the 0 - 8 h period 
(p<0 . 0 1 ) reflecting the increased recovery of paracetamol cysteine 
and mercapturic acid in the second collection period which has 
already been described. The ratio  PG/PS was significantly higher in 
the 8  - 24h collection compared with the 0 - 8 h interval (p<0.02) 
reflecting the decrease in recovery of paracetamol sulphate in the 
second collection period.
In order to determine the values of these ratios after a higher dose 
of paracetamol, a study was carried out in 4 normal volunteers each 
of whom took paracetamol 2.5g orally after fasting overnight and 
collected urine two hourly for ten hours. Individual details and 
recovery of paracetamol and its  metabolites in mg and expressed as a 
percentage are given in Appendix 4.2. Percentage recoveries of each 




Percentage recoveries of unchanged paracetamol and its  metabolites after 
administration of paracetamol 2.5g to 4 healthy volunteers by mouth.
Time
(h) n P PG PS PC PM PC + PM
2 4 7.81*1.49 60.77*4.98 25.91*3.68 4.29*0.81 1 . 2 1 * 0 . 1 2 5.50*0.78
4 4 4.36*1.07 73.54*3.15 17.00*1.36 2.88*0.96 2.22*0.32 5.10*0.78
6 4 2.68*0.47 67.98*3.46 22.78*3.32 3.33*0.42 3.21*0.52 6.55*0.38
8 3 1.58*0.13 70.53*4.30 20.54*3.67 3.77*0.41 3.58*0.57 7.35*0.88
1 0 4 1.04*0.20 71.19*3.63 20.23*2.68 3.71*0.29 3.84*0.53 7.56*0.33
Percentage recoveries of unchanged paracetamol decreased significantly  
when 8  and 10 hour values were compared with values at 2 hours (p<0.05) 
but percentage recoveries of the metabolites did not change significantly  
with time.
The ratios (PG + PS)/(PC + PM) and PG/PS were calculated for each sample 
for each individual and means and standard errors of the values are given 
in Table 3.1.6.
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Table 3.1 .6 .
(PG + PS/(PC + PM) and PG/PS ratios with time in 4 healthy 
volunteers after paracetamol 2.5g by mouth
Time (h) (PG + PS)/(PC + PM) PG/PS
2 16.79 ± 2.46 2 . 6 6  ± 0.76
4 20.54 ± 4.49 4.39 * 0.65
6 14.92 * 1.21 3.19 * 0.48
8 12.86 * 1.91 3.70 * 0.75
1 0 12.18 * 0.57 3.78 ±  0.66
(PG + PSy(PC + PM) values after paracetamol 2.5g were significantly  
higher at 2, 4 and 6  hours after ingestion than in 8  - 24h urine and 
at lOh compared with 0 - 8 h urine after paracetamol l.Og (p<0.05) 
(See Table 3.1.4) but at la te r times the ratios were not 
significantly different from values calculated for the Ig dose.
These in it ia l high values are probably due to increased conjugation 
of paracetamol with glucuronic acid and sulphate at the higher 
dose. However, (PG + PS)/(PC + PM) and PG/PS values given in Table 
3.1.6 were not significantly different during the whole ten hours. 
PG/PS values from 4h onwards after 2.5g paracetamol were 
significantly higher than 0 - 8 h and 0 - 24hour values but not 8  - 
24h values after Ig paracetamol (p<0.05) (See Table 3 .1 .6 ). This 
suggests that sulphate depletion occurred with the 2.5g dose but not 
to any greater extent than that seen after the Ig dose in the 8  - 
24h urine collection period.
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3.2 Neonatal Metabolism of Paracetamol 
Introduction
The writer is unaware of any previous studies of paracetamol 
metabolism in the neonate. Because of ethical d iffic u ltie s  in 
giving paracetamol to neonates, in this study the metabolism of 
paracetamol has been studied in neonatal urine after administration 
of paracetamol to nursing mothers for analgesic purposes so that 
infants ingested paracetamol from breast milk. I t  is like ly  that 
unchanged paracetamol but not its  more polar metabolites can cross 
from mother to infant via breast milk and paracetamol but not its  
metabolites was found in breast milk by Notarianni (1981) (personal 
communication) and i t  was shown by Berlin, Yaffe and Ragni (1980) 
that paracetamol did indeed appear in breast milk. Although these 
authors could not detect paracetamol or its  metabolites in neonatal 
urine, in the present study both parent drug and metabolites were 
found in nursing infants' urine. The metabolites of paracetamol and 
unchanged drug were therefore quantified in neonatal urine after 
maternal ingestion of paracetamol in order to assess the metabolic 
capacity of the infant as described in Chapter 2.
Procedures and Results
Urine was obtained from 6  neonates (mean age * SEM = 3.3 * 0.92 
days) after mothers had taken l-3g paracetamol up to eight hours 
before breast feeding.
Times at which mothers ingested paracetamol, times of breast feeding 
and neonatal urine collection, maternal dose and recovery of 
paracetamol in neonatal urine are given in Table 3 .2 .1 . Larger 
recoveries of paracetamol were obtained from neonates whose mothers 
took 2 or more grams of paracetamol. Recoveries in the urine of the 
twins (R.M.) were different probably due to different urine volumes 
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Table 3.2.2 shows means ± SEM of concentrations and percentage recovery 
of paracetamol and its  metabolites in urine of these 6  neonates compared 
with mean percentage recoveries in the control study (Section 3 .1 ).
Table 3 .2 .2 . Means * S.E.M. of total amount and percentage recoveries of 
paracetamol and its  metabolites excreted by neonates compared with 
percentage recoveries in the control study
P PG PS PC + PM
Neonates
Total amount (ug) 120.02*67.32 177.13*64.44 68.71*23.87 84.24*26.78
Range (n=6 ) 2.91-432.40 17.71-348.52 2.35-150.06 0-158.04
Percentage recovery 24.85*6.65 54.14*5.96 9.85*1.92 11.13*3.19
Range (n=6 ) 9.53-46.90 32.82-71.27 4.98-18.25 0-20.47
Control Study
percentage recovery 4.82*0.59 53.46*1.35 32.79*1.16 9.01*0.49
in 24 hours after  
paracetamol Ig
Variations in amount excreted in neonatal urine are introduced by 
differences in milk intake by the infants and in the length of time 
between the mother's ingestion of paracetamol and breast feeding. 
Nevertheless, i t  is  apparent that the neonates excreted a significantly  
larger amount of unchanged paracetamol (p<0.05) and significantly lesser 
amounts of paracetamol sulphate (p<0 . 0 0 1 ) compared with normal 
volunteers. Thus even i f  some metabolites were ingested by the neonates 
in breast milk, the amount of unchanged paracetamol recovered in neonatal 
urine was s t i l l  greater than in the control study.
Individual recoveries in the neonates expressed in ug and as percentages 
are given in Appendix 5.1 and 5.2 respectively.
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3.3 Paracetamol Metabolism in Patients with Rheumatoid A rth ritis  
Introduction
The metabolism of paracetamol was investigated in 22 in-patients aged 
between 36 and 78 years in the Royal National Hospital for Rheumatic 
Diseases in Bath. All twenty two were diagnosed by consultant 
rheumatologists as having rheumatoid a rth ritis  using the c rite ria  of the 
American Rheumatism Association (see Appendix 6 ) .  All 22 took 
paracetamol for analgesic purposes during their stay but were also taking 
other drugs as detailed in Appendix 7. There do not appear to have been 
any studies previously carried out on paracetamol metabolism in patients 
with rheumatoid a rth rit is . The metabolism of paracetamol could 
potentially be altered by the disease state its e lf ,  by concurrent therapy 
with other drugs or by the large amounts of paracetamol taken by patients 
with this disease.
Procedures
Urine was collected from 0 - 8 h and 8-24h in separate acidified urine 
bottles a fter paracetamol (Ig) was taken orally in the early morning. 
Urine was assayed for paracetamol and its  major metabolites by HPLC as 
described in Section 2 .7 .e ( i) .  Several patients took extra Ig doses of 
paracetamol during the 24 hours of the study and details of dosages 
obtained from hospital drug records are given in Appendix 7.
Results
Appendix 8  gives individual values of the total quantities of paracetamol 
and its  metabolites recovered and Appendix 9 shows individual values of 
the percentage recoveries of paracetamol and its  metabolites in each 
collection period for the 2 2  patients.
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Table 3.3 shows the mean percentage recoveries of paracetamol and 
its  metabolites in the 0-8h, 8-24h and 0-24h urine collection 
periods in those patients. Results over the whole 24 hour 
collection period are compared with control 0-24 hour values from 
normal volunteers after a Ig dose in Fig. 3 .3 . Significantly  
greater amounts of the glucuronide (p<0 . 0 0 1 ) ,  lesser amounts of 
sulphate (p<0 . 0 0 1 ) and lesser amounts of unchanged paracetamol 
(p<0.005) were recovered from the rheumatoid patients than from the 
controls. Percentage recoveries of the cysteine and mercapturic 
acid metabolites of paracetamol were not significantly different 
from control values.
Table 3.3 Means * S.E.M. of percentage recovery of paracetamol and 
its  metabolites in 2 2  rheumatoid patients
PG PS PC + PM
0-8h 2.75 * 0.42 60.74 * 2.50 27.53 * 2.41 8.83 ± 0.99
8-24h 2.48 * 0.45 64.78 * 1.68 23.20 ± 1.51 9.53 ± 0.78
0-24h 2.43 ± 0.37 68.13 * 1.88 25.00 * 1.52 9.38 ±  0.78
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Piç. 2.3.
ftecân^ge recovery of paracetamol and its metabolites in 
urine collected for 24 hours coiparing patients with rheumatoid 
arthritis after varying amounts of paracetamol taken by mouth 
with normal volunteers after paracetamol l.Og taken moutii 
















3.4 Metabolism of Paracetamol in Patients with Thyroid Disease 
Introduction
When thyroid function is altered, a series of physiological effects 
occur which are like ly  to affect drug absorption, metabolism or 
excretion (Shenfield, 1981). Forfar, Pottage, Toft, Irvine,
Clements and Prescott (1980) reported that in thyrotoxic patients 
paracetamol absorption was faster; there was also an apparent 
increase in total body clearance and shorter plasma h a lf - l ife  of 
paracetamol than when these patients subsequently became euthyroid. 
On the basis of antipyrine h a lf - l i fe ,  Shenfield (1981) demonstrated 
acceleration of hepatic metabolism in hyperthyroid patients and 
reduced metabolism in hypothyroid patients. Induction or inhibition  
of the hepatic mixed function oxidase system may have implications 
for the toxicity of paracetamol which may be increased i f  the rate 
of formation of the reactive intermediate is enhanced or the 
ac tiv ity  of glutathione transferase diminished. Therefore the 
effects of thyroid disease on paracetamol metabolism were 
investigated in 7 hyperthyroid patients.
Procedures
Patients whose serum thyroxine levels were in excess of 135nmol/l 
(Bold and Wilding, 1975) were admitted to the study. The patients 
took paracetamol l.Og by mouth with water in a single dose. Urine 
was collected over 0-8h and 8-24h periods and concentrations of 
paracetamol and its  metabolites were measured by HPLC.
Resul ts
Details of these 7 patients appear in Table 3 .4 .1 .
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A.M. M 61 57.5 268 >300
I.H . F 74 not measured 194 194
A. A. F 53 62.0 233 281
H.R. M 75 70.0 280 230
E.C. F 70 57.6 199 183
D.S. F 48 54.0 >300 275
G.G. F 74 63.5 176 146
Table 3.4.2 Means * S.E.M. of percentage recovery of paracetamol 
and its  metabolites in the 7 hyperthyroid patients
P PG PS PC PM PC * PM
0 - 8 h 5.38*1.42 55.86*4.20 31.79*3.67 2.94*0.33 4.04*0.75 6.97*0.74
8-2 4h 7.32*1.73 58.74*4.64 24.65*3.46 3.98*0.68 5.30*1.68 9.29*2.17
0-2 4h 5.66*1.10 57.30*4.15 29.55*3.48 3.20*0.34 4.28*0.84 7.49*0.88
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Table 3 .4 .2 . gives the percentage recoveries of paracetamol and its  
metabolites in 7 hyperthyroid patients. In Section 3.1 (the control 
study) i t  was shown that in normal volunteers percentage recoveries 
of paracetamol sulphate and paracetamol cysteine plus paracetamol 
mercapturic acid were significantly different in 0-8 hour and 8-24 
hour urine collections. In the hyperthyroid patients however the 
percentage recoveries of paracetamol and its  metabolites were not 
significantly different in the two collection periods (p>0.05).
When values from these hyperthyroid patients were compared with 
values from normal volunteers in the control study (see Fig. 3 .4 ), 
no significant differences in the percentage recoveries of 
paracetamol and its  metabolites were found in either urine 
collection or over the whole 24 hours.
An attempt was made to correlate the percentage recoveries of 
paracetamol and its  metabolites excreted in urine with individual 
FTI and thyroxine levels but no relationship was found.
Appendix 10 gives total amounts of unchanged paracetamol and its  
metabolites in mg for each individual. Appendix 11 gives the same 
values corrected for percentage recovery.
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Fig. 3.4.~^£centage recovery of paracetamol and its metabolites in 
urine collected for 24 hours ccnparing patients with sensn 
thyroxine concentrations greater than 135nmol/l with normal 



















3.5 Effect of Sallcylamide on Paracetamol Metabolism in Man 
Introduction
Sulicylamide is a mild analgetic and antipyretic which is now rarely 
used in the United Kingdom. The drug is however of interest in that 
i t  is largely conjugated with endogenous glucuronic acid and sulphate 
(Levy and Yamada, 1971). Sallcylamide thus constitutes a potentially  
useful model of a drug which may compete with paracetamol for 
sulphate and glucuronic acid. Any effects observed which can be 
attributable to the competing effects of this drug may also apply to 
other drugs taken concurrently with paracetamol which also conjugate 
with sulphate and glucuronic acid.
The work was undertaken to explore the possibility that an agent 
which competes with paracetamol for metabolic substances may decrease 
amounts of paracetamol excreted as its  glucuronide and sulphate 
conjugates thus making available increased amounts of unchanged 
paracetamol for oxidation by the mixed function oxidase system and 
increasing its  potential for hepatotoxicity.
Procedures
Two experiments were carried out:
Experiment 1:
Six normal volunteers took paracetamol l.Og by mouth with 
100ml HgO after an overnight fast. Venous blood samples 
were taken immediately before ingestion of paracetamol and 
thereafter at 45 minute intervals for 5.25h. Urine was 




Seven days la te r. Experiment 1 was repeated in the same six 
volunteers but in addition sallcylamide Ig was taken twice by 
mouth half an hour before and 2  hours after the Ig oral dose 
of paracetamol. Sallcylamide was given each time as its  
sodium salt in a final volume of 200ml. Preparation of the 
sallcylamide solution is  described in Section 2.1.d.
Urine and serum samples were analyzed by HPLC as described in 
Section 2.7 e i .  Total amounts of each urinary and serum 
metabolite were corrected for molecular weight. Urinary 
results are presented as percentage recovery.
The serum half l i f e  of paracetamol was calculated for each 
volunteer in each experiment, in addition the area under the 
serum concentration time curves (AUG) for paracetamol and its  
glucuronide and sulphate conjugates was calculatd by the 
trapezoidal rule described by Natari (1975) up to 315 minutes 
after administration of paracetamol.
Resul ts
Table 3 .5 .1  gives details  of the volunteers studied In experiments 1 
and 2.
Table 3 .5 .1  Details of volunteers studied In Experiments 1 and 2
Age Weight C igarette Alcohol Tea & Coffee
Volunteer (years) Sex (kg) usage consumption Ingestion per day
B 22 M 79 Non smoker 3-4 pints beer 
per day
3% pints tea
Pa 21 M 76 15 cigarettes  
per day
3-4 pints beer 
per day
3 pints tea
S 26 M 92 20 c igarettes  
per day
3 pints beer 
per day
2H pints coffee
Ha 25 F 58 Ex smoker 2 gins per week 2 pints coffee  
/tea
Pe 42 M 82 Non smoker 2 glasses wine 
per day
2 pints coffee 
/te a
He 22 F 44 Non smoker 1 p in t beer 
per day
2 pints coffee  
/te a
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Table 3 .5 .2 . gives the mean percentage recovery of paracetamol and its  
metabolites in urine for both experiments.
Table 3 .5 .2 . Mean * S.E.M. percentage recovery of the major metabolites 
of paracetamol and unchanged paracetamol in 6  healthy volunteers 
following paracetamol l.Og taken alone (Expt. 1) and following 
paracetamol l.Og taken with salicylamide 2.0g (Expt. 2) (Details of drug 
administration appear in the te x t).
P PG PS PC PM PC + PM
0 - 8 h
Expt.l 3.32*0.60 56.52*6.21 34.76*5.49 1.82*0.26 3.57*0.60 5.88*0.38 
Expt.2 4.28*0.56 67.53*5.70 22.57*5.39 2.28*0.22 3.33*0.63 5.86*0.79
8-2 4h
Expt.l 5.16*0.78 59.34*5.47 28.57*5.44 2.84*0.26 3.73*0.32 6.77*0.59
Expt.2 3.68*0.85 70.32*6.76 18.79*6.61 3.22*0.26 4.00*0.76 7.70*0.76
0-2 4h
Expt.l 4.26*1.08 58.92*6.10 30.80*5.71 2.27*0.17 3.74*0.34 6.30*0.42
Expt.2 3.98*0.50 68.43*5.90 21.26*5.58 2.70*0.22 3.62*0.62 6.50*0.83
Table 3.5.2 shows that the percentage recovery of paracetamol sulphate 
was considerably lower when salicylamide was taken (Expt. 2) than in the 
control study (Expt. 1) in the 0-8 hour urine collection (p<0.005). In 
8-24 hour urine there was no significant difference between Experiments 1 
and 2. In the second collection period, paracetamol glucuronide 
excretion increased after salicylamide (p<0.02). Over the whole 24 hour 
period, paracetamol sulphate was less (p<0 . 0 2 ) when salicylamide and 
paracetamol were taken together compared with paracetamol given alone. 
There were no significant changes in the excretion of the other 
metabolites in the 24 hour urine. Percentage recoveries of paracetamol 
and its  metabolites in each urine collection are shown in Fig. 3 .5 .1 .
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Fig. 3.5.1 Percentage recovery of paracetamol and its  
metabolites in 0 - 8  hour, 8 - 2 4  hour and 
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Concentrations of paracetamol, paracetamol sulphate and paracetamol 
glucuronide in serum measured in both experiments appear in Tables
3.5.3. and 3.5.4. and are shown graphically in Figs 3.5.2, 3.5.3 and
3.5.4. I t  can be seen that when paracetamol was taken with 
salicylamide, serum concentrations of paracetamol were significantly 
greater (p<0.05) from 135 to 360 minutes after dosing than when 
paracetamol was given alone. From Table 3.5.4. and Fig. 3.5.3 i t  
can be seen that serum concentrations of paracetamol sulphate were 
significantly lower when salicylamide was given with paracetamol in 
Experiment 2 from 45 minutes to 180 minutes (p<0.05) than 
corresponding times in Experiment 1 when paracetamol was given 
alone. Paracetamol glucuronide concentrations were significantly 
higher after salicylamide (Experiment 2) only at the 225 minute 
measurement as shown in Table 3.5.4 and Fig 3 .5 .4 ..
The half l i f e  of paracetamol in serum was calculated for each 
volunteer in both experiments and values compared using the paired 
' t '  test (Table 3 .5 .5 .) . The h a lf-life  of paracetamol was found to 
be significantly longer after salicylamide than when paracetamol was 
taken alone (p<0.025). The area under the serum paracetamol 
concentration time curve (AUC) was found to be significantly greater 
after salicylamide than for paracetamol taken alone (p<0.01). AUC 
for paracetamol glucuronide was not altered but the AUC for 
paracetamol sulphate was significantly decreased by salicylamide 
administration (p<0.01). Values for paracetamol half l i fe  and AUCs 
for paracetamol, paracetamol glucuronide and paracetamol sulphate 
calculated from 0 min to 315 mins are given in Table 3.5.5.
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Table 3.5.3 Concentrations of paracetamol in serum (ug/ml) in the 
control study (Experiment 1) and after salicylamide 
(Experiment 2) (Means * SEM)
Time
Experiment 1 Experiment 2
Paracetamol (ugAnl ) Paracetamol (ug/ml)
-30 m ns - Ig SAM
0  m ns Ig paracetamol Ig paracetamol
0  m ns 0.16 ± 0 . 1 2 n= 6 0 . 1 0 ± 0.07 n= 6
45 m ns 3.44 ± 0.17 n= 6 4.02 ± 0.53 n= 6
90 m ns 3.24 * 0.34 n= 6 3.52 0.35 n= 6
1 2 0  m ns - Ig SMA
135 m ns 2.87 ± 0.32 n= 6 3.61 ± 0.33 n= 6
180 m ns 1.92 ± 0.36 n= 6 3.14 1 0.30 n= 6
225 m ns 1.51 ± 0.31 n=5 2.28 ± 0 . 2 0  n= 6
270 m ns 1.14 ± 0 . 2 1 n= 6 1.87 ± 0.21 n=5
315 m ns 0 . 8 6 ± 0 . 2 1 n= 6 1.40 ± 0.18 n= 6
SAM - salicylamide
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Table 3 .5 .4 .
Time
Concentrations of paracetamol glucuronide and paracetamol 
sulphate in serum (ug/ml, corrected for molecular 
weight*) in the control study (Experiment 1) and after 
salicylamide (Experiment 2)
Experiment 1 Experiment 2
PG(ug/ml) PS(ug/ml) PG(ug/ml) PS(ug/ml)
-30 mins - Ig SAM
0  mins n Ig paracetamol n Ig paracetamol
0  mins 6 0.37*0.14 0.71*0.71 6 0 . 0 0 *0 . 0 0 0 . 0 0 * 0 . 0 0
45 mins 6 1.18*0.26 1.09*0.16 6 1.08*0.18 0.16*0.16
90 mins 6 2.50*0.49 1.41*0.21 6 3.48*1.34 0.16*0.16
1 2 0  mins Ig SAM
135 mins 6 3.18*0.69 1.25*0.20 6 3.03*0.54 0.16*0.16
180 mins 6 2.86*0.56 0.94*0.34 6 3.03*0.51 0.31*0.20
225 mins 5 2.64*0.56 0.56*0.23 6 2.96*0.64 0 . 0 0 *0 . 0 0
270 mins 6 2.07*0.30 0.47*0.32 5 2.73*0.41 0 . 0 0 * 0 . 0 0
315 mins 6 1.61*0.30 0.31*0.20 6 2.19*0.52 0 . 0 0 * 0 . 0 0
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Table 3 .5 .5 . Half l i f e  of paracetamol and AUC for paracetamol,
paracetamol glucuronide and paracetamol sulphate for each 
volunteer In Experiment 1 and Experiment 2
Half l i f e  of AUC paracetamol
paracetamol AUC paracetamol glucuronide AUC paracetamol 
(min) ug min/ml ug rain/ml sulphate ug (min)
Volunteer Expt. 1 Expt. 2 Expt. 1 Expt. 2 Expt. 1 Expt. 2 Expt. 1 Expt.
He 165.0 165.0 913.06 1149.64 703.84 1049.64 210.56 0.00
Ha 90.0 107.9 748.99 906.35 1261.62 1189.10 170.14 0.00
3 86.6 147.4 595.62 949.24 345.35 381.63 602.40 133.95
Pa 86.6 144.4 502.76 795.01 675.02 554.78 125.96 0.00
Pe 115.5 162.7 634.02 852.90 460.66 639.43 400.44 0.00
S 115.5 133.5 541.97 627.72 636.88 581.94 191.29 0.00
Mean 109.9 143.5 656.07 880.14 680.56 732.75 283.46 22.32
S.E.M. 12.4 8.6 62.00 70.66 129.21 128.46 74.58 22.32
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When the data from the volunteers in Experiment 1 are compared with 
those in the control study (Section 3.1) who took paracetamol l.Og 
no significant differences were found in the percentage urinary 
recoveries of unchanged paracetamol paracetamol glucuronide and 
paracetamol sulphate. However, the six volunteers in Experiment 1 
excreted a significantly lower amount of paracetamol cysteine 
(p<0.001) over the 0-8h, 8-24h and 0-24h collection periods and 
significantly less paracetamol mercapturate in the 8-24h (p<0.002) 
and 0-24h (p<0.05) urine collections than did subjects in the 
control study (Section 3 .1 ). Percentage recovery of(PC + PM)was 
significantly lower in the 6  volunteers in Experiment 1 in 0-8h 
(p<0.02), 8-24h (p<0.001) and 0-24h urine (p<0.01) than in the 
control study.
Appendix 12 gives individual values of paracetamol and its  
metabolites in mg excreted in urine for Experiment 1 and 2.
Appendix 13 gives individual values of percentage recovery of 
paracetamol and its  metabolites in urine for both experiments. 
Appendix 14 gives serum concentrations of paracetamol, paracetamol 
glucuronide and paracetamol sulphate for both experiments.
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3.6 Patients with Paracetamol Overdose 
Introduction
Overdose is the most important and common circumstance in which 
paracetamol toxicity is found. The metabolic mechanism of the 
toxicity of paracetamol has already been described (Section 1.4. 
1 . 2 ); a certain proportion of a therapeutic dose of paracetamol is 
believed to be converted to a reactive intermediate which combines 
with glutathione before excretion. In overdose however, there is 
insufficient glutathione to cope with the increased amounts of 
active metabolite formed and liv e r  damage may occur as a result of 
alkylation of hepatic macromolecules by the toxic intermediate. The 
normal treatment for paracetamol poisoning, as discussed in Section
1.4 .1 .4 , is L-methionine by mouth or j^acetyl cysteine 
intravenously. These antidotes should be given within 10 hours of 
ingestion of the overdose. After this time covalent binding of 
paracetamol to liv e r  macromolecules has probably occurred and giving 
amino acids to a damaged liv e r may provoke hepatic encephalopathy. 
The metabolic profile of paracetamol was therefore studied after 
high doses of the analgesic had been ingested by patients who 
attempted suicide, in order to determine the metabolism of 
paracetamol in overdose and the effects that these antidotes had on 
paracetamol metabolites.
Procedures
Patients were managed as follows:
after gastric lavage had been performed in the Casualty Department 
of the Royal United Hospital, Bath, a urine sample was collected 
where possible. Methionine 2.5g was then administered through the 
washout tube. Blood was taken for measurement of paracetamol 
concentration. Patients were then transferred to the Clinical
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Pharmacology Unit. Subsequent management depended on the result of 
the plasma paracetamol concentration estimation in relation to the 
recommended treatment schedule issued by Duncan, Flockhart, and Co. 
manufacturers of Parvolex (see overleaf). Patients in whom plasma 
paracetamol concentrations indicated treatment with acetyl 
cysteine received this drug. Those patients in whom plasma 
paracetamol concentrations indicated that treatment with ^-acetyl 
cysteine was not necessary received L-methionine by mouth. Urine 
samples were collected at approximately 2  hourly intervals in 
acidified urine containers and were assayed for paracetamol 
glucuronide, paracetamol sulphate, paracetamol cysteine, paracetamol 
mercapturic acid and unchanged paracetamol as previously described.
Results
Results are presented separately for each individual because the 
number of tablets ingested varied widely between patients.
Tables 3.6.1 - 3.6.10 show results from 10 overdosed patients.
Since doses ingested were usually unknown or unreliably reported, 
records are given of total amounts of paracetamol and its  
metabolites recovered and expressed in mg normalized to the 
molecular weight of paracetamol for each urine sample. Times at 
which patients reported they ingested paracetamol and total intake 
are recorded where this information is available. The ratios of 
(PG)/(PS) and (PG + PS)/(PC + PM) are also calculated for each urine 
sample. I t  can be seen that for many patients, as the treatment 
progresses the ratios of (PG)/(PS) and (PG + PS)/(PC + PM)
decrease. Two graphs are plotted, the f ir s t  showing these two
ratios for the patient described in Table 3.5.1 and the second 
showing the these ratios of the patient described in Table 3.5.10. 
for purposes of illus tra tion  (Figs. 3.6.1 and 3 .6 .2 ).
Both these patients are compared with normal volunteers described in 
Section 3.1 who had ingested paracetamol 2.5g and collected urine 2 
hourly for ten hours. Values of (PG)/(PS) and (PG + PS)/(PC + PM)
ratios for these normals are given in Table 3 .1 .6 .



















Table 3 .6 .1
P I, Female, 49 y r.
PG+PS
Time Event P PG PS PC+PM PG/PS PC+PR
16.00 Admission 150.67 408.97 24.93 15.34 16.40 28.28
16.20 Methionine 
2.5g P.O .
17.00 MAC, 9g l . v .
17.15 MAC, 3g l . v .
19.15 1544.62 3939.70 307.75 304.49 12.80 13.95
21.20 MAC, 6g l . v .
22.30 1027.05 5752.31 1827.39 696.04 3.19 10.89
03.00 332.50 2311.96 710.61 197.94 3.25 15.27
05.30 56.35 1442.93 446.11 167.96 3.23 11.25
07.00 4.18 97.68 31.05 19.71 3.14 6.53
08.30 6.02 131.25 41.54 35.49 3.16 4.87
Total 3121.39 14084.80 3389.38 1421.63
Total recovery of paracetamol In  urine « 22017.20mg
In th is patient the ratios o f (PG)/(PS) and (PG+PS)/(PC+PM) were In i t ia l ly  
large suggesting both sulphate and glutathione a v a ila b ility  were 
compromised. However, a fte r  treatment both ratios decrease with time.
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Table 3 .6 .2  
P2, Male, 49 y r .
PG+PS
Time Event P PG PS PC+PM PG/PS pC+Pm
13.00 ingestion of 100 tablets of paracetamol SOOrag
18.40 Methionine 2.5g p.o.
21.00 1946.70 4152.92 o.od* 298.45 13.91
21.30 NAc 10.5g i .v .
21.45 NAc 3.5g i .v .
23.30 212.07 936.39 20.63 229.17 45.39 4.18
01.00 176.15 833.48 17.06 200.88 48.85 4.23
02.00 MAC 7.0g i .v .
02.15 126.00 1317.11 66.12 160.88 19.92 8.60
11.50 6.63 721.55 95.07 60.75 7.59 13.44
15.30 9.10 284.18 39.95 36.29 7.11 8.93
17.30 1.66 40.15 6.66 9.07 6.03 5.16
22.00 2.87 83.49 18.13 -11.86 4.60 8.57
07.45 4.57 112.40 13.68 18.66 8.22 6.76
Total 2309.60 8481.67 277.30 1026.01
Total recovery of paracetamol in urine * 12094.58mg.
This table shows that in t ia l ly  no paracetamol sulphate was excreted but 
a fte r treatment with ^-acetyl cysteine and L-methionine paracetamol sulphate 
recovery in urine was increased.
* naracetamol sulphate mav have been hvdrolvsed bv bacteria or acid
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Table 3 .6 .3  
P3. Male. 31 y r .
PG+PS
Time Event P PG PS PC+PM PG/PS PC+PM
06.00-18.00 Ingestion o f 100 tablets of paracetamol SOOmg
05.00 Admission
06.00 Methionine
















571.88 3872.43 702.33 1011.17 5.51 4.52
06.30 248.12 1971.01 747.84 662.29 2.64 4.10
15.00 189.75 738.61 438.16 415.14 1.68 2.83
02.20 21.48 224.46 115.72 89.62 1.94 3.80
06.00 39.52 403.87 185.70 126.35 2.17 4.67
13.10 18.12 203.65 112.38 93.28 1.81 3.39
109
Table 3 .6 .3  Continued
P3, Male, 31 y r .
PG+PS
Time Event P PG PS PC+PM PG/PS PC+PM
16.15 5.79 75.79 32.55 28.37 2.33 3.82
19.00 9.68 55.54 66.96 43.31 0.83 2.83
01.30 9.76 52.86 54.03 44.39 0.'98 2.41
22.00 6.66 24.72 . 22.62 19.55 1.09 2.42
11.00 10.92 6.05 48.44 11.79 0.12 14.62
11.15 9.21 18.76 40.17 27.02 0.47 2.18
16.30 12.84 43.30 56.84 39.92 0.76 3.35
21.00 4.58 2.59 19.73 8.68 0.13 2.57
22.00 6.60 2.47 14.99 12.54 0.16 1.39
07.30 13.75 122.82 34.70 26.11 3.54 6.03
11.00 17.84 6.14 49.96 28.94 0.12 1.94
16.30 7.32 2.11 17.17 9.26 0.12 2.08
20.00 10.29 36.07 41.26 17.10 0.87 4.52
03.00 10.71 0.00 23.75 19.40 0.00 1.22
06.45 5.80 0.00 19.84 0.00 0.00 0.00
09.00 13.04 0.00 51.26 17.60 0.00 2.91
Total 2533.33 28427.35 4637.00 4627.49
Total urinary recovery of paracetamol In urine > 40225.17mg.
Although the ratios (PG)/(PS) and (PG+PS)/(PC+PM) were only s lig h tly  above 
normal before treatment th is  might be because glucuronic acid, sulphate and 
glutathione were depleted. Treatment with L-meth1on1ne seemed to decrease 
both ra tio s .
n o
Table 3 .6 .4  
P4, Female, 28 y r
PG+PS
Time Event P PG PS PC+PM PG/PS PC+PM
16.00 Methionine 
2.5g p .o .
16.20 8.07 29.08 26.05 5.43 1.12 10.15
i9 .s a
20.00 Methionine 
2.5g p .o .








28.57 193.13 36.30 102.73 5.32 2.23
06.00 31.84 185.44 35.71 119.01 5.19 1.86
09.40 4.07 37.73 11.97 26.60 3.20 1.86












Total recovery of paracetamol In urine ■ 2313.02mg.
Treatment with L-meth1on1ne resulted In a decrease In (PG+PS)/(PC+PM) with  
time but had no e ffe c t on (PG)/(PS)
n i
Table 3 .6 .5  
P5, Female, 38 y r
PG+PS
Time Event P PG PS PC+PM PG/PS PC+PM
22.00 Ingestion of 70 tab lets o f paracetamol SOOmg
11.00 gastric washout followed by fu ll NAc treatment (300mg/kg over 20 
hours)
18.15 377.76 4905.10 702.18 928.96 6.98 6.04
07.00 64.50 599.71 485.97 266.74 1.23 4.07
10.00 64.32 5.99 68.94 33.33 0.09 2.25
15.00 8.06 7.10 13.58 12.51 0.52 1.65
17.00 0.90 1.70 1.68 4.72 1.01 0.72
22.30 1.46 1.82 1.02 3.89 1.78 0.73
11.00 1.94 5.76 3.50 6.06 1.64 1.53
13.30 3.70 3.42 0.41 3.26 8.34 1.17
16.00 2.00 2.48 0.07 3.31 33.43 0.77
17.00 1.81 4.42 2.39 7.03 1.85 0.97
Total 526.45 5537.50 1279.74 1269.81
Total recovery of paracetamol In urine » 8613.SOmg.
Mj-acetyl cysteine decreased (PG)/(PS) and (PG+PS)/(PC+PM) with time.
The f i r s t  urine collection analysis suggests that sulphate but not 
glutathione was depleted by th is  dose of paracetamol. A fter treatment with 
Nj-acetyl cysteine, (PG)/(PS) and (PG+PS)/(PC+PM) decreased with time.
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Table 3 .6 .6 .
P6, Male, 40 y r .
PG+PS
Time Event P PG PS PC+PM PG/PS PC+PM
22.00 Ingestion o f 10 tab lets of paracetamol SOOmg 
00.15 8.86 83.22 32.06 2.37 2.60 48.44
Methionine 
2.5g p.o.
03.00 8.92 105.59 68.88 3.31 1.53 52.71
04.15 2.73 50.94 23.73 5.47 2.15 13.65
09.30 3.18 39.58 11.14 1.96 3.55 25.88
12.00 3.82 37.40 10.56 2.39 3.54 20.07
23.00 10.16 42.86 8.97 5.40 4.78 9.60
Total 37.67 359.59 155.34 20.90
Total recovery o f paracetamol In  urine > 573.SOmg
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Table 3 .6 .7  
P7, Female, 19 y r
PG+PS
Time Event P PG PS PC+PM PG/PS PG+PM







10.00 34.74 1574.37 36.98 117.79 42.57 13.68
11.00 Methionine
2.5g p.o.
01.30 18.95 108.78 7.86 10.73 13.84 10.86
07.55 4.36 41.95 21.82 9.09 1.92 7.01
22.30 4.94 18.73 1.89 2.48 9.91 8.31
Total 62.99 1743.83 68.55 140.09
Total recovery of paracetamol In urine .  2015.46mg.
Although both ratios were decreased a fte r  treatment with L-meth1on1ne, 
(PG)/(PS) rose again In the la s t urine collection  suggesting that further  
treatment with L-meth1on1ne might have been b e n e fic ia l.
There was l i t t l e  evidence that sulphate depletion had occurred In th is  
patient despite the low recoveries of the glutathione conjugates of 
paracetamol In i t ia l ly .  As (PG+PS)/(PC+PM) decreased a fte r  treatment with 
L>meth1on1ne, th is  drug may have made more glutathione available for 
conjugation.
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Table 3 .6 .8  
P8 , Female, 29 y r
PG+PS
Time Event P PG PS PC+PM PG/PS PC+PM




2.5g p .o .
03.00 102.68 798.18 304.44 60.78 2.62 18.14
04.00 52.41 469.64 168.10 34.52 2.79 18.47
05.00 Methionine
2.5g p .o .
06.00 40.98 747.93 233.93 76.97 3.20 12.76
08.18 31.22 656.18 222.00 71.59 2.96 12.27
0940 Methionine
2.5g p .o .
10.00 22.02 468.77 155.34 66.04 3.02 9.45
11.10 11.32 227.96 73.35 41.26 3.11 7.30
13.00 8.49 242.38 77.36 43.64 3.13 7.33
Total 269.12 3611.04 1234.52 394.81
Total recovery of paracetamol In urine > 5509.49 mg.
Methionine treatment appeared only to a ffe c t (PG+PS)/(PC+PM) In th is  patien t.
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Table 3 .6 .9  
P9, Female, 28 y r
PG+PS
Time Event P PG PS PC+PM PG/PS PC+PM
12.45 71.41 890.98 52.48 110.29 16.98 8.55
Methionine
2.5g P .O .
21.45 143.85 3444.21 172.20 570.89 20.00 6.33
Methionine
2.5g p.o .
05.45 30.80 409.42 66.12 53.15 6.19 8.95
Methionine
2.5g p .o .
20.45 9.73 116.39 68.76 35.95 1.69 5.15
Methionine
2.5g p .o .
07.00 16.41 93.86 109.06 44.49 0.86 4.56
Total 272.20 4954.86 468,62 814.77
Total recovery of paracetamol In  urine « 6510.45mg.
In th is  patient treatment with L-meth1on1ne appeared to Increase recoveries 
of both sulphate and glutathlonlne conjugates of paracetamol
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Table 3.6.10  
PIO, Female, 17 y r
PG+PS
Time Event P PG PS PC+PM PG/PS PC+PM
10.50 Ingestion o f 48 tab lets o f paracetamol SOOmg
12.30 Gastric washout + methionine 2.5g p .o .
12.45 Methionine 
2.5g p .o .
13.00 264.15 2134.05 175.94 57.37 12.13 40.26
14.30 Methionine
2.5g p.o.
17.00 142.17 2787.94 216.15 111.74 12.90 26.88
19.00 32.30 1185.08 118.63 58.38 9.99 23.33
20.00 16.47 446.53 46.85 28.94 9.53 17.05
21.00 1126.72 8204.07 593.34 665.43 13.83 13.22
21.30 16.72 494.77 41.01 59.06 12.06 9.07
08.15 8.42 724.40 84.13 87.46 8.61 9.24
09.15 67.04 1721.87 381.12 282.74 8.49 6.81
11.15 1.17 53.35 8.28 6.83 6.44 9.02
Total 1675.16 16113.41 1378.26 1088.87
Total recovery o f paracetamol In urine « 20255.70mg.
L-methlonlne resulted In a decrease In (PG+PS)/(PC+PM) but had l i t t l e  e ffe c t  
on (PG)/(PS) suggesting that I f  further treatment with L-meth1on1ne had been 
given elim ination o f paracetamol might have been hastened
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Fig. 3.6.1 Values of G/S and G+S in urine for the patient shown in
C+M
Table 3.6.1 compared with normals who ingested paracetamol 
2.5g (as described in Section 3.1) All values are
corrected for molecular weight164.26 -j
times of Ltm en t
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Fig. 3.6.2 Values of G/S and G+S in urine for the patient shown in
Ü+R
Table 3.6.10 compared with normals after paracetamol 2.5g 
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3.7 A possibly toxic Intermediate metabolite of paracetamol 
Introduction
After 1c has been taken in overdose, the toxicity of paracetamol may 
be manifest as fulminant hepatic fa ilu re . Recently renal tubular 
necrosis has been shown to follow paracetamol overdose - sometimes 
in the absence of liv e r  damage (Cobden et a l,  1982). Both these 
effects are thought to be due to covalent binding of a reactive 
metabolite of paracetamol to microsomal protein (Mitchell et a i,  
1977). This reactive metabolite is thought to arise as a result of 
oxidation by the cytochrome P-450 mixed function oxidase system and 
in therapeutic doses is safely detoxicated by conjugating with 
glutathione; the products of this reaction appear in urine as 
paracetamol cysteine and paracetamol mercapturic acid. However 
glutathione ava ilab ility  is limited so that after high doses of 
paracetamol sufficient of the reactive metabolite is le f t  
unconjugated to bind to liv e r and possibly kidney macromolecules to 
cause cell death.
The identity of the toxic intermediate has been debated for many 
years. hydroxy paracetamol was in ita lly  considered to be a like ly  
condidate and was thought to act by spontaneous dehydration to 
N-acetyl benzoquinonimine which is known to covalently bind to 
protein and to react with glutathione to form a paracetamol- 
glutathione conjugate (Hinson, Nelson and Mitchell, 1977). However, 
toxic ity  mediated by hydroxy paracetamol was refuted by Healey, 
Calder, Young e t a l, (1978) and by Gemborys, Gribble and Mudge 
(1978) because of its  h a lf - l ife  (15 minutes at physiological pH) 
indicating that i t  was not dehydrated as rapidly as was previously 
postulated, and because of its  limited toxic ity . The f^-acetyl 
benzoquinonimine has not been rejected as a possible toxic 
metabolite although its  mechanism of formation is not known.
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During the analysis of urine from overdose patients, several 
additional drug-related peaks were noted which were not present in 
blank urine and i t  was thought possible that these peaks might 
represent metabolites of paracetamol which arose from the toxic 
pathway. Therefore these metabolites were examined with a view of 
increasing information of the metabolism of paracetamol.
Procedures
Paracetamol 1.5g was taken orally  by normal volunteers and a ll urine 
passed in the f ir s t  8  hours was collected in unacidified urine 
bottles. Aliquots were treated with e-glucuronidase and sulphatase 
and incubated at pH5 at 37°C overnight. As well as the known 
metabolites of paracetamol (paracetamol glucuronide, paracetamol 
sulphate, paracetamol cysteine and paracetamol mercapturic acid) the 
urine was examined for the presence of 2-OH and 3-OH paracetamol by 
HPLC as described in Section 2 .7 .e . i i .  Peaks corresponding to the 
retention times of 2- and 3-OH paracetamol were collected by 
preparative HPLC and sent for mass spectrometric analysis on a Vg 
Micromass 258 mass spectrometer.
Substituted benzenes have been reported to form acid-labile  
pre-aromatic metabolites (Knight and Young, 1958). In order to 
determine whether the oxidation products of paracetamol metabolism 
arose from such species, urine was further treated with HCl at pH 
0.3 at 37°C for 20 hours and was then re-assayed for 0 -substituted 
and S-substituted metabolites. Standard samples of 0- and S- 
substituted metabolites were incubated under identical conditions to 
assess any effect of this treatment on the results.
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Results
Standards of the two 0-substituted metabolites were verified as 
authentic by mass spectrometry. Examination of the urinary 
metabolic profile  of paracetamol by HPLC after treatment with 
8 -glucuronidase and sulphatase revealed the presence of two peaks 
which had identical retention times to the 2-OH and 3-OH paracetamol 
standards (7 min 20s and 7 min 55s respectively). Preparative HPLC 
permitted the collection of samples of 2-OH and 3-OH paracetamol 
present in urine after ingestion of paracetamol and these were 
subjected to direct insertion mass spectrometry. 3-OH paracetamol 
was shown to be a urinary metabolite of paracetamol but 2-OH 
paracetamol was present in too low a concentration to permit mass 
spectrometric analysis.
After enzymic hydrolysis followed by acid treatment for 20 hours 
(jo in tly  performed by Dr L Notarianni and myself) there was found to 
be a decrease in the concentrations of the oxidation products of 
paracetamol compared with concentrations before acid treatment.
When standard samples of 0- and S- substituted metabolites were 
incubated for 2 0  hours under acid conditions (again performed 
jo in tly ) breakdown of these metabolites was found to be 
considerable. The breakdown followed a f ir s t  order degradation 
process with the following rate constants; 2- and 3-hydroxy 
paracetamol— 0.031 hr“\  3- 5-cysteinyl-paracetamol- -0.055 
hr“  ̂ breakdown therefore had to be considered in calculating the 
amounts of oxidised metabolites present.
Table 3.7 shows the mean concentrations of 3-OH paracetamol and 
S-substituted metabolites of paracetamol after enzymic hydrolysis 
alone and after enzymic hydrolysis followed by acid treatment. 
Results are also shown in Fig. 3 .7 .1 . Decomposition of these 
metabolites as shown in Fig. 3 .7 .2 . was allowed for when assessing 
the concentrations of these metabolites in urine before acid 
treatment by applying the above rate constants.
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Table 3.7. Concentrations of 3-OH paracetamol and S-substituted 
metabolites in human urine after paracetamol 1.5g 
administered to normal volunteers
Conditions
Concentration (ug/ml)
3-hydroxy paracetamol S-metabol ites
Urine after enzymic 
hydrolysis (sulphatase 
and 6 -glucuronidase) 7.55 ± 0.94* 2.66 ± 0.35*
Urine after enzymic 
hydrolysis and incubated 
at pH 0.3 for 20 hours 14.64 ±  3.91 13.88 ± 1.92
n = 14, p<0.02 n = 8 , p<0 . 0 0 1
Results shown above indicate that acid-labile species present in 
urine were converted to 3-hydroxy paracetamol and paracetamol 
cysteine plus paracetamol mercapturic acid by incubation at pH 0.3 
for 20 hours. Concentrations of 2-OH paracetamol did not change 
significantly after the 20 hour acid treatment. In order to follow 
the time course of the formation and decomposition of 0 -substituted 
and S-substituted metabolites in urine, one urine sample was 
incubated at pH 0.3 at 37°C (following enzymic hydrolysis). 
Concentrations of 0- and S-substituted metabolites were measured by 
Dr L Notarianni at intervals for 20 hours. This time course is 
shown in Fig. 3 .7 .3 . I t  can be seen that in this urine sample, 
concentrations of 2-OH paracetamol also rose in ita lly  as a result of 
the treatments but by 2 0  hours, concentrations had fallen again due 
to breakdown.
The mass spectrum of a standard of 3-OH paracetamol and a mass 
spectrum of 3-OH paracetamol urine after preparative HPLC following 








-0.18 + 0.18(n»14)* 






7.05 + 2.39 (n-14)* 








11.22 + 1.63 (n-8)* 
p <  0 .0 0 1
MeantSEX concentrations (ug/ml) o f 0 -  and S - 
su b stltu ted  m etabolites o f paracetamol in  human urine  
before (E) and a f te r  incubation a t  pH 0 .3  and 37°C fo r  
20 h r (E+A). E represents values fo r urines p re trea ted  
w ith  S-glucuronidase and sulphatase and corrected fo r  
degradation as described in  the te x t .  S tudent's t - t e s t  
fo r  p aired  data was used to assess the s t a t is t ic a l  
significeuice o f  the re s u lts .
124
Fig. 3.7.2. Decomposition of 2-hydroxy paracetainol, 3-hydroxy 
paracetamol, 3-S- cysteinyl paracetamol and 3-S- 














Fig. 3.7. 3. Time course of concentrations of 0 and S- substituted 
metabolites of paracetamol in urine incubated at pH 0.3 
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Chapter 4
Discussion of Paracetamol Results in man
4.1 Control Study
In this study the urinary metabolic profile  of paracetamol after a 
therapeutic Ig or SOOmg (children) dose administered to normal 
volunteers was established using high performance liquid  
chromatography. Previous findings by Cummings, King and Martin 
(1967) showing that the major metabolites of paracetamol are 
paracetamol-4-glucuronide and paracetamol-4-sulphate were confirmed 
and in agreement with the work of Potter, Thorgeirsson, Jollow and 
Mitchell (1974) i t  was found that these metabolites made up some 80% 
of the administered dose. A smaller percentage of paracetamol 
appears in the urine as its  3-S-cysteinyl and 
3-S-(^-acetylcysteinyl) derivatives and these metabolites arise 
presumably from conjugation of the P-450 oxidation product of 
paracetamol with glutathione. These metabolites were f ir s t  
described by Jagenburg and Toczko, (1960).
The present results showed that in every volunteer but one, more of 
the glucuronide conjugate than the sulphate conjugate was recovered 
(53.46 * 1.35% and 32.79 ± 1.16% in 24 hour urine respectively). I t  
was found that the percentage recoveries of paracetamol glucuronide 
and paracetamol sulphate in this population were negatively 
correlated (although absolute amounts of these metabolites were 
found to be positively correlated largely as a result of large 
variations in the total amounts of these two metabolites excreted). 
The negative correlation between paracetamol glucuronide and 
paracetamol sulphate implies that these two pathways were in 
competition.
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Recoveries of paracetamol sulphate were significantly lower in the 
second urinary collection period ( 8  - 24 hours) than in 0 - 8  hour 
urine (p<0.002). This suggests that even after a therapeutic dose 
of paracetamol, sulphate normally available for conjugation is being 
noticeably depleted. Bray, Humphries, Thorpe, White and Wood (1952) 
suggested that because of the limited capacity of the total sulphate 
pool sulphate ava ilab ility  may readily be exhausted. This suggests 
that with increasing doses of paracetamol sulphate conjugation may 
become a less utilized  pathway due to decreased a va ilab ility  of 
sulphate. Figs. 3.1.4, 3.1.5 and 3.1.6 suggest that paracetamol 
gl ucuroni dation and sulphation are competing pathways but in the 
present study there was no apparent increase in paracetamol 
glucuronide recovered in 8  - 24 hours to compensate for the 
decreased excretion of paracetamol sulphate. However, there was a 
significant increase (p<0.05) in the percentage recoveries of the 
glutathione conjugates of paracetamol ( i .e .  paracetamol cysteine and 
mercapturic acid). Since these two metabolites arise via the 
oxidation pathway of paracetamol this suggests that sulphate 
depletion was sufficient to result in increased production of the 
reactive intermediate of paracetamol. I f  glutathione a va ilab ility  
is compromised sufficiently hepatotoxicity may result. The 
implication exists that co-administration of compounds which also 
u tiliz e  sulphate for conjugation may also increase the risk of 
tox ic ity . The relationship between depletion of hepatic 
glutathione, arylation of live r macromolecules and hepatic damage 
was f ir s t  described by Mitchell, Jollow, Potter, G ille tte  and Brodie
(1973) in mice. Glutathione has been demonstrated to act as a 
nucleophile with a number of electrophilic substances and more 
recently has been found also to have a role as a detoxicant acting 
as a reducing agent or as a cofactor. I t  has been suggested that 
high in tracellu lar concentrations of glutathione may be essential 
for the prevention of cytotoxicity as a result of drug metabolism 
(Orrenius and Jones, 1978).
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In the past, studies on the effects of age on drug metabolism have 
largely been confined to measurement of plasma half l i f e .  I t  has 
been found by several workers that the half lives of drugs such as 
antipyrine (O'Malley, Crooks, Duke and Stevenson, 1971), aminopyrine 
(Jori, Di Salle and Quadri, 1972), phenylbutazone (O'Malley et a l, 
1971), warfarin, (Hewick, Moreland, Shepherd and Stevenson, 1975), 
phenytoin, (Hayes, Langman and Short, 1975) and diazepam (Klotz, 
Avant, Hoyurnpa, Schenker and Wilkinson, 1975) were increased in the 
elderly (over 60 years of age) compared with younger people (aged 
under 50 years).
The half l i f e  of paracetamol was found to be longer in people over 
73 years old than people under the age of 27 years by Triggs,
Nation, Long and Ashley (1975) and by Briant, Liddle, Dorrington and 
Williams (1975) who compared 20 - 40 year olds with people over the 
age of 65 years. In the present study in 0 - 8  hour urine, 
paracetamol cysteine plus mercapturic acid recovery decreased 
significantly with age (p<0 . 0 1 ) due to a significant decrease in the 
percentage recovery of paracetamol cysteine. These results suggest 
that with increasing age either the percentage of a given dose of 
paracetamol oxidised to the reactive intermediate decreases or that 
further metabolism of this intermediate to yield the products of 
conjugation with glutathione in urine diminishes with age. Kato and 
Takanaka (1968) demonstrated that in old rats the live r weight to 
body weight ratio and liv e r  cytochrome P-450 content was lower and 
liv e r microsomal preparations from old rats had a lower activ ity  in 
metabolizing a number of substrates resulting in an increased 
sensitiv ity to a number of agents. Lauterbur, Vaishrav, S tillw ell 
and Mitchell (1980) showed that in male rats the rate of glutathione 
turnover decreased with increasing age. Rumack and Peterson (1978) 
demonstrated that children are less susceptible to the toxic effects 
of paracetamol than adults. Results from this study tend to endorse 
this as the higher percentage recoveries of cysteine and mercapturic 
acid metabolites in the younger age groups suggest an increased
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a b ility  to conjugate with glutathione and perhaps an increased 
capacity for detoxifying the reactive metabolite.
Results from this study also showed that following the decreased 
recoveries with increasing age of the S-substituted metabolites of 
paracetamol in the 0  - 8  hour urine collections there was a 
significant (p<0.05) increase in the percentage recovery of 
paracetamol glucuronide with increasing age in 8  - 24 hour urine. 
This suggests that, rather than a decreasing a b ility  to conjugate 
with glutathione with increasing age, the decrease in the oxidation 
products of paracetamol arises as a result of a smaller proportion 
of paracetamol undergoing cytochrome P-450 oxidation with age. This 
conjugation of paracetamol with glutathione is greatest in children 
and with increasing age the mixed function oxidase system may become 
impaired.
I t  is of interest that other workers have found the half l i f e  of 
paracetamol to be increased in older people (Crooks, O'Malley and 
Stevenson, 1976). The present study showed that in 24 hour urine 
from the over 30s the proportion of unchanged paracetamol increased 
with age although individual percentage recoveries of individual 
metabolites was found not to change with age. This is consistent 
with a general decrease in drug metabolizing a b ility  with age 
resulting in increased proportions of unchanged drug recovered in 
urine. I t  should be added that catechol derivatives of paracetamol 
which arise from P-450 oxidation were not measured in this study 
(see Section 3.7) and alterations in recoveries of these metabolites 
with age might give an indication of whether oxidation or 
glutathione conjugation decreased with increasing age.
The effects of these changes in metabolism are unlikely to be of 
clinical significance as the changes are small (less than 1 % 
increased or decreased percentage recovery of metabolite per year of 
age). Although the percentage recovery of paracetamol increased 
with age in the over 30s, there were marked differences between
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individuals in urinary recoveries of each metabolite and parent 
drug. Other workers have reported a wide intersubject variation in 
the percentage recoveries of the glucuronide and sulphate 
metabolites of paracetamol (Caldwell, Davies and Smith, 1980). This 
appears to be the f ir s t  study in vivo to show that recoveries of 
urinary metabolites and parent drug change with age.
Although there was a significant correlation between age and 
(PG+PS)/(PC+PM), in a ll subjects when the results for female 
volunteers alone were examined no such correlation existed. These 
findings could represent a c lin ica lly  unimportant sex difference in 
paracetamol metabolism but may also be explained by the fact that 
female volunteers showed a much higher scatter in this ratio than 
the males. Sex differences in drug metabolism reported in the 
lite ra tu re  are scarce but include the finding that men are slower 
metabolisers of antipyrine (O'Malley, Crooks, Duke and Stevenson, 
1971).
Because of their relationships with age, i t  follows that percentage 
recoveries of paracetamol glucuronide are negatively correlated with 
recoveries of paracetamol plus mercapturic acid in each urine 
collection period.
Values of (PG+PS)/(PC+PM) and (PG)/(PS) were calculated for each 
individual in the age study and the means were calculated. When 
they were compared with values in the study in which 4 volunteers 
took 2.5g paracetamol, i t  was found that (PG)/(PS) ratios in the 
la tte r  study did not a lte r significantly over a 1 0  hour period.
This w ill be discussed la te r in relation to the metabolism of 
paracetamol after overdosage. Likewise (PG+PS)/(PC+PM) did not 
change significantly over the f ir s t  10 hours a fter ingestion. The 
slight decrease observed is probably due to a decrease in sulphate 
recovered with time and not to increased cysteine plus mercapturic 
acid recoveries.
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4.2 Paracetamol metabolism in  neonates
The metabolism of paracetamol was studied in six nursing infants 
after their mothers were given from 1 to 3g of paracetamol. The 
parent drug and its  four metabolites were detectable in the urine of 
a ll six babies. This finding contrasts with that of Berlin, Yaffe 
and Ragni (1980) who also used an HPLC method of analysis and could 
detect neither paracetamol nor its  metabolites in the urine of 
nursing infants. When paracetamol recoveries of each metabolite and 
unchanged paracetamol in neonates were examined in the present study 
i t  was found that the infants excreted substantially higher amounts 
of unchanged paracetamol but lower amounts of paracetamol sulphate 
than had subjects in the control study. Despite th is, unlike the 
control study, there was no increase seen in the products of 
cytochrome P-450 oxidation suggesting that there may either be lower 
concentrations or lower ac tiv ities  of the mixed function oxidase 
system or glutathione transferase in neonates than in older 
subjects. As percentage recoveries of the cysteine and mercapturic 
acid metabolites of paracetamol in neonates were similar to values 
in the control study, there is no evidence to suggest that neonates 
may have different sensitivities to the hepatotoxic effects of 
paracetamol than do adults. Results from mice described by Hart and 
Timbrel1 (1979) showed that levels of cytochrome P-450 and hepatic 
glutathione concentrations in neonatal mice was less than in adult 
mice. Therefore, in human neonates either the formation of the 
reactive metabolite of paracetamol or its  detoxication may be less 
developed than in adults.
Mancini, Sonaware and Yaffe (1980) reported that young mice and rats 
were less vulnerable to paracetamol toxicity compared with adult 
animals by determining LD̂ q values for paracetamol at different 
ages. Pulkkinen (1963) and Percy and Yaffe (1964) described a 
significant a b ility  of rats
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and mice to form sulphate esters in contrast to their other 
conjugating systems such as the formation of glutathione conjugates, 
glycine conjugates and glucoronide conjugation (Testa and Jenner, 
1976). The present results suggest that a species difference may 
exist in the deficiency of neonatal man to conjugate with sulphate 
although its  other drug metabolising enzymes appear to be well 
developed by this age.
4.3 Metabolism of paracetamol in patients with rheumatoid a rth ritis
The metabolic profile of paracetamol has been studied in patients 
with rheumatoid a rth rit is . Glynn (1972) described classical 
chronic a rth ritis  as being a two phase disease in which the f ir s t  
phase possibly results from a systemic infection by an organism 
which has a tendency to settle in the jo in ts. Here i t  excites an 
inflammatory reaction probably as a result of a local immune 
response. This phase may las t as long as a year but after that a 
second phase may follow which results, in most instances, from 
development of autoimmunisation to some antigen or antigens produced 
by the in it ia l inflammation. Whatever the cause, rheumatoid 
a rth ritis  is a chronic crippling disease that requires analgesic 
drugs. In the present study, patients with rheumatoid a rth ritis  
defined by a physician according to the c rite ria  of the American 
Rheumatism Association (see Appendix 6 ) took paracetamol at their 
normal doses.
There are more variables to be taken into account in this study than 
in the control study because these patients may d iffe r  in their 
a b ility  to metabolise paracetamol as a consequence of their disease 
state, the high doses of paracetamol taken and concurrent therapy 
with other drugs.
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I t  was found that these patients showed higher percentage recoveries 
of paracetamol glucuronide and lower percentage recoveries of 
paracetamol sulphate and of unchanged paracetamol than normal 
volunteers a fter a Ig dose of paracetamol in the control study. 
Percentage recoveries of the glutathione conjugates of paracetamol 
were not significantly different from those found in normal 
volunteers. As many rheumatoid patients took more than Ig of 
paracetamol in the 24 hours of the study, these patients were 
compared with the four normal volunteers in the control study who 
took paracetamol 2.5g. The rheumatoid patients showed a 
significantly higher percentage recovery of paracetamol sulphate 
than those controls who took 2.5g paracetamol (p<0.05) suggesting 
that less sulphate depletion had occurred in the rheumatoid 
patients. This may however, be a result of the d ifferent dosing 
regimens between controls and rheumatoid patients namely that the 
controls took paracetamol 2.5g at the beginning of the study while 
the rheumatoid patients took Ig doses throughout the day. Thus, 
depletion of endogenous sulphate may have occurred early after 
dosing but the rheumatoid patients may have been able to replete 
their sulphate pools by normal dietary intake of precursors of 
sulphate.
I t  is known that serum sulphydryl (SH) concentrations are low in 
patients with rheumatoid a rth ritis  but a fter treatment with 
D-penici11 amine, aurothiomalate, fenclofenac and benoxaprofen serum 
SH concentrations rise to normal in those patients showing c lin ical 
improvement (Hall, Blake and Bacon, 1981). Low serum SH 
concentrations probably reflect reduced glutathione ava ilab ility  and 
suggest that a deficiency in the in tracellu lar detoxication 
mechanism may exist in patients with rheumatoid a rth ritis  (Munthe, 
Kass and Jellum, 1981). As paracetamol is thought to be detoxified 
by conjugation of its  active metabolite with glutathione (Mitchell 
et a l, 1973) a decrease in glutathione concentration might result in
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increased susceptibility to paracetamol tox ic ity . In the present 
study at least ten of the patients with rheumatoid a rth ritis  were 
being treated with drugs containing thio groups so that their 
glutathione concentrations may not have been compromised.
As there was no indication in the rheumatoid patients of increased 
utiliza tio n  of the toxic pathway of paracetamol metabolism despite 
their large total daily consumption of paracetamol there seem to be 
no grounds for believing that rheumatoid a rth ritis  patients run a 
special risk of hepatotoxicity from paracetamol taken in the doses 
used in this study.
4.4. Metabolism of paracetamol in patients with thyroid disease
Thyrotoxicosis appeared to have no appreciable effect on the 
metabolism of a Ig dose of paracetamol when recoveries of each 
metabolite and unchanged paracetamol were compared with recoveries 
in normal volunteers in the control study. Crooks, Hedley, Macnee 
and Stevenson, (1973) studied the activ ity  of liv e r microsomal
enzymes in female thyrotoxic and hypothyroid patients by examining
35antipyrine and S-methimazole h a lf - l ife . Half-lives of both 
drugs were increased in patients with untreated hypothyroid disease 
while they were decreased in patients with thyrotoxicosis. These 
workers suggested that changes in drug metabolising activ ity  
occurred in abnormal thyroid states and that this also resulted in 
increased clearance in hyperthyroid patients. When the percentage 
dose of paracetamol recovered in 24 hours was compared in normal 
volunteers and hyperthyroid patients no s ta tis tic a lly  significant 
difference was found. However the scatter between individuals was 
quite large so any differences between the groups were probably 
masked by the interindividual differences. I t  does at least appear 
that recoveries of the glutathione conjugates of paracetamol were 
not affected by thyrotoxicosis nor was the percentage recovery of 
unchanged paracetamol diminished (which might have resulted from an 
accelerated metabolism).
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4.5. The e ffe c t of salicylamide on paracetamol metabolism in  man
Salicylamide was administered to 6  volunteers concurrently with a 
therapeutic dose of paracetamol in order to determine how a 
metabolic competing agent might affect the metabolism of 
paracetamol. When salicylamide was present, paracetamol serum 
concentrations were significantly higher than when paracetamol was 
given alone presumably because clearance of paracetamol was 
reduced. Serum and urinary concentrations of paracetamol sulphate 
were lower after salicylamide suggesting that depletion of 
endogenous sulphate had occurred as both paracetamol and 
salicylamide conjugate with this anion. This led to a significant 
lengthening of the h a lf-life  of paracetamol and the area under the 
serum paracetamol concentration time curve was significantly higher 
after salicylamide. The AUC for paracetamol sulphate was 
significantly lower after salicylamide but because the AUC for 
paracetamol glucuronide was not significantly increased i t  appears 
that glucuronidation does not compensate to ta lly  for the increased 
unchanged paracetamol. Furthermore the AUC for unchanged 
paracetamol was increased. This may be because endogenous 
glucuronic acid is also compromised by salicylamide with which i t  
also conjugates. The urinary excretion pattern however gave no 
suggestion of glucuronic acid depletion as unchanged paracetamol was 
not increased after salicylamide and paracetamol glucuronide 
recovery was increased compared with control values.
Levy and Yamada (1971) also administered paracetamol to healthy 
human subjects in the presence and absence of salicylamide and found 
that the excretion rate of paracetamol sulphate and glucuronide 
decreased after salicylamide. This may have been a result of 
competition for secretion at kidney tubules between the conjugates 
of salicylamide and paracetamol. However, as these workers 
collected urine samples every 1 5 - 3 0  minutes, they were able to 
monitor small changes in the rate of excretion of each metabolite.
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I t  is interesting that in the present study there was no evidence 
for increased production of the toxic metabolite because 
concentrations of urinary cysteine and mercapturic acid were not 
increased by salicylamide treatment. This suggests that depletion 
of sulphate available for conjugation does not necessarily lead to a 
potentially toxic situation.
4.6. Paracetamol metabolism after overdose
Since paracetamol is freely available i t  has become one of the more 
popular drugs for deliberate self poisoning. A knowledge of its  
metabolism was an aid in the original derivation of a regimen for 
treating paracetamol overdose. After high doses paracetamol is 
associated with hepatotoxicity and the rationale behind the 
treatment of paracetamol poisoning is to provide a suitable 
substrate to conjugate with the toxic metabolite of paracetamol. 
Glutathione its e lf  prevents in vitro covalent binding to microsomal 
protein but glutathione administered to man is not thought to cross 
cell membranes readily (Prescott, Newton, Swainson et a l, 1974).
However glutathione administered intravenously to mice was found to 
be taken up by the liv e r  and to protect against the hepatotoxic 
effects of a large dose of paracetamol (Strolin-Benedetti et a l, 
,1975). I t  was found by Mitchell et a l,  (1973) that glutathione 
precursors such as cysteine and cysteamine could prevent 
experimental paracetamol-induced hepatic necrosis. Prescott e t al
(1974) reported that intravenous cysteamine was successful in 
treating patients with massive paracetamol overdoses; however this 
treatment had unpleasant side effects. In consequence more 
acceptable alternatives were investigated and oral methionine was 
found to effect moderate protection against paracetamol- induced 
hepatotoxicity (Crome, Yale, Volans et a l, 1976). ^-acetyl cysteine 
was administered orally by Peterson and Rumack (1977) and by 
intravenous infusion by Prescott et a l, (1977) and both found this
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drug to be very effective without significant side effects. The 
structures of these compounds in relation to glutathione which 
conjugates with paracetamol in the 3-position are shown below.
The success of sulphur containing amino acids has been attributed  
either to direct conjugation with the reactive intermediate of 
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In order to examine whether these compounds indeed act by combining 
either directly or indirectly with the reactive metabolite of 
paracetamol, the metabolic profile of 1 0  patients admitted to the 
casualty department of the Royal United Hospital, Bath suffering 
from paracetamol poisoning was examined. The patients were treated 
with either L-methionine or acetyl cysteine as dictated by blood 
concentrations of paracetamol and time after ingestion of the 
analgesic as described earlie r. The la tte r  parameter is often 
d iff ic u lt  to determine as information given by these patients is 
often inaccurate (Schnaps, Hal ken, Davy and Tirash, 1980). Values 
of the ratios (PG)/(PS) (PG+PS)/(PC+PM) were calculated for each 
urine collection obtained from the individual patients.
Before treatment values of these ratios (where obtained) in overdose 
patients were very much higher than the mean values in normal 
volunteers for whom PG/PS ranged from 0.24 - 4.23 and 
(PG+PS)/(PC+PM) ranged from 4.88 - 30.53 in 24 hour urine suggesting 
that sulphate and glutathione depletion had occurred. In the seven 
cases P.3, P.4, P.6 , P.7, P.8 , P .9 and P.10 to whom L-methionine 
alone was given, the ratio of PG/PS decreased with time in three 
(P.3, P.7 and P.9) and the ratio of (PG+PS)/(PC+PM) decreased with 
time in a ll seven. In the other 3 cases to whom N_-acetyl cysteine 
was administered alone or in combination with L-methionine, (P .l,
P.2 and P.5) ratios of (PG)/(PS) and (PG+PS)/(PC+PM) decreased with 
time in a ll three cases. This suggests that both agents serve to 
increase the urinary products of glutathione conjugation with the 
toxic metabolite of paracetamol. The results further suggest that 
N -̂acetyl cysteine and methionine increase the ava ilab ility  of 
sulphate for conjugation with paracetamol. As sulphate conjugation 
accounts for some 33% of the excreted material after therapeutic Ig 
doses of paracetamol, low concentrations of endogenous sulphate w ill
lead to a slower rate of decay of parent drug. Balanowskaand Gessner (1980)
described sulphation as a high a ffin ity , low capacity pathway which 
is readily saturable. Sulphate depletion may result in a relatively
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greater proportion of paracetamol undergoing oxidation to the active 
metabolite causing an even greater demand on glutathione, ^-acetyl 
cysteine and L-methionine, by increasing the ava ilab ility  of 
sulphate w ill therefore aid paracetamol elimination and hence reduce 
the amounts of oxidised intermediate formed. Possible routes of 
metabolism which L-methionine and ^-acetyl cysteine may undergo to 
produce glutathione or cysteine to conjugate with the reactive 
metabolite and produce sulphate are shown in Fig. 4.1.
I t  might be argued that with time, depletion of sulphate and 
glutathione might be replenished by intermediary metabolism 
resulting in decreased ratios. However by this time toxicity might 
well have occurred. Comparison of values of the ratios (PG)/(PS) 
and (PG+PS)/(PC+PM) after a Ig dose with values from the four normal 
individuals who took paracetamol 2.5g (Section 3.1) showed that with 
no treatment the ratios did not a lte r significantly over the ten 
hour period. Therefore the decrease in each ratio  which occurred 
after treatment in the overdose patients may be attributed to the 
effects of N-acetyl cysteine and L-methionine.
I t  is important to distinguish between increases and decreases in 
production of the cysteine and mercapturic acid metabolites of 
paracetamol as indicators of increased production of the reactive 
metabolite in judging the potential of a given clinical situation 
for tox ic ity . After therapeutic doses a rise in the recovery of 
cysteine and mercapturic acid metabolites suggests an increased 
production of the reactive metabolite and that there are adequate 
resources of glutathione to detoxify i t .  After paracetamol overdose 
i t  must be assumed that glutathione ava ilab ility  is compromised so 
that now a decrease in cysteine and mercapturic acid metabolites of 
paracetamol may represent the inherently more dangerous situation 
that already sufficient concentrations of the hepatotoxic metabolite 









Prescott (1981) found intravenous N-acetyl cysteine to be more 
successful than intravenous L-methionine in treating severe 
paracetamol poisoning and also found that cysteamine produced 
unpleasant side effects. Vale, Meredith and Goulding (1981) found 
oral methionine to be just as effective as intravenous ^-acetyl 
cysteine but found that incidence and severity of liver damage 
increased i f  treatment was delayed beyond 1 0  hours (both methionine 
and N^-acetyl cysteine should be given within eight hours for most 
effective protection against liv e r damage). These authors suggested 
that i f  patients were vomiting, j^-acetyl cysteine could be given 
intravenously but otherwise methionine should be used as i t  is  
inexpensive, reaches the live r directly i f  given orally and the 
total treatment is competed within 1 2  hours (compared with 2 0  hours 
for intravenous N-acetyl cysteine).
Tredger, Smith, Davis and Williams (1980, 1981), found in v itro  that 
f^-acetyl cysteine decreased the covalent binding of paracetamol to 
mouse hepatic microsomes but methionine showed no such effect, 
^-acetyl cysteine also decreased the concentrations of 
NADPH-cytochrome c reductase. Thus N-acetyl cysteine's protective 
effect against paracetamol-induced hepatotoxicity may be exerted by 
processes affecting the binding of a reactive paracetamol metabolite 
and to a lesser degree the formation of that metabolite. These 
authors concluded that methionine's effectiveness in vivo is due to 
mechanisms other than those involving interactions with the mixed 
function oxidase system or its  products. They suggested that as 
methionine was metabolised in vivo to homocysteine, cysteine and 
glutathione, these too might be responsible for its  effects.
Gal insky and Levy (1979) found that oral administration of acetyl 
cysteine to rats caused an increased formation of paracetamol 
sulphate and concluded that this may be partly responsible for its  
protective effect. Gal insky, Slattery and Levy (1979) found that 
administration of sodium sulphate to rats (as a bolus dose i.p .
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followed by an intravenous infusion over 2  hours) caused increased 
paracetamol sulphate formation and enhanced the elimination of 
paracetamol. When i t  was f ir s t  shown by Prescott, Newton, Swainson, 
Wright, Forrest and Mathews (1974) that cysteamine was a successful 
scavenger of the reactive metabolite, McLean (1974) suggested that 
methionine or cysteine (as glutathione precursors) could be added to 
paracetamol tablets. I f  i t  is found c lin ica lly  in man that 
administration of sodium sulphate has a protective e ffect, i t  may be 
feasible to include sodium sulphate or another source of sulphate in 
paracetamol - containing pharmaceutical products as suggested by 
Gal in sky et a l , (1979).
4.7. A possible toxic intermediate metabolite of paracetamol
Knight and Young (1958) found that for various substituted benzenes 
e.g. naphthalene, conjugation of an epoxide (a product of hepatic 
oxidation) with glutathione in it ia l ly  resulted in the production of 
acid-labile derivatives which they termed pre-mercapturates. These 
compounds are relatively stable in urine at pHS but undergo rapid 
dehydration in strong acid to give the corresponding aromatic 
metabolites. Results presented above indicate the presence of 
similar unaromatised metabolites of paracetamol and greatly 
increased amounts of S-substituted metabolites (pcO.OOl) and 
3-hydroxy paracetamol (p<0.02) were found after incubation at 
pHO.3. These results are however an underestimate of concentrations 
of acid-labile metabolites released by acid treatment becuase no 
account was taken of the continuing conversion of acid-labile  
metabolites to final compounds during acid treatment. These 
acid-labile species which constitute a large proportion of the 
oxidised metabolites of paracetamol may be considered to be hydroxy 
dihydrobenzenes of the type shown in Fig. 4 .7. Recovery of 
unaromatised and aromatised 2 -hydroxy paracetamol was consistently 
and substantially less than that of 3-hydroxyparacetamol probably 
















Although, largely as a result of in v itro  work the hepatotoxic 
metabolite of paracetamol is believed to be acetyl 
benzoquinonimine (Hinson, Pohl and G ille tte , 1979), i t  may be 
proposed as an alternative that toxicity may be due to the 2,3- or 
3,4-oxides of paracetamol, either of which could give rise to 
3-hydroxy paracetamol. Recent work by Hinson, Pohl, Monks, G ille tte  
and Guengerich (1980) suggests that the S-substituted metabolites 
which are believed to derive from the toxic intermediate, are formed 
by a pathway distinct from that which gives rise to 3-hydroxy 
paracetamol. The present results suggest that pathways of 0- and 
S-substitution are linked. As considerable amounts
of acid-labile forms of both groups of the ultimate oxidation 
products are found in urine, this suggests that these arise from 
nucleophilic attack on an epoxide ring (which may occur at either 
the 2- or 3-position) to produce, in it ia l ly ,  a hydroxydihydrobenzene 
(Fig. 4 .7 .1 ). As both 2-OH paracetamol and 3-OH paracetamol were 
found in urine, i t  is proposed that the pathways of 0 - and 
S-substitution originate from 4-hydroxy-2,3-dihydroacetanilide-2, 
3-oxide ( I I  in Fig. 4 .7 .1 ). Epoxides have been shown to be 
intermediates in the metabolic formation of phenols and 
transhydrodiols (see Garner, 1976) and the fast ring opening and 
closing of arene oxides via carbonium ions is thought to be 
responsible for their activ ity  with even weakly necleophilc sites on 
cell macromolecules (Jerina and Daly, 1974). In addition, epoxides 
are believed to be mediators in the tissue necrosis induced by a 
number of aromatic compounds, for example bromobenzene (Brodie,
Reid, Cho, Sipes, Krishna and G ille tte  (1971). I t  is therefore 
proposed that 4 -hydroxy-2, 3-dihydroacetanilide-2, 3-oxide is like ly  
to be an hepatotoxic metabolite of paracetamol in man.
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Chapter 5
Paracetamol Metabolism in Animals - Results 
General Introduction
Davis and his colleagues f ir s t  noted in 1974 that certain species 
including hamsters and mice are susceptible to paracetamol-induced 
live r necrosis (Davis, Potter, Jollow and Mitchell, 1974). Other 
species such as rats, rabbits and guinea pigs were found to be 
re lative ly  resistant to the hepatotoxic effects of paracetamol. I t  
w ill be apparent that man may be described as a susceptible species.
A variety of factors are believed to a lte r paracetamol metabolism 
and some of those which might be relevant to man were investigated 
in animal species. The effects of inducing agents and agents which 
compete for metabolic substrates were investigated because these may 
promote the metabolism of paracetamol by the potentially toxic 
oxidation pathway as indicated by an increase in cysteine and 
mercapturic acid excretion. Repeated dosing studies were also 
performed to see i f  there were any indications of tox ic ity . Because 
paracetamol serum half lives were not measured in overdosed human 
patients, experiments were carried out in rabbits to determine 
whether the effects that L-methionine showed in human overdosed 
patients (increasing the recovery of paracetamol as its  sulphate and 
glutathione conjugates) could be reproduced in rabbits and whether 
they resulted in a decrease in the area under the serum 
concentration time curve of paracetamol and/or a shorter plasma 
elimination h a lf - l i fe .
Four studies were carried out:
1) Effect of enzyme inducing agents on paracetamol metabolism.
2) Paracetamol metabolism following single and repeated doses.
3) Effect on paracetamol metabolism of agents which compete for
metabolic substrates.
4) Effect of L-methionine on paracetamol metabolism.
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In these experiments one susceptible species (the mouse) and one 
non-susceptible species (the guinea pig) were chosen for study.
These species were also studied so that the pattern of metabolites 
associated with toxicity could be examined.
5.1 Effect of inducing agents on the metabolism of paracetamol in 
guinea pigs and mice
Introduction
The effects of phenobarbitone, phenylbutazone and rifampicin on the 
metabolism of paracetamol were studied in guinea pigs and mice. The 
enzyme inducing effects of phenobarbitone, phenylbutazone and 
rifampicin after repeated dosing for several days are well known 
(Gelboin, 1971; Burns, 1971; Goldberg, 1980). Walker, Kelleher, 
Dixon and Losowsky, (1973) showed that phenobarbitone-pretreated 
mice showed a greater degree of liv e r necrosis than those treated 
with paracetamol alone. Jollow, Thorgeirsson, Potter, Hashimoto and 
Mitchell, 1974 showed that pretreatment with inducing agents known 
to potentiate hepatotoxicity increased the formation of paracetamol 
mercapturic acid. They also showed that the fraction of paracetamol 
converted to the mercapturic acid conjugate was highest in mice and 
hamsters (the most susceptible species) and lowest in species such 
as the ra t which were less susceptible to paracetamol's hepatotoxic 
effects. Wright and Prescott (1973) suggested that a 'potentially  
induced' group of paracetamol-poisoned patients developed more 
severe hepatic necrosis than 'non-induced' patients. However 
Prescott, Critchley, Balali-Mood and Pentland (1981) failed to find 
an increase in the cysteine and mercapturic acid conjugates of 
paracetamol in patients with microsomal enzyme induction although 
they did excrete less unchanged drug and paracetamol sulphate and 
correspondingly more paracetamol glucuronide than did healthy 
volunteers.
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This study was therefore carried out to confirm that pretreatment 
with phenobarbitone, phenylbutazone and rifampicin resulted in an 
increase in the oxidation pathway in these 2  species, suggesting a 
predisposition towards toxic ity . These effects could then be 
compared with results obtained from repeated dosing studies and 
after the simultaneous administration with paracetamol and metabolic 
competing agents.
Procedures
24 male mice and 4 male guinea pigs were pretreated with
either:
1) phenobarbitone lOOmg/kg i .p . per day for four days 
or 2) phenobarbitone lOOmg/kg i.p . per day for seven days
or 3) phenylbutazone lOOmg/kg i.p . per day for four days
or 4) rifampicin 80mg/kg i.p . per day for five  days.
Paracetamol 150mg/kg was given intraperitoneally on the morning of 
the final day using standard solutions of 75mg/ml in 0.9% saline for 
guinea pigs and 15mg/ml in 0.9% saline for mice. Guinea pigs and 
mice were housed in metabolic cages for the collection of urine for 
24 hours after dosing with paracetamol. Urine was then analyzed by 
HPLC for paracetamol and its  metabolites. Details of the standard 
solutions of inducing agents are given in Table 5.1.1 and 5.1.2 for 
guinea pigs and mice respectively. Cytochrome P^^q concentrations 
were measured but are not presented because of marked variation in 
the results obtained presumably because of a methodological error. 




Percentage recoveries of unchanged paracetamol and its  metabolites 
in 24 hour urine are given in Tables 5.1 .1 . and 5 .1 .2 . and 
individual quantities in mg and percentage recoveries of paracetamol 
and its  metabolites are given in Appendix 15 for guinea pigs and 
Appendix 16 for mice.
I t  can be seen from Table 5 .1 .1 . that paracetamol cysteine and 
mercapturic acid recoveries were increased significantly by a ll 
three inducing agents in guinea pigs (p<0.05) but recoveries of the 
other metabolites of paracetamol were not altered. Control 
paracetamol glucuronide concentrations were low because one guinea 
pig excreted approximately 0% as the glucuronide conjugate. These 
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Fig. 5.1.1 Effect of phenobarbitone pretreatment on paracetamol 
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Fig. 5.1.2 Effect of phenylbutazone pretreatment on paracetamol 
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Examination of the effects of these 3 agents on paracetamol metabolism in 
mice (Table 5 .1 .2 .) revealed that 4-day and 7-day phenobarbitone 
pretreatment significantly reduced paracetamol glucuronide recovery 
(p<0.05) and significantly increased the percentage recoveries of 
paracetamol cysteine and mercapturic acid compared with controls 
(p<0.001). Phenylbutazone significantly increased paracetamol 
mercapturic acid recoveries (p<0.025) but not paracetamol cysteine and 
rifampicin increased the percentage of paracetamol cysteine plus 
paracetamol mercapturate recovered (p<0 . 0 0 1 ) while also decreasing the 
recovery of unchanged paracetamol (p<0.05) when compared with controls. 
None of the other metabolites of paracetamol was significantly increased 
or decreased by these 3 agents in mice. These results are plotted in 
Fig. 5 .1 .4 , 5.1.5 and 5.1 .6 .
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Fig. S 1.4.
Effect of phenbbàzbitone pretreatment on paracetamol metabolism 
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Fig. 5.1.5 E ffect of phenylbutazone pretreatment on paracetamol
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Fig. 5.1.6.
Effect of rlfanpicln pretxeatiaent on paracetamol mstabolian 
in mice (means ± S.E.M.)
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5.2 Paracetamol metabolism in animals following single and repeated 
doses
Introduction
The effects of a single dose of paracetamol lOOmg/kg and of paracetamol
lOOmg/kg twice daily for 9 days (guinea pigs) or 11 days (mice) on the
urinary metabolites of paracetamol were investigated.
Procedures
a) Single doses
i )  4 male guinea pigs were given paracetamol lOOmg/kg i .p . in a single
dose using a standard solution of lOOmg/ml in 0.9% saline. The 
guinea pigs were housed in individual metabolic cages (Associated 
Crates Limited) and maintained in a constant lig h t (5am-7pm) - dark
(7pm-5am) cycle. Urine from the guinea pigs was collected for 24
hours after dosing and was analyzed by HPLC for paracetamol, 
paracetamol glucuronide, paracetamol sulphate, paracetamol cysteine 
and paracetamol mercapturic acid as described in Section 2 .7 .e .
i i )  24 male mice were given paracetamol lOOmg/kg i .p . in a single dose
using a standard solution of lOmg/ml in 0.9% saline. The mice were
housed in metabolic cages (North Kent Plastic) and maintained in a 
constant lig h t (5am-7pm) - dark (7pm-5am) cycle. Urine from the 
mice was collected for 24 hours after dosing and was assayed for 
paracetamol and its  metabolites by HPLC.
b) Repeated doses
i)  4 male guinea pigs were given paracetamol lOOmg/kg i.p . morning and
evening for 9 days using a standard solution of lOOmg/ml in 0.9% 
saline. The guinea pigs were housed in individual metabolic cages 
(Associated Crates Limited) and maintained in a constant ligh t
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(5am-7pm) - dark (7pm-5am) cycle. Urine from the guinea pigs was 
collected in separate containers for the periods 0-24h, 24-72h, 
72-120h, 120-168h and 168-216h after dosing and was analyzed by 
HPLC for paracetamol and its  metabolites.
i i )  24 male mice were given paracetamol lOOmg/kg i .p . morning and
evening for 11 days using a standard solution of lOmg/ml in 0.9% 
saline. The mice were housed in metabolic cages (North Kent 
Plastic) and maintained in a constant lig h t (5am-7pm) - dark 
(7pm-5am) cycle. Urine from the mice was collected in separate 
containers for the periods 0-24h, 24-72h, 72-120h, 120-168h, 
168-216h and 216-264h urine after dosing and was analyzed by HPLC 
for paracetamol and its  metabolites.
Results
Values obtained for each metabolite of paracetamol in urine were 
converted to the weight of paracetamol using correction factors 
given in Appendix 1 and then expressed as percentage recovery of 
the total recovery of parent drug and metabolites in each urine 
collection period.
Results after single doses of paracetamol are given in Table
5.2 .1 . Individual results are given in Appendix 17 and Appendix 
18. Mean results for repeated doses of paracetamol in guinea pigs 
and mice are given in Table 5.2.2 and 5.2.3 and individual results 
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Percentage recoveries of paracetamol and its  metabolites a fter  
repeated doses in guinea pigs and mice are shown in Figs. 5 .2 .1 . and
5.2.2 . respectively.
When the percentage recoveries of unchanged paracetamol and its  
metabolites for single and repeat dosing in guinea pigs were 
compared, the recoveries in the f ir s t  24 hours of the repeated dose 
study were not significantly different from recoveries in the single 
dose study. In 24-72h urine, percentage recovery of paracetamol 
glucuronide was significantly (p<0.05) lower than after the single 
dose; in 72-120h urine percentage recovery of paracetamol 
glucuronide was significantly lower (p<0.025) while unchanged 
paracetamol was significantly higher (p<0.025) than after the single 
dose; in 120-168h urine, percentage recoveries of paracetamol 
glucuronide were significantly higher (p<0.05) and of unchanged 
paracetamol were significantly lower (p<0.05) than after the single 
dose. When repeat dosing over the 9 day period was examined in 
guinea pigs using the paired ' t ‘ test, there were found to be no 
significant changes in the recoveries of urinary metabolites over 
the whole 9 days except for a significant increase in paracetamol 
cysteine percentage recovery in the las t 2  days (p<0 . 0 0 1 ) compared 
with the f ir s t  24 hour period. There was a trend for paracetamol 
glucuronide recovery to decrease and unchanged paracetamol to 
increase over the whole period but this did not reach statis tica l 
significance.
When urinary recoveries after a single dose of paracetamol lOOmg/kg 
were compared with repeated twice-daily dosing over 1 1  days in mice 
marked differences were found. In the f ir s t  24 hours of their 
repeated dosing regimen, mice excreted significantly higher amounts 
of paracetamol glucuronide (p<0 . 0 2 ) and paracetamol cysteine plus 
mercapturic acid (p<0.05) due to increased recoveries of paracetamol
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Fig. 5.2.1 Effect of repeated dosing on paracetamol metabolism in 
guinea pig showing percentage recovery (means ± S.E.M.) 
of paracetamol and its  metabolites. Concentrations of 




















Fig. 5.2.2 Effect of repeated dosing on paracetamol metabolism in 
mice showing percentage recovery (means ± S.E.M.) of 
paracetamol and its  metabolites. Concentrations of 
paracetamol sulphate were below detection (< 1 0 yg/ml)
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cysteine (p<0.005) and lower recoveries of unchanged paracetamol 
(p<0.005) and paracetamol sulphate (p<0.005) than mice after the 
single lOOmg/kg dose. However, paracetamol glucuronide recovery 
decreased significantly with repeated dosing compared with the 
single dose recovery (p<0.05) in periods 72-120h and 120-168h 
although glucuronide excretion appeared to increase (though not to a 
significant extent) towards the end of the 1 1  day period compared 
with the single dose. The decrease in glucuronide excretion was 
accompanied by a significant increase in unchanged paracetamol in 
urine (p<0.05) in the same periods when compared with the single 
dose value. The amount of paracetamol sulphate excreted was always 
lower after repeated dosing than with the single dose (p<0.005). 
Recoveries of paracetamol cysteine plus mercapturic acid were 
significantly increased in the 168-216h and 216-264h collections 
(p<0.005) compared with the single dose values. These were due to 
significant increases in paracetamol cysteine recoveries (p<0 . 0 0 1 ) 
after repeated doses while mercapturate recoveries did not change.
Repeat dosing in mice was examined to compare the metabolic pattern 
seen in the f ir s t  24 hours with that seen in each subsequent 2 day 
period. There was a significant decrease in the recovery of 
paracetamol glucuronide (p<0.05) accompanied by a significant 
increase in paracetamol recovered unchanged (p<0.025) over the 11 
days. No detectable paracetamol sulphate was excreted by any of the 
mice during the 0 - 1 1  day period in contrast to the finding with the 
single dose. Percentages of paracetamol cysteine plus mercapturic 
acid recovered were significantly decreased in the 72-120h period 
(p<O.OS) but a t la ter collection periods the trend was reversed and 
by the 216-264 hour period recoveries of these metabolites were 
significantly increased (p<0.05) compared with recoveries in the 
0-24h period. When paracetamol cysteine recoveries alone were 
examined, they were found to be significantly lower from 24h-120h 
compared with the f ir s t  24 hours (p<0.05) but by the 216-264h period 
were significantly higher (p<0.025) than recoveries in 0-24 hour 
urine. Paracetamol mercapturate concentrations did not a lte r until 
they became significantly higher in the 216-264h period compared 
with 0-24 hour urine.
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5.3 The E ffect o f Metabolic Competing Agents on Paracetamol
Metabolism in  Guinea Pigs and Mice
Introduction
In this experiment the effects of three drugs which could a lte r the 
metabolism of paracetamol by competing for metabolic substrates were 
studied. Salicylamide may compete with paracetamol for sulphate and 
glucuronic acid (Levy and Yamada, 1971). L-ascorbic acid and 
a-tocopherol also conjugate with sulphate but also have other 
properties which appear to protect the live r from the toxic ity  of 
paracetamol (Raghuram, Krishnamurthi and Kalamegham, 1978; Walker, 
Kelleher, Dixon and Losowsky, 1974).
Procedures
4 male guinea pigs were given paracetamol 100mg/kg i.p . in a single 
dose using a standard solution of lOOmg/ml in 0.9% saline. The 
competing agent was given immediately before this in a dose of 
lOOmg/kg i .p .  using a standard solution of lOOmg/ml in 0.9% saline 
for L-ascorbic acid and salicylamide and a standard solution of 
200mg/ml for a-tocopherol. Guinea pigs were housed in individual 
metabolic cages (Associated Crates Limited) for 24 hours in a 
constant lig h t (5am - 7pm) - dark (7pm-5am) cycle for urine 
collection. Urine was analyzed by HPLC for paracetamol and its  
metabolites.
24 male mice were given paracetamol 100mg/kg i .p . in a single dose 
using a standard solution of lOmg/kg in 0.9% saline for L-ascorbic 
acid and salicylamide and a standard solution of lOmg/ml in 
d is tille d  water for a-tocopherol. Mice were housed in metabolic 
cages (North Kent Plastic) for 24 hours in a constant ligh t (5am - 
7pm) - dark (7pm - 5am) cycle for urine collection. Urine was 
analyzed by HPLC for paracetamol and its  metabolites.
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Resul ts
Table 5.3 .1 . and 5 .3 .2 . give the percentage recoveries of unchanged 
paracetamol and its  metabolites and its  four major metabolites after 
paracetamol lOOmg/kg alone and after the same dose of paracetamol 
given with lOOmg/kg of each competing agent to guinea pigs and 
mice. The results are plotted in Figs. 5 .3.1, 5.3.2 and 5.3 .3 . for 
guinea pigs and Figs 5 .3 .4 , 5.3.5 and 5.3.6 for mice. Individual 
results are given in Appendix 21 (guinea pigs) and Appendix 22 
(mice).
The three competing agents appear to a lter the metabolism of 
paracetamol in guinea pigs to a similar extent. All three caused a 
significant increase in the percentage recovery of paracetamol 
glucuronide (p<0.05) accompanied by a significant decrease in 
unchanged paracetamol (p<0.05). L-ascorbic acid and salicylamide 
did not change the metabolic profile of paracetamol significantly in 
mice but a-tocopherol significantly increased the recoveries of 
paracetamol glucuronide and paracetamol cysteine and mercapturic 
acid (p<0.05) and decreased the recovery of unchanged paracetamol 
(p<0.025). None of the percentage recoveries of other metabolites 
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Effect o$~salicylamlde on paracetamol metabolism in guinea pigs 
(means ± S.E.M.)
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Fig. 5.3.3 Effect of a-tocopherol on paracetamol metabolism 
in guinea pigs (means ± S.E.M.)
percentage recovery
100
O ICO mg/kg paracetamol
• 100 mg/kg paracetamol + 
100 mg/kg «-tocopherol
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Fig. 5.3.4 Effect of salicylamide on paracetamol metabolism in 
mice (means ± S.E.M.)
percentage recovery 
100-1
O 100 mg/kg paracetamol
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Flo. 5•3.5.
Effect of L-ascorbic acid on paracetanol metabolism in mice 
(means ± S.E.M.)
100 ̂  percentage recovery
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• 100 mg/kg paracetamol
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5.4 Metabolism of paracetamol in rabbits in the presence of 
L-methioni ne
Introduction
Results presented in Section 3.6 suggested that L-methionine 
administered to patients with paracetamol poisoning caused increased 
recoveries of the sulphate and cysteine plus mercapturic acid 
conjugates of paracetamol compared with recoveries of these 
metabolites before treatment. The experiments described below were 
carried out to examine the overdose situation in detail and were 
carried out in rabbits because of the relative ease of obtaining 
blood samples from this species compared with small laboratory 
animals. Although Davis et a l, (1974) suggested that the rabbit is 
not a species susceptible to paracetamol-induced hepatotoxicity ( 8 % 
showed some degree of centrilobular hepatic necrosis after 
paracetamol 750mg/kg), its  urinary metabolic profile is similar to 
man.
Procedures
As no males were available, 3 female rabbits were used throughout 
the study, each acting as its  own control. Table 5.4.1. details the 
doses of paracetamol and L-methionine given in Experiments 1, 2 ,, 3, 
3 repeat and 4 which occurred in sequence. During each experiment 
blood samples (approximately 3m1 from each rabbit) were taken every 
45 minutes for 5.25 hours after dosing. Food and were allowed ad 
libitum and rabbits were housed in individual metabolic cages 
(Associated Crates Ltd) for 24 hours after dosing so that urine 
could be collected. Serum and urine samples were analyzed by HPLC 
as described in Section 2.7.b. At least fourteen days were allowed 
to elapse between experiments so that recovery of blood volume might 
be achieved. The area under the serum concentration time curve was 
calculated using the trapezoidal rule described by Natari (1975) 
from 0 - 3 1 5  minutes.
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Values of AUC for each animal during each experiment from 0 - 315 
minutes after dosing are given in Table 5 .4 .2 . When these figures 
were corrected for rabbit weight (shown in brackets), there was 
found to be a significant increase in AUC after paracetamol 400mg/kg 
(Experiment 2) compared with after paracetamol lOOmg/kg in 
Experiments 1, 3 and 3 repeat (p<0.02). There was no significant 
difference between AUCs in Experiments 1, 3 and 3 repeat after doses 
of lOOmg/kg (p>0.05). When methionine 400mg/kg was given with 
paracetamol 400mg/kg in Experiment 4, there was no significant 
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Table 5.4.3 AUC ra tios  fo r Experiments 2 and 4 to  Experiment 1
Rabbi t dose ratio
AUC Expt. 2 
AUC Expt. 1 dose ratio
AUC E x p t .  4 
AUC E x p t .  1
Rabbit A 4 1 1 . 0 4 5.3
Rabbit B 4 5.8 4 4.1
Rabbit C 4 11.3 4 4.4
Table 5.4.3 gives AUC ratios for Experiment 2 and 4 relative to 
Experiment 1 for each rabbit. I t  can be seen that after paracetamol 
400mg/kg in Experiment 2 there is no indication of 
proportionality between AUC ratio  and dose ratio  compared with 
paracetamol lOOmg/kg (Expt. 1). In Experiment 4 though when 
paracetamol 400mg/kg and L-methionine 400mg/kg were given in 
conjunction the data now suggest that f i r s t  order kinetics are 
resumed although changes in two rabbits were more marked than in the 
th ird .
Serum concentrations of paracetamol against time are shown in Figs 
5.4.1 . 5 .4 .2 , 5 .4 .3 , 5 .4 .4 , and 5.4.5. Figs 5 .4 .6 , 5 .4 .7 , 5 .4 .8 , 
5.4.9 and 5.4.10 show serum concentrations of paracetamol 
glucuronide and paracetamol sulphate in each experiment and levels 
of cysteine and mercapturic acid metabolites of paracetamol where 
these appeared in high enough concentrations. Concentrations of 
these four metabolites are (corrected for molecular weight) and 
expressed as percentage recovery and these values are also given in 
Table 5 .4 .4 . I t  can be seen that while mercapturic acid 
concentrations in serum were low (and were only detectable in 
Experiments 1 and 2) compared with serum cysteine levels, in urine 
mercapturate levels showed a mean of 8.3% ± 1.3% compared with mean 
urinary cysteine levels of 0.8% ± 0.3% (n = 12, calculated from 
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Fig. 5.4.6 Serum concentrations of the glucuronide, sulphate, 
cysteine and mercapturate conjugates of paracetamol 
after lOCmg/kg orally  (Experiment 1)
Key: ■ paracetamol glucuronide 
A paracetamol cysteine 
□ paracetamol mercapturic acid 
yg/mi A  paracetamol sulphate30.
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Fig. 5.4.7 Serum concentrations of the glucuronide and sulphate 
conjugates of paracetamol after 40Cmg/kg orally  
(Experiment 2)
























Fig. 5.4.8 Serum concentrations of the glucuronide, sulphate and 
cysteine conjugates of paracetamol after lOOmg/kg 
paracetamol orally (Experiment 3)


























Fig. 5.4.9 Serum concentrations of the glucuronide, sulphate and
cysteine conjugates of paracetamol after lOOmg/kg orally  
(Experiment 3 repeat)
Key: ■ paracetamol glucuronide 
























































3 Q . O £
to L
3 0)





s_ R3 o o
3 &_ E E
<-> fd 03 fO
3 Q . 4-> ■M
<U <U
O ) cn O U
fO (O
o> &_ s_
JZ cn <o 03





























Table 5.4.4 Percentage urinary recovery o f paracetamol and i t s
metabolites
P PG PS PC PM PC + PM
Expt. 1 
Rabbit A 1.46 68.44 18.42 0 . 2 1 11.46 11.67
Rabbit B 1.35 71.85 14.80 0.16 11.83 11.99
Rabbit C 1 . 0 2 71.39 16.95 0.24 10.40 10.64
Expt. 2 
Rabbit A 8 8 . 6 6 2.78 5.69 0.09 2.78 2.87
Rabbit B 80.86 0.70 10.58 0 . 1 1 7.74 7.85
Rabbit C 33.67 55.87 6.31 0.55 3.59 4.14
Expt. 3 rpt 
Rabbit A 0 . 1 0 74.51 15.63 0.42 9.34 9.76
Rabbit B 19.76 48.62 16.45 0.41 14.76 15.17
Rabbit C 0.30 78.71 14.07 0.93 5.99 6.92
Expt. 4 
Rabbit A 0.39 80.38 12.13 3.17 3.92 7.09
Rabbit B 4.59 81.27 7.43 1 . 2 0 5.51 6.71
Rabbit C 0 . 6 6 4.70 7.46 2.24 4.93 7.17
After the hiah dose of naracetamol ( 4 n o m r r / k a )  in 
experiment 2 liver damage may well have occurred
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Fig. 5.4.11 Urinary excretion of paracetamol and i ts  metabolites 
in rabb its . Results are expressed a a percentage 
recovery fo r each o f three rabbits in  four 
experiments
Ratbit A RaUalt B Babbit C
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Urinary concentrations of paracetamol cysteine plus mercapturic acid 
were significantly decreased after paracetamol 400mg/kg (Experiment 
2) compared with both the control lOOmg/kg dose in Experiment 1 
(p<0.05) and Experiment 3 repeat (p<0.02). Two out of 3 rabbits 
showed an increase in the percentage cysteine and mercapturic acid 
recovery when L-methionine was given just prior to paracetamol 
400mg/kg (Experiment 4) compared with paracetamol 400mg/kg alone 
(Experiment 2). However, when compared with concentrations found in 
Experiment 1, cysteine and mercapturic acid concentrations after 
methionine were significantly lower (p<0 . 0 2 )
I t  can also be seen from Table 5.4.4 and Fig 5.4.11 that after the 
400mg/kg dose of paracetamol administered in Experiment 2, the 
amount excreted as paracetamol glucuronide was markedly decreased, 
accompanied by an increase in paracetamol recovered unchanged 
(compared with values in Experiments 1 and 3 repeat) although this 
did not reach significance when a paired ' t '  test was used.
However, peak serum concentration of paracetamol glucuronide in 
Experiment 2 showed the opposite, that is that peak serum 
glucuronide concentrations were higher than paracetamol 
concentrations (as shown in Table 5 .4 .5 ). In Experiment 4, Table 
5.4.5 shows that peak serum paracetamol concentrations were lower 
than in Experiment 2 and paracetamol glucuronide peak levels were 



























3 10) o<J •*“
k . 4->
197
Table 5.4.6 gives values for the pG/PS ratio  for each rabbit in each 
experiment in serum and urine. I t  can be seen that the PG/PS ratio  
in serum is higher over a longer period in Experiment 2 (dose of 
400mg/kg) than in Experiment 1 (dose of lOOmg/kg) (although this 
change does not reach significance) suggesting that sulphate 
depletion may have occurred. However, in urine in these two 
experiments the reverse occurred (because l i t t l e  paracetamol 
glucuronide was excreted, as has already been described). After 
L-methionine (Experiment 4) PG/PS ratios in serum remained similar 
to values in Experiment 1 because glucuronide concentrations were 
not as high as in Experiment 2.
In this series of experiments there was l i t t l e  to be gained from 
examination of (PG+PS)/(PC+PM) ratios as paracetamol glucuronide was 
present in by far the greatest amounts in both serum and urine 
except in Experiment 2 in which unchanged paracetamol was the 
dominant excretory product.
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Table 5 .4 .6  PG/PS ra tio  fo r each rabb it in urine (corrected fo r molecular 
welght)
Minutes 45 90 135
Serum
180 225 270 315 Urine
Expt. 1 
Rabbit A 2.55 3.87 3.39 5.29 9.87 3.71
Rabbit B 7.29 1.88 7.94 4.85
Rabbit C 5.84 2.56 2.35 3.15 4.21
Expt. 2 
Rabbit A 16.33 19.32 21.42 29.30 26.01 27.51 38.26 0.49
Rabbit B 5.18 7.66 8.10 10.33 10.94 17.11 20.69 0.07
Rabbit C 5.29 6.52 6.54 8.07 7.31 9.90 9.28 8.85
Expt. 3 
Rabbit A 4.18 3.78 3.74 6.18 12.59 17.99
Rabbit B .5.44 6.35 6.97 13.44 00 1.86
Rabbit C 3.79 3.57 4.29 4.54 00
Expt. 3 rept 
Rabbit A 3.57 4.41 4.88 6.49 15.10 CO 4.77
Rabbit B 8.13 7.04 2.96
Rabbit C 4.10 4.26 4.24 4.62 5.59
Expt. 4 
Rabbit A 5.31 5.62 6.28 7.33 5.42 4.65 4.45 6.62
Rabbit B 5.25 6.97 7.89 8.49 8.53 9.01 10.61 10.93
Rabbit C 5.57 5.41 5.02 5.01 5.03 5.00 5.63 11.34
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Chapter 6
Paracetamol Metabolism in Animals - Discussion
The capacity of paracetamol to cause hepatic necrosis was f ir s t  
noted in 1964 when Eder carried out toxicity studies in cats. Ten 
years la ter i t  was reported that serious hepatic necrosis also 
occurred in man after high doses of paracetamol (Davidson and 
Eastham, 1966 and Thomson and Prescott, 1966) and more recently i t  
was reported that some species were susceptible to 
paracetamol-induced hepatic necrosis while other species seemed to 
be resistant to the hepatotoxic effects of paracetamol (David, 
Potter, Jollow and Mitchell, 1974). A table summarising the dose 
levels of paracetamol causing centrilobular liv e r  necrosis and 
mortality of various species taken from Davis et a l, 1974 is shown 
in Table 6.1. I t  is interesting that susceptibility to hepatic 
necrosis and mortality seem to be inversely related in this but 
death in the species most resistant to paracetamol hepatotoxicity 
may have been caused by glycogen depletion.
In the experiments carried out in the present animal studies, i t  was 
decided to examine the metabolism of paracetamol in the guinea pig 
(a non-susceptible species) and in the mouse (a susceptible 
species). The metabolism of paracetamol after pretreatment with 
three e n ^ e  inducing agents, during repeated dosing and during the 
concurrent administration of three metabolic competing agents was 
studied.
The metabolism of paracetamol in the presence of L-methionine was 
also examined in rabbits. Rabbits might, (from Table 6.1) be 
described as a non-susceptible species but they show a similar 
urinary metabolic profile to man and in addition have a large enough 
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6.1 Effects o f three enzyme inducting agents on paracetamol
metabolism in  mice and guinea pigs
In the present study the effects of phenobarbitone, phenylbutazone 
and rifampicin on the metabolism of paracetamol in mice and guinea 
pigs were examined.
In guinea pigs control recoveries of paracetamol cysteine and 
mercapturic acid were zero but small amounts of these metabolites 
were recovered after pretreatment with each of the three inducing 
agents. The low recoveries of these metabolites may be due to a 
limited a b ility  of the guinea pig either to oxidise paracetamol to 
its  toxic metabolite or to detoxify the reactive intermediate to the 
cysteine and mercapturic acid metabolites via glutathione 
transferase. Davis et al (1974) found this species to be relatively  
resistant to the glutathione depletion, covalent binding and hepatic 
necrosis cuased by paracetamol (despite causing a high percentage 
mortality probably as a result of glycogen depletion). These 
results suggest that guinea pigs form low amounts of the toxic 
intermediate metabolite even after induction of the P-450 system.
In mice a ll three inducing agents markedly increased the proportions 
of paracetamol cysteine plus mercapturic acid recoveries and 
decreased the proportion of paracetamol glucuronide recovered.
Since concentrations of the glutathione conjugates were high even in 
control animals (nearly 16% of the percentage recovery) this route 
represents a major pathway even when compared with sulphate 
conjugation. Although sulphate conjugation remained low, i t  is  
possible that glucuronide conjugation (which tends to predominate 
over sulphate conjugation i f  there is a high circulating  
concentrations of paracetamol) would decrease as a result of the 
greater amounts being oxidised and then conjugated with glutathione
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caused by the inducing agent. Alternatively the inducing agents may 
have caused glucuronic acid depletion. Balonowska and Gessner 
(1980) described glucuronyl transferase in rats as having a much 
higher Km value for paracetamol than sulphotransferase. Thus 
sulphate becomes a predominant route of metabolism i f  low 
concentrations of paracetamol are present and the V max for 
sulphation is lower than that for glucuronidation. However, these 
observations may be more applicable to man and rat in which species 
sulphate conjugation is a more prominent pathway.
Several studies have shown that paracetamol is activated
metabolically by a cytochrome P-450-dependent drug metabolising
enzyme located in the endophasmic reticulum of the liv e r to an
arylating agent which binds covalently probably to amine acids on
liv e r proteins. Pretreatment with various inducers of drug
metabolising activ ity  were shown by Jollow, Thorgeirsson, Potter,
Hashimoto and Mitchell, (1974) to increase the formation of the
mercapturic acid metabolite of paracetamol and to potentiate hepatic
necrosis in some species while inhibitors of drug metabolising
enzymes inhibited the metabolism of paracetamol and protected
against hepatic necrosis. This suggested that paracetamol-induced
hepatic necrosis was mediated by a toxic metabolite of paracetamol
(Mitchell, Jollow, Potter, Davis, G ille tte  and Brodie, 1973).
Jollow, Mitchell, Potter, Davis, G ille tte  and Brodie, (1973) found
the pretreatment with inducers or inhibitors of drug metabolism
increased and decreased respectively the extent of covalent binding
which in turn altered the severity of hepatic necrosis in some
species. They found that peak concentrations of the binding of 
3H-paracetamol preceded the development of recognisable necrosis 
by one to two hours. In hamsters, however, i t  was found that 
pretreatment with phenobarbitone markedly increased the excretion of 
paracetamol glucuronide and excretion of paracetamol mercapturate 
was unaffected while 3-methylcholanthrene pretreatment enhanced the 
excretion of the mercapturic acid metabolite (Jollow et a l,  1974).
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This suggests that in hamsters oxidation of paracetamol to its  toxic 
metabolite may perhaps be mediated by cytochrome P-448 alone while 
in mice and rats oxidation to the reactive intermediate may involve 
both cytochrome P-448 and P-450.
Rifampicin has been described as an inducer of drug metabolism by 
several workers (e.g. Mi guet, Mavier, Soussey and Dhumsaur, 1977, 
Ohnhaus and Park, 1979, Goldberg, 1980). Bolt and Remmer (1976) 
found that induction of NADPH-cytochrome c reductase occurred a fter 
pretreatment of rats with 20mg/kg rifampicin over 5 days. Recently 
Prescott, Critchley, Balali-Mood and Pentland (1981) examined the 
metabolism of paracetamol in man after pre treatment with rifampicin 
or anticonvulsants. They found that glucuronide conjugation of 
paracetamol was increased, that sulphate conjugation and unchanged 
paracetamol excretion were decreased but cysteine and mercapturic 
acid metabolites were largely unchanged. This implies that only a 
small induction of the potentially toxic pathway had occurred ( i f  at 
a ll)  so that treatment of man with rifampicin or anticonvulsants 
does not appear to increase the toxicity of paracetamol. The 
increase in glucuronidation suggests that these inducers may act in 
a similar fashion to phenobarbitone in hamsters and may even protect 
against paracetamol-induced liv e r disease.
Phenylbutazone caused a significant increase in the proportion 
recovered as the cysteine plus mercapturic acid metabolites of 
paracetamol by increasing the percentage recovery of mercapturate 
but not paracetamol cysteine. Phenylbutazone has been reported to 
cause the induction of hepatic microsomal enzymes in man and as 
phenylbutazone and paracetamol may be used concurrently in 
rheumatoid a rth ritis  and gout, i t  may be important to determine the 
metabolism of paracetamol in man in the presence of phenylbutazone 
(or indeed any commonly used drug know to induce drug metabolising 
enzymes). Although results from Prescott e t. a l. (1973) suggest 
that inducing agents may not increase the toxicity of paracetamol in
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man, i t  was reported by Critchley, Cregen, Balali-Mood, Pentland and 
Prescott (1982) that in some heavy drinkers, chronic consumption of 
alcohol may enhance the recovery of paracetamol as its  cysteine and 
mercapturic acid metabolites. I f  the metabolism of paracetamol in 
man is similar to hamster metabolism rather than mouse metabolism of 
paracetamol then induction of paracetamol hepatotoxicity may be via 
a P-448-type mechanism rather than a phenobarbitone-type reaction. 
Thus the possibility is raised that phenobarbitone-type inducers 
might increase the proportion of paracetamol excreted as its  
glucuronide (a safe pathway) while inducers of P-448 might result in 
increased formation of the reactive metabolite of paracetamol and 
hence might lead to tox ic ity .
6.2 The effect of repeated dosing of paracetamol in mice and guinea 
pigs
A study of the metabolism of paracetamol has been carried out in 
mice and guinea pigs to determine the urinary metabolic profile  of 
paracetamol in these species after repeated dosing. When repeated 
and acute dosing studies were compared, there were found to be 
significant decreases in the percentage recoveries of paracetamol 
glucuronide and increase in the percentage recoveries of unchanged 
paracetamol in both species after repeated dosing suggesting that 
glucuronic acid available for conjugation may have become depleted. 
In mice, percentage recoveries of the cysteine and mercapturic acid 
metabolites f ir s t ly  decreased and then, towards the end of the study 
increased again. Buttar, Chow and Downie (1977) found that in rats, 
paracetamol caused a dose-dependent depletion of hepatic glutathione 
with maximum depletion occurring 3 hours after acute dosing, 
returning to normal by 12 hours after low doses. However, before 
returning to normal, live r glutathione concentrations became 
significantly greater than control values suggesting a glutathione 
rebound action. They also found that when animals were treated for 7 
days with paracetamol Ig/kg b.d. liv e r glutathione concentrations
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were significantly higher after 7 days than in rats treated with a 
single dose of paracetamol (Ig /kg). From the present results the 
increases in percentage recovery of paracetamol cysteine plus 
mercapturic acid with time may relect a greater ava ilab ility  of 
glutathione for conjugation with the oxidised metabolite perhaps as 
a result of a homeostatic feedback mechanism while in it ia l ly  
glutathione may not have been so freely available. Thus the 
decreased cysteine and mercapturic acid recoveries may have 
reflected a potentially toxic situation as glucuronide conjugation 
was also decreased. Further experiments could be carried out to 
determine hepatic glutathione concentrations during the whole period 
so that the true course of the in it ia l depletion of glutathione and 
the possibility of an increased glutathione ava ilab ility  with time 
might be assessed.
Barker, Carle and Anvras (1977) described 3 cases of toxic hepatitis 
in man asociated with the chronic ingestion of 5 - 8 g paracetamol 
per day for a period of several weeks. They suggested that 
hepatotoxicity after chronic ingestion may be quite common 
especially in those patients with predisposing conditions. Chronic 
administration of paracetamol to patients with inflammatory jo in t  
disease might show a similar metabolic pattern to the repeat dosing 
in mice although there was no evidence of this in the study 
described in Section 3.3. Therefore the 'glutathione rebound 
action' of paracetamol seen after single high doses of paracetamol 
in rats (Buttar et a l, 1977) might also occur after repeated dosing 
in mice and might also explain the lack of evidence for increased 
susceptibility to paracetamol toxicity in the rheumatoid patients.
6.3 Metabolism of paracetamol in the presence of competing agents
The effects of three metabolic competing agents on the metabolism of 
paracetamol in mice and guinea pigs were determined. Salicylamide 
has been reported to conjugate both with glucuronic acid and 
sulphate in man (Levy and Yamada, 1971), ascorbic acid conjugates 
with endogenous sulphate (Raghuram, Krishnamurthi and Kalamegham, 
1978) and a-tocopherol conjugates with glucuronic acid.
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In addition ascorbic acid and a-tocopherol have both been reported 
to act as antioxidants (Burns, 1975, Cohn, 1975).
In guinea pigs, a ll 3 agents were found to increase paracetamol 
glucuronide recovery and to decrease unchanged paracetamol recovery 
(p<0.05). In mice, a-tocopherol increased paracetamol glucuronide 
recovery and increased paracetamol cysteine plus mercapturic acid 
recoveries (p<0.05) while reducing the recovery of unchanged 
paracetamol (p<0.025). Salicylamide and ascorbic acid did not 
significantly a lter the percentage recoveries of the metabolites of 
unchanged paracetamol in mice. I t  thus appears that a ll 3 agents 
induce glucuronyl transferase activ ity  in the guinea pig and in the 
mouse a-tocopherol appears to act by inducing glucuronyl transferase 
activ ity  and by increasing the products of oxidation of paracetamol 
either by inducing the formation of the reactive intermediate or by 
increasing the activ ity  of glutathione transferase. Thus 
a-tocopherol in vivo does not, under these experimental conditions, 
appear to be acting in its  capacity as an anti oxidant. Free 
D-glucuronic acid, formed from UDP-glucuronic acid by enzymic 
hydrolysis is a precursor in the biosynthesis of L-ascorbic acid 
(Lehninger, 1972). I t  is possible that the increase in paracetamol 
glucuronide seen after L-ascorbic acid administration to guinea pigs 
is related to this biochemical pathway. Perhaps normally a certain 
proportion of free glucuronic acid is sequestered for the formation 
of the small amount of L-ascorbic acid that guinea pigs produce 
(compared with other species). Thus administration of exogenous 
L-ascorbic acid may make glucuronic acid available for conjugation 
with paracetamol. Some workers have suggested that the dosage form 
of L-ascorbic acid may be important (Butterworth, Evans, Hargreaves 
and Pelling, 1982) and i t  is possible that intraperitoneal 
administration of L-ascorbic acid may not reach its  site of action 
in mice. L-ascorbic acid has been shown to inh ib it covalent binding
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in v itro  (Lake, Harris, Phillips and Gangolli, 1981) and these 
authors suggested that endogenous L-ascorbic acid formed in rodent 
and human liv e r  and exogenously applied L-ascorbic acid may 
supplement endogenous protective mechanisms (such as reduced 
glutathione) by maintaining SH-activated en^me systems in their 
reduced form. Alternatively, L-ascorbic acid might act to reduce 
the oxidised metabolite although the present results do not support 
this hypothesis. Following this the reactive intermediate may 
either proceed along other minor pathways of metabolism or may even
form a complex with ascorbic acid itse lf.^  Altematlvelv the increase in
alucuronidation may h a v e !been effected because of methionine's 
nrotective effect on the liver
6.4 MetaDonsm or paracetamm m rabbits in the presence of 
L-methionine
The effects of L-methionine on paracetamol metabolism in rabbits was 
studied. Rabbits were not considered by Davis et a l, (1974) to be a 
species susceptible to paracetamol-induced hepatic necrosis. AUCs 
calculated for the higher dose of paracetamol with and without 
L-methionine were not significantly different from each other but 
both were significantly higher than those calculated for the 
lOOmg/kg doses of paracetamol (p<0.05).
Assuming complete absorption of drug from the gut an increase in the 
AUC may be considered to be due either to saturation of the drug 
elimination process or to saturation of certain metabolic processes. 
As peak serum concentrations of both paracetamol and paracetamol 
glucuronide were lower in general when methionine was given than
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paracetamol 400mg/kg alone, L-methionine may have decreased the rate 
or extent of absorption of paracetamol. Methionine may also have 
increased the rate of elimination of paracetamol perhaps by inducing 
glucuronyl transferase activ ity  as paracetamol glucuronide recovery 
in urine was higher after L-methionine that paracetamol 400mg/kg 
alone. The large AUC of paracetamol in Experiment 2 may be the 
result of glucuronic acid depletion or saturation of glucuronyl
transferase activ ity . Altemativelv hvdrolvsis of the alucuronide 
bacteria could account for the low amounts of recovered.
I t  is suggested that in rabbits the enzyme catalyzing the 
transformation of paracetamol cysteine to paracetamol mercapturic 
acid (^-acetyl transferase) is located in the kidney as serum 
concentrations of paracetamol cysteine were higher than paracetamol 
mercapturic acid concentrations but in urine the reverse was true. 
Jones et a l, (1978) considered that both of the metabolic reactions 
transforming paracetamol glutathione to paracetamol cysteine and 
mercapturic acid occur in the kidney.
After the high dose of paracetamol alone (Experiment 2), although 
peak glucuronide concentrations in serum were higher than peak serum 
concentrations of paracetamol, the opposite was true in urine. This 
suggests that paracetamol glucuronide was broken down by 
6 -glucuronidase present perhaps in the kidney. I t  is however also 
feasible that paracetamol glucuronide was hydrolyzed exogenously as 
the metabolic cage did not allow for the complete separation of 
urine and faeces. I t  would be surprising i f  this were to be the 
explanation though as this effect would have been seen in the other 
experiments. There did not appear to be any effect on the total 
percentage of the administered dose of paracetamol excreted although 
i t  was d if f ic u lt  to assess as there was such a wide variation in the 
percentage dose excreted.
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There is l i t t l e  evidence that L-methionine acts to increase the 
ava ilab ility  of sulphate or glutathione for conjugation with 
paracetamol in rabbits. Thus L-methionine does not appear to act 
similarly in man and rabbits. However recoveries of paracetamol 
sulphate and paracetamol cysteine plus mercapturic acid in urine 
appeared to be lower after 400mg/kg paracetamol alone than lOOmg/kg 
paracetamol and similar effects have been noted in man (see Section 
3 .5 ). I
L-methionine. I t  is apparent therefore that the rabbit is not an 
ideal model for the effects of L-methionine on paracetamol 
metabolism observed in man.
In conclusion from these experiments on paracetamol metabolism in 
animals, some reasons are suggested as to why some species are 
susceptible and why some are non-susceptible. The mouse (a 
susceptible species) metabolises a large proportion (approximately 
25%) of a dose of paracetamol to the reactive metabolite and this is 
normally successfully scavenged by glutathione until some 45% is 
depleted. The guinea pig however does not appear to oxidise 
paracetamol to its  toxic metabolite to any significant extent and 
this may be the reason why the formation of only small amounts of 
paracetamol cysteine and mercapturic acid are seen. This was f ir s t  
suggested by Jollow et a l, (1974). I t  is interesting that although 
the rabbit is not a susceptible species (from Davis et a l, 1974), 
percentage recoveries of paracetamol cysteine and mercapturic acid 
in urine of the same order of magnitude as those seen after a 
therapeutic Ig dose of paracetamol administered to man. Man is 
considered to be susceptible to paracetamol-induced hepatic necrosis 
and this descrepancy may perhaps be explained by the presence of 
pre-aromatic derivatives of paracetamol found in human urine. To 
fu lly  categorize a species as being susceptible or non-susceptible 
to paracetamol hepatotoxicity, these pre-aromatic metabolites, plus 




Aspirin Results in Man
7.1 Control Study 
Introduction
In order to examine the effects of rheumatoid a rth ritis  and overdose 
on aspirin metabolism a study was undertaken to determine the 
metabolism of aspirin (acetylsalicylic acid, ASA) in normal 
volunteers a fter a therapeutic dose. The major urinary metabolites 
of aspirin were quantified. Although Caldwell, O'Gorman and Smith 
(1979) carried out an investigation into the glycine conjugation of 
salicylate in 85 healthy volunteers, these were aged between 20 and 
31 years and no age related studies of salicylate metabolism appear 
to have been reported.
Procedures
As in the control paracetamol study, human volunteers were hospital 
and laboratory workers or their children. Those aged over 60 years 
were contacted through local general practitioners. Each gave an 
account of smoking habits and of other drugs being taken and details 
are given in Appendix 23. Aspirin 600mg was taken by each subject 
orally early in the morning after emptying the bladder and fasting 
overnight. All urine passed in the subsequent 8  hours ( 0 - 8  hour 
collection) and in the period 8  - 24h after dosing ( 8  - 24 hour 
collection ) was collected in separate acidified plastic urine 
bottles. Urine was analysed by HPLC as described in Section 2.7 for 
the major urinary metabolites of aspirin i .e .  salicylic acid (SA), 
salicyluric acid (SUA) and the ester and ether glucuronides (SG).
In some cases i t  was possible to quantify the gentisic acid 
metabolite (GA) but in general i t  was found to chromatogram with an 
endogenous urinary peak and could not be resolved. In any case less 
than 5% of a given dose of aspirin is oxidised to gentisic acid 
(Woodbury and Fingl, 1975), and this was confirmed in the present 
study when measurement of gentisic acid was possible.
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In this and subsequent studies in which aspirin and its  metabolites 
were quantified in urine corrections were made for molecular weight 
to express each as the equivalent of SA (using correction factors 
given in Appendix 1) so that the fractional contributions of each 
metabolite and aspirin excreted unchanged to total recovery could be 
compared. Salicylic acid was chosen as the standard for calculating 
recovery since this is the convention in the lite ra tu re . A 600mg 
dose of aspirin is equivalent to 460.2mg salicylic  acid. The 
sal icy1 glucuronides were measured as salicylic acid after treatment 
with e-glucuronidase, thus no correction factor was necessary in 
this case. There was considerable interindividual variation in 
total amounts excreted and results are expressed as percentage dose 
excreted or as percentage recovery of aspirin and its  metabolites in 
each urine collection. When quantification of gentisic acid could 
be achieved values were included when calculating percentage dose, 
excreted and percentage recoveries.
Results
Table 7.1.1 gives the percentage dose of acetyl sa licylic  acid and 
its  metabolites recovered in each collection period. Individual 
results (expressed both in mg and as percentage recovery) are given 
in Appendix 24 and Appendix 25 respectively. Forty one subjects 
were studied of which there were 18 males and 23 females.
Table 7.1.1 Means * SEN of percentage dose excreted of acetyl 
salicylic  acid and its  metabolites in 41 subjects
Collection period Percentage dose excreted
0 - 8 h 46.11 ± 3.51
8  - 24h 27.18 ±  2.57
0 - 24h 73.27 ± 3.64
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When individual results were examined i t  was found that the 
percentage dose recovered was negatively corrected with age in 0  - 8  
hour urine (r  = -0.493, p<0.01) but not in 8  - 24 hour urine or over 
the whole 24 hour period. These results are plotted in Fig. 7 .1.1.
Urinary pH was measured in 25 volunteers and a positive correlation 
was found between percentage recovery of salicylic acid in 0  - 8  
hour urine (r  = 0.526, p<0.01) but not in 8  - 24 hour urine.
Acetyl salicylic acid reached quantifiable concentrations in only 11 
volunteers (mean percentage recovery 4.14 ± 0.82 in 24 hour urine 
and gentisic acid was quantified in only 5 volunteers (mean 
percentage recovery 1.65 ± 0.60 in 24 hour urine.
Table 7.1.2 gives percentage recoveries of salicylic acid, 
salicyluric acid and the sal icy 1  glucuronides in each collection 
period in 41 volunteers and these results are plotted in Fig. 7.1.2
Table 7.1.2 f^an * SBA of percentage recovery of sa licylic  acid, 
salicyluric acid and salicyl glucuronides in 41 normal 
volunteers
Collection period n SA SUA SG
0 - 8 h 41 6.00 ± 1.31 83.96 ± 1.73 9.16 ± 1.14
8  - 24h 41 2.60 ± 0.85 88.79 ± 1.76 5.79 ± 1.42
0 - 24h 41 4.68 ± 0.85 85.65 ± 1.28 8.35 ± 0.87
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Fig. 7.1.1.
Percentage dose excreted of acetyl salicylic acid and its 
metabolites fron normal volunteers v6o tock aspirin GCCmg 
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Table 7.1.2 shows that the major metabolite of acetyl salicylic  acid 
was salicyluric acid which accounted for some 90% of the excreted 
metabolic products. Percentage recoveries of salicylic  acid were 
significantly lower in 8  - 24 hour urine than 0 - 8  hour urine. 
Salicyluric acid concentrations and salicyl glucuronide concentrations 
were not significantly different in 0 - 8  hour and 8 - 2 4  hour 
periods.
Table 7.1.3 gives the percentage recoveries of the salicylic acid, 
salicylurate and glucuronic acid metabolites of acetyl salicylic  
acid with age presented in cohorts of ten years. These results are 
plotted in Fig 7 .1 .3 , 7.1.4 and 7.1.5.
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Table 7.1.3 Percentage recoveries of sa licy lic  acid, sal ley!urate and 
glucuronide metabolites of acetyl sa licy lic  acid (means * 
5ëM) from normal volunteers who took acetyl sa licy lic  
acid 60Qng by mouQT
Age
n SA SUA SG
0 - 8h 
11 - 20 4 6.24 3.38 81.85 5.11 10.77 3.22
21 - 30 9 3.33 1.92 84.86 4.17 11.13 1.74
31 - 40 7 11.17 5.07 77.12 5.00 9.74 3.81
41 - 50 7 6.31 2.19 81.18 4.38 10.82 2.57
51 - 60 5 2.53 1.93 86.13 1.13 11.35 1.40
61 - 70 7 4.87 3.31 90.61 3.27 4.52 1.68
Over 80 2 10.93 10.93 89.07 10.93 0.00 0.00
8 - 24h 
11 - 20 4 0.00 0.00 37.52 3.16 10.17 3.02
21 - 30 9 0.00 0.00 86.07 5.76 8.51 5.38
31 - 40 7 1.11 0.43 84.99 3.99 7.16 3.29
41 - 50 7 1.38 1.22 93.07 3.23 4.03 1.64
51 - 60 5 6.13 2.58 92.47 2.27 1.40 0.60
61 - 70 7 4.70 2.40 90.34 3.90 4.96 2.11
Over 80 2 12.78 12.78 87.21 12.78 0.00 0.00
0 - 24h 
11- 20 4 4.56 2.38 82.70 3.72 11.24 2.46
21 - 30 9 2.46 1.32 85.00 2.80 10.77 2.55
31 - 40 7 6.69 2.33 80.30 3.77 10.22 2.39
41 - 50 7 4.00 1.12 86.59 2.64 7.60 1.64
51 - 60 5 4.34 1.35 88.70 1.13 6.97 0.66
61 - 70 7 4.02 2.14 89.80 2.71 5.83 0.96
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Regression coefficients were calculated for the percentage recovery 
of each metabolite on age. The 8 - 2 4  hour proportional output of 
salicylic  acid increased significantly with age (r  = 0.524, p<0.001) 
with a regression coefficient of 0.135 ± 0.035 which is 
significantly different from zero (p<0.001). 0 - 8  hour and 0 - 2 4
hour percentage recoveries of salicylic  acid were not related to 
age. Percentage recovery of salicyl glucuronides was negatively 
correlated with age in 0 - 8  hour urine (r  = -0.334, p<0.05) with a
regression coeffcient of 0.117 ± 0.053 which is significantly
different from zero (p<0.05). The same trend was observed in 8 - 2 4  
hour urine but the standard error was large and statis tica l 
significance at the 5% level was not reached.
Overall in 0 - 2 4  hour urine there was a significant decrease in 
output of the salicyl glucuronides with age (r = -0.454, p<0.01) 
with a regression coefficient of 0.120 ± 0.038 which is 
significantly different from zero (p<0.01). Percentage recovery of 
salicyluric acid was not correlated with age. The regressions of 
each metabolite on age are plotted in Figs. 7 .1 .6 , 7.1.7 and 7.1.8  
for each urine collection period.
When the intercorrelations of each metabolite are examined i t  is  
found that salicylic  acid recovery was negatively related to the 
percentage recovery of salicyluric acid (r  = -0.679, p<0.001 in the
0 - 8  hour urine, r = -0.316, p<0.001 in the 8 - 2 4  hour and r =
-0.649, p<0.001 over the whole 24 hours). Percentage recoveries of 
salicyl glucuronides and salicyluric acid were also negatively 
related (r  = -0.644, p<0.001 for 0 - 8  hour urine, r = -0.656, 
p<0.001 in 8  - 24 hour urine and r = 0.748, p<0.001 in 0 - 24 hour 
urine). Percentage recovery of the salicyl glucuronides was 
unrelated to salicylic acid. Figs. 7.1.9 and 7.1.10 show the 
correlations between salicylic  acid and salicyluric acid and between 
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Fig. 7.1.9 Percentage recovery of salicylic  acid against percentage 
recovery of salicyluric acid from normal volunteers who 
took aspirin 600mg by mouth
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Fig. 7.1.10.
Percentage recovery of salicyluric acid against percentage 
recovery of salicyl glucuronides from normal volunteers who 
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7.2 Metabolism of aspirin in patients with rheumatoid a rth ritis  
Introduction
A study was undertaken to compare the metabolism of aspirin in 
patients with rheumatoid a rth ritis  with the metabolism of aspirin in 
normal volunteers in the control study (Section 5 .1 ). Rheumatoid 
patients constitute a group of like ly  chronic users of aspirin who 
are thus potentially at risk of aspirin related renal or hepatic 
disease. I t  was therefore of interest to record whether aspirin 
metabolism changes with chronic use. There were very few 
in-patients who regularly or occasionally took aspirin for analgesia 
at the time of the study in the Royal National Hospital for 
Rheumatic Diseases in Bath but 5 patients were investigated.
Procedures
Five in-patients who were taking aspirin on a regular basis were 
studied. The patients took aspirin SOOmg early in the morning 
between 6.30am and 7.30am and urine was collected for 8  hours (0 - 
8 h urine) and from 8  to 24 hours after dosing ( 8  - 24h urine) in 
acidified plastic bottles. During the 24 hour period of the study 
patients took additional aspirin and other drugs according to their 
normal dosing regimen. Details of other drugs being taken, age and 
sex for each patient are given in Appendix 26.
Results
Percentage recoveries of salicylic  acid, salicyluric acid and 
salicyl glucuronides were calculated for each urine collection 
period. Results are given in Table 7.2.1 and presented graphically 
in Fig. 7.2.1. Individual results of recovered metabolites 
expressed in mg corrected for molecular weight with respect to 
salicylic acid and as percentage recovery for each urine collection 
period are given in Appendix 27.
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Fig. 7.2.1
Percentage recovery of the metabolites of acetyl salicylic 
acid in patients with i±eumatoid arthritis and nomal volunteers 
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The urinary metabolic profile displayed by rheumatoid patients was 
similar to that of the controls. However, percentage recovery of 
salicylic acid in 0 - 8  hour urine (0.26 ± 0.26) and 0 - 2 4  hour 
urine (0.51 ± 0.51) but not 8 - 2 4  hour urine (0.64 ± 0.64) was 
significantly lower (p<0 . 0 0 1 ) than values for controls ( 0 - 8  hour: 
6.00 ± 1.31, 8 - 2 4  hour: 2.60 ± 0.85; 0 - 2 4  hour: 4.68 ± 0.85). 
Percentage recovery of the salicyl glucuronides was also lower in 
rheumatoid patients in 0  - 8  hour urine (2.13 ± 1.34), (p<0.001) and 
in 0 - 24 hour urine (2.48 ± 1.54) (p<0.002) but not in 8 - 2 4  hour 
urine (3.24 ± 2.31) when compared with values in normal volunteers 
( 0 - 8  hour 9.16 ± 1.14; 8 - 2 4  hour 5.79 ± 1.42; 0 - 2 4  hour 8.35 ± 
0.87). In the rheumatoid patients there was a greater percentage 
recovery of salicyluric acid in 0 - 8  hour (94.55 * 3.04) (p<0.01) 
and 0 - 2 4  hour (94.24 ± 8.77) (p<0.01) but not 8 - 2 4  hour urine 
(3.24 ± 2.31) compared with control results ( 0 - 8  hour 83.96 ±
1.73; 8 - 2 4  hour 88.79 ± 1.76; 0 - 2 4  hour 85.65 ± 1.28).
Table 7.2.1 Means  ̂ SEM of percentage recoveries of salicylic
acid, salicyluric acid and salicyl glucuronides in 5 
patients with rheumatoid a rth ritis  after 
administration of aspirin 600mg.
Collection period SA SUA SG
0  - 8 h 0.26 ±0.26 94.55 ± 3.04 2.13 ± 1.34
8  - 24h 0.64 ± 0.64 93.04 ± 3.52 3.24 ± 2.31
0 - 24h 0.51 ± 0.51 94.24 ± 2.77 2.48 ± 1.54
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7.3. Metabolism of aspirin in overdose 
Introduction and Procedures
The metabolism of aspirin after overdose was examined in six 
patients. Five of the six were admitted within 7 hours of aspirin 
ingestion but one was not admitted until approximately 24 hours 
after overdose. Sequential urine samples were analysed by HPLC for 
unchanged acetyl salicylic acid, salicyluric acid, salicylic  acid 
and the salicyl glucuronides as previously described (Section 
2 .7 .b ( i i i )  and 2 .7c).
Resul ts
Individual results and clin ical details are given in Tables 7.3 .1 , 
7.3.2, 7 .3 .3 , 7.3.4, 7.3.5 and 7.3.6 below and are shown graphically 
in Figs. 7 .3 .1 , 7.3.2, 7.3.3 and 7.3.4.
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Table 7.3.1
A l, female 20yr
Time Event
mg expressed as equivalent o f SA 
SUA ASA SA SG SUA SG
s r  3%
18.00 80 tablets of aspirin  
i ngested
19.55 Admitted to Casualty 
Dept.; gastric wash-out
22.00 67.5 25.5 473.5 88.7 0.1 0.2
23.00 30.2 3.3 156.0 83.4 0.2 0.5
23.30 plasma salicy late  
580mg/l
24.00 20.1 2.8 178.4 65.3 0.1 0.4
01.00 25.2 3.4 303.4 9.2 0.1 0.0
02.00 39.4 5.1 618.6 19.6 0.1 0.1
04.00 25.7 0.0 155.6 38.4 0.2 0.2
04.30 34.3 0.0 498.8 0.0 0.1 0.0
05.15 20.2 0.0 204.4 0.0 0.1 0.0
08.10 120.6 0.0 158.6 0.0 0.8 0.0
10.00 70.0 0.0 201.0 53.5 0.4 0.3
11.15 29.7 0.0 24.2 9.2 1.2 0.4
14.00 108.2 0.0 60.8 21.1 1.8 0.3
20.15 70.4 0.0 2.9 24.5 24.3 8.5
22.15 83.5 0.0 28.8 N.M. 2.9
06.15 301.2 0.0 19.2 84.2 15.2 4.4
Total of individual metabolites 1046.2 40.1 3084.2 497.1
N.M. 3 not measured
Total recovery *  4667.6rag
The results are plotted in F ig . 7 .3 .1
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Fig. 7.3.1.
Gr^ih shewing cumulative recovery of each metabolite corrected 
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Table 7 .3 .2  
A2. Male 19yrs
Time Event
mg expressed as equivalent of SA 
SUA ASA SA SG SUA SG
3T 3%
21.00 40 Anadin tab lets plus
3 pints of lager Ingested
Admitted to Casualty Dept. 






Total of Individual metabolites
105.2 4.3 36.4 22.4 2.9 0.6
249.3 5.6 79.7 31.1 3.1 0.4
341.6 6.1 70.0 39.5 4.9 0.6
696.1 16.0 186.1 92.9
Total recovery > 991.Img The results are plotted In Fig. 7 .3 .2 .
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Fig. 7.3.2.
Graph showing cumulative recovery of each metabolite corrected 
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Table 7 .3 .3  
A3, male 82yr
Time Event
mg expressed as equivalent of SA 
SUA ASA SA SG SUA SG
9 T  3%"
Overdose time not known but estimated 
to  be about 24 hours before 
admission
14.45 Plasma sa licy la te  790mg/l 
no gastric wash-out, 
urine a lka lin isa tio n
18.15 116.2 0.0 55.1 111.4 2.1 2.0
20.15 82.2 0.0 34.2 47.2 2.4 1.4
22.15 66.3 0.0 164.4 46.4 0.4 0.3
00.15 53.9 0.0 66.0 27.5 0.8 0.4
02.15 52.8 0.0 13.7 32.1 3.8 2.3
04.15 64.0 0.0 99.4 . 46.4 0 .6 0.5
06.15 67.7 0.0 172.4 13.5 1.0 0.2
08.30 74.0 0.0 77.5 17.3 1.0 0.5
10.15 56.3 0.0 57.6 27.8 1.0 0.5
12.30 113.5 0.0 51.3 44.3 2.2 0.9
14.30 84.4 0.0 2.1 21.4 40.2 10.2
16.30 86.8 0.0 0.6 7.1 144.7 11.8
18.30 85.6 0.0 0.7 27.5 122.3 39.3
20.30 55.1 0.0 0.5 13.0 110.2 26.0
23.30 94.7 0.0 1.4 25.5 67.6 18.2
01.15 68.1 0.0 0.0 22.8 00 00
03.15 76.9 0.0 0.0 18.1 00 CO
05.30 60.6 0.0 0.0 18.3 00 00
Total of individual metabolites 1359.1 0.0 796.9 567.6
























































Table 7 .3 .4  
A4, female 28yr
Time Event
expressed as equivalent of SA 
SUA ASA SA SG SUA SG
37T
20.00 36 Aspro tab lets ingested
21.50 Admitted to Casualty Dept.
22.00 Plasma sa licy la te  34Crag/l
23.30 40.4 70.9 170.9 40.9 0.2 0.2
01.30 18.5 29.6 172.3 12.2 0.1 0.1
07.30 24.1 1.4 11.9 97.2 2.0 8.2
Total of individual metabolites 83.0 101.9 355.1 150.3
Total recovery » 690.3mg, The results are plotted In F ig . 7 .3 .4
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Fig. 7.3.4.
Graph shewing cumulative recovery of each metabolite corrected 
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Table 7 .3 .5  
AS, Female, 15yr
rag expressed as equivalent of SA 
Time Event SUA ASA SA SG SUA SG
Vr  3T
17.30 32 tablets of aspirin
1ngested
00.23 Admitted to Casualty Dept, 
plasma sa licy la te  400rog/l
06.20 200.4 0.0 266.7 138.0 0.8 0.5
10.00 156.0 0.0 320.0 217.1 0.5 0.7
11.00 61.9 0.0 353.5 253.7 0.2 0.7
13.30 81.2 0.0 343.3 309.0 0.2 0.9
19.45. 293.5 0.0 399.0 639.5 0.7 1.6
Total of individual metabolites 793.0 0.0  1682.5 1557.3
Total recovery > 4032.8mg
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Table 7 .3 .6  
A6, Female, l ^ r
mg expressed as equivalent of SA 
Time Event SUA ASA SA SG SUA SG9T 3%"
17.00 Estimated time o f overdose
32 tab le ts  of aspirin  ingested
21.00 Admitted to Casualty Dept.; 
gastric  wash-out
07.15 394.1 0.0 207.5 188.9 1.9 0.9
09.55 59.7 0.0 3.4 62.4 17.6 18.4
10.00 508.1 0.0 36.9 194.4 13.8 5.3
16.00 296.2 0.0 3.4 132.8 87.1 39.0
22.00 370,5 0.0 138.3 18.7 2.7 0.1
Total o f individual metabolites 1628.6 0.0 389.5 597.2
Total recovery .  2615.3mg
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I t  can be seen that in general the amount of salicylate recovered in 
urine was considerably less than the reported intake presumably as a 
result of the gastric wash-out for the patients described in Table 
7.3.1 and 7.3.6 possibly also because of exaggeration by the 
patients of the number of tablets they had ingested. (The recovered 
dose is expressed in terms of salicylic acid - this should be 
multiplied by 300/230 = 1.30 to convert to the conventional 300rag 
aspirin tablets.
I t  can be seen from Tables 7 .3.1, 7.3.4 and 7.3.5 that the major 
metabolite recovered was salicylic  acid. The patients whose details 
are given in Table 7 .3 .2 ., 7 .3.3. and 7.3.6 were admitted to 
Casualty only some 24 hours after overdose and the major metabolite 
present in urine was salicyluric acid presumably because salicylic  
acid had been metabolized and excreted by the time that urine 
collections were started. The percentages of the total recovery of 
salicylate recovered as salicyluric acid and the sal icy 1  
glucuronides in the six overdosed patients were compared with the 
percentage recoveries of these two metabolites in 24 hour urine from 
normal volunteers after aspirin 600mg. The recovery of salicyluric 
acid was found to be less (p<0 . 0 0 1 ) and the recovery of the salicyl 
glucuronides was greater (p<0.01) in the overdose patients. I t  can 
be seen from Tables 7.3.1 - 7.3.6 that in it ia lly  the ratios SUA/SA 
and SG/SA were low but increased with time as salicylic acid was 




Discussion of Aspirin metabolism in man
8.1. Control Study
In the present study the metabolism of aspirin was studied in normal 
volunteers. The percentage excretion of a single 600mg dose of 
aspirin was measured and the percentage recoveries of salicyluric  
acid, salicyl glucuronides and salicylic  acid in urine were 
quantified. Previous findings that these are the major metabolic 
products of acetyl salicylic  acid excreted in urine were confirmed 
(Baldoni, 1915 , Smith, Gleason, Stroll and Ogorzalik, 1946;
Salassa, Boll man and Dry, 1948; Schachter and Manis, 1958; Bedford, 
Cunnings and Martin, 1965; Levy, 1965).
I t  was found that the percentage of the total dose of aspirin 
excreted decreased significantly with age, the percentage recovery 
of the salicyl glucuronide also decreased signficantly (p<0.05) with 
age in 0 - 8  hour urine. A decrease in kidney function with age may 
contribute to both effects since glomerular f iltra t io n  rate and 
effective renal plasma flow diminish with increasing age (Davies and 
Shock, 1950). Davison (1971) suggested that active tubular 
secretion as well as glomerular f iltra t io n  of the unbound salicylate  
occurrs and reduction in effective renal plasma flow may thus lim it  
loss by active tubular secretion.
The present results showed that there was substantial individual 
variation both in the total recovery of salicylate in 24 hours and 
in the percentage recoveries of each metabolite. Caldwell, O'Gorman 
and Smith (1979) reported similar variation in normal volunteers 
after acetyl salicylic  acid 900mg by mouth. Levy (1965) calculated 
that above a threshold value of aspirin 360mg (equivalent to 
salicylic  acid 276mg) saturation of the formation of salicyluric  
acid occurred. Levy and Hollister (1964) found marked individual
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differences in the apparent half l i f e  of salicylate elimination 
which was probably due to individual differences in the capacity to 
form salicyluric acid. Individual variation in the present study 
probably reflects the same phenomenon. Although i t  might have been 
tending towards zero order kinetics, the major metabolite recovered 
was salicyluric acid.
Results in the study also showed that the percentage recovery of 
salicy lic  acid was positively correlated with urinary pH but only in 
the f ir s t  8  hours probably because the percentage recovery of 
salicylic  acid was so much lower in 8  - 24 hour urine as a result of 
further metabolism. Excretion of the acidic conjugates of salicylic  
acid would tend to lower the urinary pH. This in turn would tend to 
favour reabsorption of unionized free salicylate which would then be 
available to re-enter the circulation and reach the liv e r to be 
further metabolised.
The increase in percentage recovery of unchanged salicylic  acid with 
age in 8  - 24 hour urine may have been a direct consequence of the 
negative correlation with age of the salicyl glucuronides in 0  - 8  
hour and 0 - 2 4  hour urine i f  the formation of salicyluric acid was 
rate lim ited. Salicylurate recovery is unlikely to be correlated 
with age i f  saturation kinetics had indeed been approached. 
Alternatively, a b ility  to conjugate salicylate with glucuronic acid 
and glycine may diminish with increasing age or clearance by tubular 
transport of salicylate might not occur to such an extent in older 
people. Montgomery and Sitar (1981) found the serum concentrations 
of salicyluric acid (and gentisic acid) were increased in patients 
older than 60 years on chronic acetyl salicylic  acid therapy.
However, these workers did not measure the urinary metabolites of 
acetyl sa licylic  acid so their study and the present work are not 
directly comparable.
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The negative correlation of salicyl glucuronide recoveries in urine 
with age is in contrast to effects of age on paracetamol metabolism; 
i .e .  that glucuronidation increased with age presumably as a 
consequence of the decreasing recoveries of paracetamol cysteine 
plus mercapturic acid with age. However, as conjugation with 
glycine is the major conjugation pathway for salicylate, the age 
effect seen in the recovery of salicyl glucuronides may well be 
secondary to other metabolic or renal effects, whereas for 
paracetamol, glucuronidation is a more important pathway.
8.2. Aspirin metabolism in patients with rheumatoid a rth ritis
In the present small study on the metabolism of aspirin in patients 
with inflammatory jo in t disease, i t  was not possible to measure the 
total percentage excretion of the administered dose of aspirin for 
reasons already described (Section 7 .2 ). However the metabolic 
profile  in these 5 patients does appear to d iffe r from that observed 
in normal volunteers as the rheumatoid patients excreted much lower 
quantities of unchanged salicylic acid and salicyl glucuronides than 
did the normal volunteers. The findings of Burry and Dieppe (1976) 
and Kimberly and Klotz (1977) that serum creatinine concentrations 
were raised and creatinine clearance was diminished in volunteers 
who received aspirin for at least 7 days may be of relevance; that 
is , that the clearance of glucuronic acid and unchanged salicylate  
may also be decreased by the continuous salicylate therapy. Results 
in the present study raise the possibility that glycine ava ilab ility  
may be increased in rheumatoid a rth ritis  or that chronic therapy 
with aspirin may induce glycine N-acylase (the en^me catalyzing the 
transfer of glycine to salicylic acid). Additional work needs to be 
carried out to measure plasma concentrations of salicylate and its  
metabolites and possibly to examine this system in vitro to 
understand these processes further.
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8 .3 , Aspirin metabolism a fte r  overdose
Table 8 .3 . gives excretion rates of s a licy lu ric  acid and the 
salicyl : glucuronides in overdose patients compared with normal
volunteers.
Table 8 .3  mean rate of excretion of sa licy lu ric  acid and the salicyl 
glucuronides in normal volunteers and overdose patients
1) Overdose patients
Period over Total
Overdose which urine SUA SUA SG SG recovery
patient Table was collected mg*/h uinol/h mg*/h wnol/h rag*
Al 7 .3 .1 32h 0 rain 32.4 235 17.03 123 4611.3
A2 7 .3 .2 3h 0 rain 232.0 1681 30.98 224 .991.0
A3 7 .3 .3 35h 15 rain 38.6 280 16.10 117 3027.5
A4 7 .3 .4 8h 0 rain 10.4 75 18.79 136 690.5
AS 7.3 .5 13h 25 rain.- 58.6 425 115.11 834 6226.1
A6 7 .3 .6 14h 45 rain 110.4 800 40.49 293 2645.1





rag*/h 22.2 *  1.7 5.3 -  60.7 2.7 * 0 .4 0.0 -  10.7
uraol/h 161 *  12 38 -  440 20 * 3 0 - 7 8
*  expressed as equivalent of SA
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Values for excretion rates of salicyluric acid in normal volunteers 
ranged from 38 - 440pmol/h (mean of 161 ± 12umol/h) and are similar 
to values obtained by Levy (1965) which ranged from 250 - 400wmol/h. 
In Levy's study the maximum dose of salicylate ingested was 3.6g.
In the overdose patients values ranged from 75 - 1681umol/h. Thus 
both normal volunteers and overdose patients exhibit a great in ter­
individual difference in excretion rate of this metabolite of 
aspirin, a rate which does not appear to depend on the dose of 
aspirin recovered in urine. Results from the present study suggest 
that glycine depletion occurred after the high doses of aspirin 
ingested by these patients and that this may be compensated for by 
increased conjugation with glucuronic acid. Fig. 8.3 shows the 
frequency distribution of the percentage of salicylate recovered in 
urine as salicyluric acid in normals and in overdose patients. I t  
can be seen that salicyluric acid recovery was lower in the overdose 
patients than after a therapeutic dose in normal volunteers. I t  has 
been known for many years that large doses of salicylate persist in 
the body for much longer periods than lower doses and half l i f e  may 
rise to as long as 30 hours because salicyluric acid excretion is 
dose-dependent. This is apparently due to a limited a b ility  to form 
the glycine conjugate because Levy, Amsel and E llio tt  (1969) showed 
that administration of salicyluric acid to normal volunteers 
followed first-order excretion kinetics. Bedford, Cummings and 
Martin (1965) suggested that the lim itation is not the supply of 
glycine because glycine 4g administered with 0.64g aspirin to 
volunteers did not affect the total salicylate excretion. However, 
at a dose of aspirin 0.64g i t  is unlikely that salicylurate 
formation was capacity lim ited. At high doses however, glycine 
depletion may occur (as the body pool of glycine may be limited) or 
alternatively the enzyme catalyzing the transfer of glycine to 
salicylic  acid (glycine ^-acylase) may be operating maximally but 
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A further difference noted between the urinary metabolites in normal 
volunteers a fter a therapeutic dose and patients with aspirin 
overdose included the excretion of unchanged acetyl salicylic acid in 
three out of six of the overdose patients. The reason why no 
acetyl sa licylic  acid was detected in the urine of overdose patients 
A3, A5 and A6  (results presented in Table 7.3.3, 7.3.5 and 7.3.6 of 
Section 7.3) was probably because urines for analysis were collected 
from only 1 1  hours after reported overdosage time and possibly a ll 
acetyl salicylic  acid has been excreted by then. I t  was not to be 
expected that significant quantities of unchanged acetyl salicylic  
acid would be excreted in the urine of normal volunteers because i t  
is rapidly hydrolyzed in plasma but more may be seen in the overdose 
patients simply becuase the dose is greater and because urine 
collections were more frequent.
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Chapter 9
Comparison of aspirin and paracetamol metabolism in man
The major routes of metabolism which are u tilized  by aspirîpi and 
paracetamol have been outlined in Chapter 1, After absorption, 
aspirin is deacetylated to salicylic  acid which then conjugates with 
glycine to form salicyluric acid and with glucuronic acid to give 
the ester and ether glucuronides. Thus aspirin undergoes Phase I 
metabolism followed by Phase I I  metabolism and the major excretion 
products after therapeutic doses are salicyluric acid (85.65 ±
1.28%) with the glucuronides accounting for 8.35 ±  0.87%. In 
contrast, paracetamol forms mainly Phase I I  metabolites and the two 
major metabolites excreted are the glucuronide and sulphate 
conjugates which account for 53.46 * 1.35% and 32.79 ± 1.16% 
respectively of the total recovery. However at least 9.01 ± 0.49% 
of an administered dose of paracetamol is oxidised to an 
intermediate metabolite (a Phase I product) which then conjugates 
with glutathione to give paracetamol cysteine mercapturic acid or 
may react to give further oxidised metabolites (e.g. 2 - hydroxy and 
3-hydro)^ paracetamol).
The present study permits the metabolism of aspirin and paracetamol 
to be compared in normal volunteers, in patients with rheumatoid 
a rth ritis  and in overdosed patients. Although both drugs have been 
freely available without prescription for many years, a study on the 
metabolism of these analgesic anti-inflammatory drugs in relation to 
age in normal volunteers a fter a therapeutic dose has not previously 
been reported. The percentage dose of aspirin excreted in urine in 
24 hours had a mean value of 73.27 ± 3.64% and this is similar to 
the percentage of the dose of paracetamol that was found to be 
excreted in 24 hours (76.59 ± 4.53%). I t  was found that the 
metabolic profiles of both drugs varied with age. The total dose of 
aspirin recovered in 0  - 8  hour urine expressed as a percentage 
decreased with increasing age. The percentage dose of paracetamol 
excreted did not vary with age. Although both drugs conjugate with
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glucuronic acid, the percentage recovery of paracetamol glucuronide 
increased with increasing age in 24 hour urine while the percentage 
recovery of the salicyl glucuronides in 24 hour urine decreased with 
increasing age. This raises the possibility that the engyme 
glucuronyl transferase which catalyses the conjugation of glucuronic 
acid with salicylic  acid may be different from that which catalyses 
paracetamol glucuronidation. As the percentage recovery of 
paracetamol cysteine was found to decrease with increasing age, the 
increase in paracetamol glucuronide recovery with age might serve to 
compensate. I t  was also found that the percentage recovery of 
unchanged salicylic  acid increased with increasing age in 8  - 24 
hour urine and this may relate to a decrease in salicyl glucuronide 
recovery with age.
The metabolism of aspirin and paracetamol in patients with 
rheumatoid a rth ritis  was also investigated. Rheumatoid patients 
might be considered to be at risk of toxicity from these drugs 
because of the large doses taken repeatedly over a period of time for 
analgesia (up to 5g of paracetamol and 1800mg of aspirin per day), 
and also because of concurrent therapy with other drugs possibly 
causing drug interactions. I t  is also possible that the disease 
state i ts e lf  may a lte r the metabolism of these compounds. Although 
there was no indication of an increase in the recoveries of 
paracetamol cysteine plus mercapturic acid in these patients, there 
was a greater recovery of paracetamol glucuronidesand lower 
recoveries of paracetamol sulphate and unchanged paracetamol than in 
the normal volunteers which could reflect conditions in which 
greater use may be made of the oxidation pathway. Similarly in RA 
patients there was a greater percentage recovery of salicyluric acid 
and lower percentage recoveries of the salicyl glucuronide and 
unchanged salicylate than in controls who took a therapeutic 600mg 
dose of aspirin. These results suggest that metabolism may be 
altered in rheumatoid patients. Endogenous sulphate available for 
conjugation with paracetamol may have been depleted as a result of 
the high doses being taken causing a compensatory increase in 
glucuronic acid conjugation. Alternatively induction of the enzymes
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responsible for glycine and glucuronic acid conjugation might have 
occurred either as a result of the disease per se or by other drugs 
taken concurrently with aspirin and paracetamol.
The time courses of the urinary metabolic profile of aspirin and 
paracetamol after overdose were also followed. In aspirin overdose, 
the major metabolite recovered in urine ini ta lly  was salicylic  acid 
suggesting that the pathways of metabolism of salicylic acid were 
saturated or depleted. After paracetamol overdose, the recovery of 
unchanged paracetamol was only slightly higher (as a percentage) 
than the recovery in normal volunteers after a therapeutic Ig dose. 
By calculating the ratios paracetamol glucuronide/paracetamol 
sulphate (PG/PS) and paracetamol glucuronide plus paracetamol 
sulphate/paracetamol cysteine plus paracetamol mercapturic acid (PG 
+ PS)/(PC + PM) i t  was possible to show that in it ia l recoveries of 
paracetamol sulphate and paracetamol cysteine plus mercapturic acid 
were lower than after therapeutic doses. There was no suggestion of 
glucuronic acid depletion at the doses of paracetamol ingested by 
these patients. After overdose of aspirin there was evidence that 
glycine but not glucuronic acid depletion had occurred but 
recoveries of both these metabolites increased with time and i t  
appears that conjugation with glucuronic acid might increase to 
compensate for the glycine depletion.
M itchell, McMurtry, Statham and Nelson (1977) showed that aspirin is 
converted in the kidney to a highly reactive alkylating agent by 
cytochrome P-450 dependent microsomal mixed function oxidase. This 
intermediate is thought normally to be inactivated by conjugation 
with reduced glutathione and tubular necrosis only occurs when 
glutathione is depleted. Thus paracetamol and aspirin may cause 
toxicity in a similar fashion and protection against their toxicity  
may be effected by the body in similar ways. A further theory is  
that acidic anti-inflammatory drugs such as aspirin decrease renal 
blood flow, glomerular f ilt ra t io n  rate and sodium and water 
excretion. This may be a result of inhibition of prostaglandin
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synthesis and in particular prostaglandin E which is a renal 
medullary vasodilator. Prescott (1965) showed that ten individuals 
receiving 3.6g aspirin per day a ll showed a significant increase in 
the output of renal tubular cells and red blood cells a fter a latent 
period of about 24 hours. Paracetamol also has anti-prostaglandin 
activ ity  and can cause renal damage in overdose.
I t  is surprising that although aspirin was f ir s t  used c lin ica lly  in 
1899 and its  effects on renal function f ir s t  noted in 1917 
(Prescott, 1979), i t  has only recently been reported that aspirin 
may be associated with hepatotoxicity (Russell, Sturge and Smith, 
1971). I t  is therefore possible that salicylate is converted to a 
reactive metabolite in the liv e r as i t  is in the kidney (Mitchell et 
a l, 1977). However, compared with paracetamol, hepatic injury due 
to aspirin is usually re lative ly  mild, i t  is cumulative and appears 
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,. 268 Appendices
Appendix I
Molecular weights and correction factors of paracetamol and its  
metabolites
Molecular weight Correction factor
paracetamol 151 1.000
paracetamol glucuronide 327 0.462
paracetamol sulphate 230 0.656
paracetamol cysteine 270 0.559
paracetamol mercapturic acid 312 0.484
2-hydroxy paracetamol 168 0.899
3-hydroxy paracetamol 168 0.899
Molecular weights and correction factors of aspirin and its  metabolites
Molecular Weight Correction factor
salicylic  acid 138.18 1.000
acetyl sa licylic  acid 180.20 0.767
salicyluric acid 195.20 0.708
Gentisic acid 176.10 0.785
Thus a 600mg dose of aspirin is equivalent to 460.2mg salicylic acid. As 
the sal icy 1  glucuronides were measured as salicylic  acid after treatment 
with s-glucuronidase no correction factor was necessary.
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PS PC PM P PG
8-24h 
PS PC PM
1 3.72 37.40 41.53 8.66 4.96 1.93 49.30 16.23 12.59 13.95
2 6.34 53.78 28.62 6.97 4.29 5.68 64.35 18.70 7.71 3.55
3 2.02 52.64 33.81 5.68 5.86 1.50 54.01 39.51 4.80 0.13
4 2.53 58.70 32.28 5.94 0.53 0.06 46.51 39.13 6.91 7.38
5 5.33 56.21 34.55 3.16 0.75 0.78 60.55 30.47 3.58 4.62
6 1.23 56.89 35.39 6.13 0.35 1.33 52.64 38.53 5.07 2.43
7 10.35 39.19 39.01 6.95 4.49 2.23 23.84 62.07 6.36 5.80
8 2.54 35.93 47.45 4.56 9.51 5.19 36.01 35.25 8.26 14.93
9 7.79 24.42 58.19 8.65 0.94 9.04 32.49 30.57 19.97 7.93
10 2.19 74.19 16.44 3.15 4.02 0.91 50.58 36.66 7.63 4.21
11 26.31 40.98 24.44 2.52 5.74 19.78 57.57 13.33 0.00 9.31
12 1.37 51.11 39.73 1.65 . 6.13 0.61 85.98 10.71 1.52 1.19
13 1.91 45.90 43.07 3.54 5.57 5.82 49.83 33.58 3.63 7.13
14 2.98 34.00 49.31 3.89 9.81 7.87 34.91 41.47 4.73 11.02
15 2.73 46.08 42.55 3.02 5.62 8.41 51.51 25.84 3.91 10.33
16 4.46 58.95 32.44 1.51 2.64 5.16 62.45 29.80 1.89 3.59
17 9.10 52.54 31.85 4.04 2.47 4.77 53.84 26.17 11.74 3.47
18 6.73 62.23 21.18 4.48 5.38 2.34 78.57 8.02 3.78 7.29
19 17.40 70.76 8.51 1.38 1.94 1.33 40.12 43.83 10.59 4.12
20 7.17 55.57 30.58 1.45 5.24 7.88 54.94 30.17 0.81 6.20
21 3.79 49.09 43.08 3.69 0.36 2.46 51.64 38.02 7.13 0.75
22 4.43 45.84 42.22 2.21 5.30 6.96 72.85 12.11 2.24 5.83
23 4.76 61.80 29.27 2.18 1.98 6.39 63.39 21.19 3.62 5.41
24 3.88 57.39 36.33 1.39 1.00 5.50 55.35 33.96 2.41 2.78
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Appendix 3 continued:
Volunteer No. P PG
0-24h
PS PC PM
1 6.46 39.52 37.01 10.44 6.56
2 6.16 56.69 25.90 7.17 4.09
3 1.88 53.04 35.49 5.42 4.17
4 0.93 50.75 36.75 6.57 5.00
5 2,27 59.13 31.81 3.44 3.35
6 1.26 55.77 36.22 5.85 0.91
7 8.99 36.56 42.88 6.85 4.71
8 3.14 35.95 44.69 5.48 10.74
9 8.20 27.07 49.14 12.36 3.24
10 1.82 67.33 22.32 4.45- 4.08
11 25.05 44.19 22.29 2.04 6.43
12 1.20 59.03 33.13 1.62 5.01
13 2.67 46.67 41.22 3.56 5.88
14 4.44 34.27 46.97 4.14 10.17
15 3.95 47.25 38.95 3.21 6.63
16 4.66 59.94 31.69 1.38 2.91
17 7.51 53.02 29.76 6.87 2.84
18 5.06 68.44 16.18 4.22 6.10
19 4.86 46.86 36.06 8.57 3.64
20 7.49 55.28 30.39 1.16 5.67
21 2.96 50.67 39.93 5.83 6.01
22 4.87 50.52 37.01 2.21 5.39
23 5.53 62.55 25.44 2.87 3.61
24 4.25 36.62 45.74 4.79 8.60




No. P PG PS PC PM P PG PS PC PM
25 4.29 58.70 32.86 1.88 2.27 16.47 63.05 11.38 2.13 6.96
26 3.92 36.39 46 .52 4.76 8.41 8.24 39.39 36.31 5.16 10.90
27 12.76 58.05 18.84 4.97 5.38 20.77 51.67 17.94 4.25 5.37
28 0.68 54,.58 38.57 5.11 1.05 4.60 68.79 14.48 9.98 2.15
29 4.65 70 .90 13..29 3.06 3.11 2.34 57.94 15.00 18.14 6.58
30 3.31 50..43 39.14 2.27 4.82 2.11 48.74 33.73 4.82 10.85
31 1.94 56 .72 35.66 1.84 3.73 1.29 60.57 30 .68 1.62 5.84
32 2.12 52 .89 28..62 8.63 7.74 2.51 58.82 25.19 7,.06 6.62
33 3.47 55 .68 34,.75 2.12 3.98 4.28 49.78 38.15 2.39 3.89
34 7.27 54,.98 35,.01 1.54 1.19 2.62 69.44 24.57 3,.14 0.24
35 6.53 50,.38 37,.59 3.06 2.64 3.41 55.89 34.16 3..73 2.30
36 7.47 53 .85 31 .71 3.83 3.15 1.78 51.39 29.25 14,.10 3.47
37 18.63 58,.85 18.59 2.34 1.58 6.95 74.56 14.07 1.24 3.18
38 1.87 54,.98 34,.84 1.57 6.74 8.72 70.27 14.10 1,.68 8.22
39 0.90 58,.04 34,.44 1.99 4.66 0.01 72.32 21 .54 2.76 3.37
40 1.40 58..59 34,.94 1.19 3.83 8.78 77.18 9.13 1,.03 3.88
41 8.52 54,.10 32,.65 3.12 1.61 3.93 19.19 50 .40 23..38 3.11
42 2..02 40..36 49,.17 3.44 5.01 2.94 66.40 14 .25 9,.47 6.93
43 1.59 57..71 33..34 1.98 3.37 3,.67 55.94 21,.81 11..60 6..97
44 3.33 42..48 45..94 2.76 5.48 1,.19 48.29 37 .47 4..56 8..50
45 8.61 66,.52 22..57 1.46 0.84 4 .00 61.88 27,.47 1..96 4..68
46 0,.47 58,.39 35..40 1.93 3.81 1,.16 72.47 21..83 1..49 3..04
47 3,.85 40..23 52..23 0.41 3.22 5.30 49.52 39..53 1..34 4..28
48 0 .20 44..52 46..30 1.02 7.95 4..97 47.02 37..49 3.,28 7..24
49 2.99 41..99 45,.40 3.94 5.68 1,.88 79.14 6..36 7,.86 4..76
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Appendix 3 continued:
Volunteer No. ? PG
0-24h
PS PC PM
26 4.35 56.80 35.65 1.68 1.51
27 15.40 55.95 18.54 4.74 5.38
28 3.10 63.36 23.69 8.12 1.73
29 8.45 68.78 13.57 5.52 3.68
30 2.93 49.89 37.41 3.01 6.76
31 1.72 58.05 34.01 1.77 4.46
32 2.18 54.68 27.58 8.15 7.40
33 3.89 52.63 36.51 2.26 4.71
34 • 5.34 60.97 30.68 2.20 0.80
35 5.41 52.35 36.23 3.20 2.70
36 5.31 52.92 30.78 7.73 3.25
37 11.92 67.87 15.99 1.71 2.50
38 3.09 59.82 28.28 1.60 7.21
39 0.67 61.47 31.34 2.17 4.35
40 2.65 61.66 30.68 1.16 3.83
41 7.85 48.96 35.26 6.10 1.83
42 2.43 52.10 33.42 6.16 5.88
43 1.91 57.44 33.27 3.46 3.92
44 2.04 45.97 40.85 3.84 7.29
45 5.60 63.44 25.82 1.79 3.38
46 0.70 63.10 30.86 1.78 3.55
47 4.99 47.40 42.45 1.12 4.04
48 2.57 45.76 41.92 2.14 7.60
49 2.40 61.79 24.60 6.03 5.19
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Appendix 4
4.1 Dose of paracetamol given, smoking habits, other drugs being taken 
concurrently with paracetamol during the control study, and date of 
birth  of each volunteer.
Volunteer Dose of Date of
No. Tobacco, and other drugs paracetamol Sex b irth
1 None SOOmg F 25.8.69
2 None SOOmg M 16.9.67
3 None ig M 2.5.57
4 None ig M 14.9.56
5 Antihistamines occasionally ig F 6.7.56
6 Not known ig M 1955
7 20 cigarettes/day ig F 18.10.58
8 None ig M 19.4.53
9 None ig F 13.4.56
10 Oral contraceptive ig F 19.9.52
11 None ig F 2.1.43
12 None ig M 22.11.42
13 None ig F 12.4.44
14 None ig M 14.2.49
15 None ig F 18.1.41
16 None ig M 3.1.45
17 None ig F 24.9.48
18 30 cigarettes/day ig F 11.9.46









20 None Ig F 28.5.39
21 None Ig F 17.4.39
22 None Ig F 21.1.31
23 phenytoln ig F 14.3.35
24 10 cigarettes/day ig M 9.9.39
25 None ig F 1.7.37
26 5-10 cigarettes/day ig F 24.11.32
27 None ig M 9.7.31
28 None ig F 15.8.31
29 None ig M 23.6.39
30 None ig. F 13.1.24
31 None ig M 4.4.26
32 None ig F 11.8.25
33 Distalgeslcs ig F 20.12.26
34 30 cigarettes/day ig M 25.1.21
35 None ig M 6.5.21
36 %oz pipe tobacco/day ig M 16.11.23
37 None ig F 5.2.22
38 None ig M 16.5.17
39 None ig M 17.9.17









41 diazepam 5mg nocte Ig F 3.11.15
42 propramolol IQmg x 3, 
chlordlazepoxlde lOmg nocte ig F 24.11.16
43 7-8 cigarettes/day ig M 21. 12.11
44 2oz pipe tobacco/week ig F 4.6.05
45 7oz pipe tobacco/week ig M 3.2.06
46 None ig M 13.3.06
47 None ig F 22.12.08
48 None ig F 29.12.05
49 Laslkal 20mg 00, methyl dopa 




5.1 Amount of paracetamol and its  metabolites (ug) in neonatal urine
In it ia ls P PG PS PC PM
L.D. 8 . 1 2 53.94 5.69 5.87 11.57
F.C. 26.04 30.79 2.98 0 . 0 0 0 . 0 0
R.M. (Twin) 2.91 17.71 3.58 3.36 0 . 0 0
R.M. (Twin) 85.05 309.25 56.48 35.80 0 . 0 0
D.C. 165.62 348.52 150.06 66.38 91.66
M.C. 432.40 302.57 74.68 75.53 36.74
.2 Percentage recovery of paracetamol and its  metabolites in nec
uri ne
In it ia ls P PG PS PC PM
L.D. 9.53 63.32 6 . 6 8 6.89 13.58
F.C. 43.53 51.48 4.98 0 . 0 0 0 . 0 0
R.M. (Twin) 11.71 71.27 9.46 7.56 0 . 0 0
R.M. (Twin) 17.48 63.56 11.61 7.36 0 . 0 0
D.C. 20.14 42.39 18.25 8.07 11.15
M.C. 46.90 32.82 8 . 1 0 8.19 3.98
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Appendix 6  American Rheumatism Association c rite ria  (revised 1963) 
for diagnosis of rheumatoid a rth ritis
1. Morning stiffness
2. Pain on motion or tenderness in at least one jo in t (observed by 
a physician).
3. Swelling (soft tissue thickening or flu id  - not bony overgrowth 
alone) in at least one jo in t (observed by a physician).
4. Swelling (observed by a physician) of at least one other jo in t 
(any interval free of jo in t symptoms between the two jo in t  
involvements may not be more than three months).
5. Symmetrical jo in t swelling (observed by a physician) with 
simultaneous involvement of the same jo in t on both sides of the 
body (bilateral involvement of mid-phalangeal jo in ts is 
accetable without absolute symmetry). Terminal interphalagenal 
jo in t involvement w ill not satisfy this criterion.
6 . Subcutaneous nodules (observed by a physician) over bony 
prominences on extensor surfaces, or in juxta articu lar regions.
7. X-ray changed typical of RA (which must include at least bony 
décalcification localised to or greatest around the involved 
joints and not just degenerative changes) - degenerative changes 
do not exclude patients from any group classified as rheumatoid 
arth r it is .
8 . Positive agglutination test-demonstration of the 'rheumatoid 
factor' by any method that, in two laboratories has been 
positive in not more than 5 per cent of normal controls, or 
positive streptococcal agglutination test.
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Appendix 7 Details of rheumatoid patients
Amount of
paracetamol Times when 
taken in the additional 
Age 24 hours of paracetamol 
In it ia ls  Sex (years) the study was taken Other drugs
A.S. F 55 4 12.00, 22.00 Distalgesic, nitrazepam,
06.30 naproxen
B.L. F 53 2 12.30 nitrazepam, indomethacin,
sodium aurothiomalate
R.G. M 40 4 13.00, 17.00 prednisolone, naproxen
22.00
J.H. F 60 indomethacin, penicillamine
M.P. F 41 >lg - record not obtainable
K.P. F 65 3.5 12.30, 22.00 indomethacin,
sodium aurothiomalate
M.T. F 78 4 12.00, 18.00 theophylline, naproxen,
prednisolone
K.P. F 65 5 13.30, 18.30 sodium aurothiomalate,
22.30, 06.45 indomethacin, indomethacin
J.G. F 59 >lg - record not obtainable
B.G. F 65 4 12.30, 18.30 indomethacin, connalazine
22.30
P.O. F 43 1 - penicillamine, ibuprofen
S.T. F 36 4 12.15, 18.20 diclofenac
22.30
T.S. F 65 2 12.05 piroxicam, neomycin,
aminoyphylline
J.H. F 59 >lg - indonethacin, penicillamine
R.H. F 71 >lg - prednisolone, azathioprine,
indomethacin, distalgesic
E.P. F 72 4 18.00, 22.00 ibuprofen, penicillamine,
06.00 nitrazepam
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Appendix 7 Continued 
Details of rheumatoid patients
Amount of
paracetamol Times when 
taken in the additional 
Age 24 hours of paracetamol 
In it ia ls  Sex (years) the study was taken Other drugs
A.W. F 49 4 12.30, 18.15 flurbiprofen
22.00
D.D. F 42 3 12.10, 18.35 naproxen, chlormelanone
J.P. F 73 4.5 12.30, 18.00 ibuprofen, nitrazepam
2 2 . 0 0 , 06.00
D.F. F 50 4 14.00, 18.00 clozic, flurbiprofen
22.00
V.H. F 46 >lg - penicillamine
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Appendix 14 Ind ividual serum concentrations o f paracetamol, paracetamol 
glucuronide and paracetamol sulphate (corrected fo r  
molecular weight) in  Experiment 1 and Experiment 2 as 
described in  Section 3.5
Experiment 1
Time Time Time
He ? G S Ha P G S P G S
0 0.00 0.18 0.00 0 0.00 0.00 0.00 0 0.73 0.47 2.81
45 2.95 0.79 0.94 44 3.32 2.09 0.94 45 4.06 0.65 1.88
72 4.46 2.53 0.94 94 4.06 4.55 1.88 90 3.07 1.23 1.88
34 4.03 3.10 0 .94 135 3.65 6.23 0.94 135 2.50 1.23 1.88
79 3.27 3.10 0.94 180 2.33 5.41 0.00 180 1.18 1.37 1.88
25 2.62 2.53 0.94 225 1.59 4.84 0.00 225 - - -
268 2.08 2.38 0.00 270 1.18 3.39 0.00 270 0.76 1.23 1.88
315 1.86 1.95 0.00 318 0.76 2.81 0.00 320 0.52 0.65 0.94
Time
(min) Concentration ug/m1 











0 0.24 0.33 0.00 0 0.00 0.05 0.00 0 0.00 0.00 0.00
45 3.81 1.66 0.94 47 3.15 0.50 0.94 46 3.32 1.37 0.94
91 2.50 2.87 0.94 94 2.58 1.37 1.88 91 2.74 2.53 0.94
135 2.16 3.10 0.94 135 2.74 2.24 1.88 136 2.16 3.10 0.94
178 1.01 2.53 0.00 180 2.41 2.09 1.88 180 1.34 2.67 0.94
224 0.76 2.09 0.00 228 1.51 1.81 0.94 226 1.09 1.95 0.94
268 0.60 1.95 0.00 268 1.18 1.66 0.94 271 1.01 1.81 0.00
313 0.52 1.66 0.00 316 0.93 1.23 0.94 317 0.60 1.37 0.00
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Appendix 14 Cont'd Serum concentrations of paracetamol. paracetamol glucuronide 
and paracetamol sulphate (corrected for molecular weight) in 





(min) Concentration ug/ml (min) Concentration ug/ral
He P PG PS Ha P PG PS B P PG PS
0 0.00 0.00 0.00 0 0.16 0.00 0.00 0 0.00 0.00 0.00
48 5.87 1.81 0.00 48 2.25 0.50 0.00 45 4.97 0.94 0.94
94 5.06 4.69 0.00 90 3.24 2.09 0.00 105 3.65 1.66 0.94
139 4.30 4.26 0.00 136 4.39 4.84 0.00 135 3.57 1.23 0.00
184 3.65 3.82 0.00 188 4.14 5.12 0.00 182 3.15 1.66 0.94
232 2.68 3.82 0.00 228 2.82 5.70 0.00 225 2.50 1.23 0.00
281 2.35 2.96 0.00 277 2.00 5.27 0.00 277 1.92 1.23 0.00
324 1.86 2.81 0.00 323 1.42 4.26 0.00 325 1.18 0.65 0.00
Time
(min) Concentration ug/ml 











0 0.00 0.00 0.00 0 0.41 0.00 0.00 0 0.00 0.00 0.00
46 4.22 1.23 0.00 49 3.07 0.94 0.00 44 3.73 1.08 0.00
93 3.65 2.81 0.00 90 2.91 1.87 0.00 90 2.58 2.38 0.00
139 2.91 1.67 0.00 141 4.06 2.87 0.94 137 2.41 2.38 0.00
183 2.66 2.67 0.00 188 3.24 2.67 0.94 187 2.00 2.24 0.00
230 2.00 2.38 0.00 228 2.16 2.38 0.00 227 1.51 ■ 2.24 0.00
280 - - - 275 2.00 2.38 0.00 271 1.09 1.81 0.00
323 1.09 2.09 0.00 320 2.00 2.09 0.00 319 0.85 1.23 0.00
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Appendix 15 15.1 Individual quantities (mg corrected for molecular 
weight) of paracetamol and its  metabolites recovered in 
24 hour urine after administration of 3 inducing agents 
in saline or saline alone to guinea pigs.
P PG PS PC PM
paracetamol 150mg/kg G1 4.26 31.70 0.85 0 . 0 0 0 . 0 0
G2 4.38 32.20 1.73 0 . 0 0 0 . 0 0
G3 6.32 0 . 0 0 0.83 0 . 0 0 0 . 0 0
G4 4.62 57.14 1.42 0 . 0 0 0 . 0 0
paracetamol 150mg/kg after G1 0 . 6 6 29.08 0.56 0.44 0.23
7 day pretreatment with G2 0.29 19.90 0.39 0 . 0 0 0 . 1 1
phenobarbitone lOOmg/kg G3 0.32 22.78 1 . 1 0 0.15 0.13
paracetamol 150mg/kg after G1 0.41 22.95 0.43 0.05 0.24
4 day pretreatment with G2 0.40 31.47 0.84 0 . 1 0 0 . 0 0
phenylbutazone lOOmg/kg G3 0.84 51.07 1 . 2 2 0.06 0.34
G4 0.56 13.97 0.40 0.09 0 . 0 0
paracetamol 150mg/kg after G1 0.30 2.47 0.19 0 . 0 2 0.03
5 day pretreatment with G2 0.36 44.19 4.28 0.03 0.30
rifampicin 80mg/kg G3 0.18 7.65 0.28 0.03 0.07
G4 0.30 2.47 0.19 0 . 0 2 0.03
G5 2.36 44.19 4.28 0.03 0.30
G6 0.18 7.65 0.28 0.03 0.07
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15.2 Individual percentage recoveries of paracetamol and its  metabolites 
in 24 hour urine after administration of 3 inducing agents in 
saline or saline alone to guinea pigs
P PG PS PC PM
paracetamol 150mg/kg G1 11.57 8 6 . 1 2 2.31 0 . 0 0 0 . 0 0
G2 11.43 84.05 4.52 0 . 0 0 0 . 0 0
G3 88.39 0 . 0 0 11.61 0 . 0 0 0 . 0 0
G4 7.311 90.44 2.25 0 . 0 0 0 . 0 0
paracetamol 150mg/kg after G1 2.13 93.90 1.87 1.42 0.74
7 day pretreatment with G2 1.40 96.18 1 . 8 8 0 . 0 0 0.53
phenobarbitone lOOmg/kg G3 1.3 92.98 4.49 0.61 0.61
paracetamol 150mg/kg after G1 1.70 95.31 1.78 0 . 2 1 1 . 0 0
4 day pretreatment with G2 1 . 2 2 95.92 2.56 0.30 0 . 0 0
phenylbutazone 1 0 0 mg/kg G3 1.57 95.40 2.28 0 . 1 1 0.64
G4 3.73 93.01 2 . 6 6 0.60 0 . 0 0
paracetamol 150mg/kg after G1 9.97 82.06 6.31 0 . 6 6 1 . 0 0
5 day pretreatment with G2 0.73 89.89 8.71 0.06 0.61
rifampicin 80mg/kg G3 2.19 93.18 3.41 0.36 0.85
G4 9.97 82.06 6.31 0 . 6 6 1 . 0 0
G5 0.73 89.89 8.71 0.06 0.61
G6 2.19 93.18 3.41 0.36 0.85
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Appendix 16 16.1 Individual quantities (mg corrected for molecular
weight) of paracetamol and its  metabolites recovered in 
24 hour urine after administration of 3 inducing agents 
in saline or saline alone to mice
paracetamol 150mg/kg
paracetamol 150mg/kg after 
4 day pretreatment with 
phenobarbitone lOOmg/kg
paracetamol 150mg/kg after 
7 day pretreatment with 
phenobarbitone lOOmg/kg
paracetamol 150mg/kg after 
4 day pretreatment with 
phenylbutazone lOOmg/kg
paracetamol 150mg/kg after 
5 day pretreatment with 
rifampicin 80mg/kg
P PG PS PC PM
Ml 0 . 0 1 0.36 0.04 0.05 0 . 0 0
M2 0.04 0.08 0 . 0 1 0 . 0 2 0 . 0 1
M3 0.08 1.36 0.35 0.29 0 . 0 0
M4 0 . 1 2 0.57 0 . 1 2 0 . 1 2 0.07
M5 0 . 1 1 0.07 0.03 0 . 0 0
M6 0 . 0 1 0.03 0 . 0 0 0 . 0 1 0 . 0 0
Ml 0.07 0.60 0 . 0 1 0.24 0.08
M2 0.07 0.43 0 . 0 0 0.16 0.06
M3 0.08 0 . 8 8 0 . 2 0 0.33 0 . 2 1
M4 0.05 0.42 0 . 0 1 0.26 0.14
M5 0.05 1.85 0.15 1 . 2 1 0.49
M6 0.07 0.81 0.03 0.32 0.15
Ml 0.19 3.70 0.26 2 . 2 1 0.60
M2 0.24 3.16 0.38 2 . 0 0 0.56
M3 0.35 4.22 0.31 2.84 0 . 6 6
M4 0.23 2.95 0.24 2.72 0 . 6 8
M5 0.24 2.42 0 . 0 8 1.70 0.50
M6 0 . 1 1 2.28 0.16 1.51 0.33
Ml 0.84 6.19 0.62 1.62 0.42
M2 1.49 13.33 1.05 2.92 1.33
M3 1.24 8.50 0.67 2.04 0.47
M4 2.84 21.73 2.48 4.77 0.70
M5 1.15 9.86 1 . 1 1 2.38 0.70
M6 1.54 12.46 1.35 3.63 0.62
Ml 0 . 1 1 3.87 0.45 2 . 1 1 0.17
M2 0 . 0 0 0.16 0 . 0 1 0.08 0 . 0 1
M3 0.06 2.24 0.33 1 . 1 1 0.06
M4 0 . 0 2 0.18 0 . 0 0 0 . 1 2 0.04
M5 0.06 1 . 6 8 0.18 0.72 0.05
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16.2 Individual percentage recoveries of paracetamol and its  metabolites 
in 24 hour urine after administration of 3 inducing agents in 
saline or saline alone to mice
paracetamol 150mg/kg
paracetamol 150mg/kg after 
4 day pretreatment with 
phenobarbitone lOOmg/kg
paracetamol 150mg/kg after 
7 day pretreatment with 
phenobaribitone lOOmg/kg
paracetamol 150mg/kg after 
4 day pretreatment with 
phenylbutazone lOOmg/kg
paracetamol 150mg/kg 
5 day pretreatment with 
rifampicin 80mg/kg
P PG PS PC PM
Ml 1.19 78.98 7.98 11.85 0 . 0 0
M2 26.97 50.94 6.57 11.06 4.47
M3 4.00 64.99 16.95 14.06 0 . 0 0
M4 12.58 59.32 12.58 12.19 3.32
M5 10.56 64.83 6.43 18.18 0 . 0 0
M6 15.15 64.34 0 . 0 0 20.52 0 . 0 0
Ml 6.63 60.23 0.94 24.00 8 . 2 0
M2 1 0 . 2 0 59.68 0 . 0 0 22.47 7.65
M3 4.53 51.61 11.97 19.35 12.53
M4 5.92 47.14 1.62 29.94 15.39
M5 11.29 44.42 3.58 29.05 11.67
M6 5.16 58.19 2.48 23.38 10.80
Ml 2.73 53.16 3.74 31.75 8.62
M2 3.78 49.84 5.99 31.54 8.83
M3 4.18 50.36 3.70 33.89 7.88
M4 3.37 43.26 3.52 39.88 9.97
M5 4.86 48.99 1.62 34.41 1 0 . 1 2
M6 2.50 51.94 3.64 34.40 7.52
Ml 8.67 63.88 6.40 16.72 4.33
M2 7.40 66.25 5.22 14.51 6.61
M3 9.60 65.79 5.18 15.79 3.64
M4 8.73 66.82 7.63 14.67 2.15
MS 7.56 64.87 7.30 15.66 4.60
M6 7.86 63.57 6.89 18.52 3.16
Ml 1.64 57.68 6.71 31.44 2.53
M2 0 . 0 0 61.54 3.85 30.77 3.85
M3 1.58 58.95 8 . 6 8 29.21 1.58
M4 5.56 50.00 0 . 0 0 33.33 1 1 . 1 1
M5 2.23 62.45 6.69 26.76 1 . 8 6
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Appendix 17
Individual mg quantities corrected for molecular weight of paracetamol 
and its  metabolites in 0-24 hour urine after paracetamol lOOmg/kg in 
guinea pigs and mice
P PG PS PC PM
guinea pig 1 2.56 6.95 0 . 0 0 0.07 0.19
guinea pig 2 2.78 7.28 0 . 0 0 0.06 0.39
guinea pig 3 7.26 0.55 0.09 0 . 0 2 0.05
guinea pig 4 0.50 0.29 0 . 0 0 0 . 0 0 0 . 0 0
mouse 1 2.69 3.61 0.355 2.07 0.50
mouse 2 1 . 6 6 7.31 0.34 2.62 0.46
mouse 3 1.35 1 1 . 2 0 1 . 0 1 3.22 0.31
mouse 4 6.61 1.74 0.34 2.77 0 . 8 6
mouse 5 0.59 0.94 0 . 0 0 0.61 0.05
mouse 6 7.48 3.44 0.39 2.92 0.50
Appendix 18
Individual percentage recoveries of paracetamol and its  metabolites in 
0-24 hour urine after paracetamol lOOmg/kg in guinea pigs and mice
P PG PS PC PM
guinea pig 1 26.20 71.41 0 . 0 0 0.72 1.94
guinea pig 2 26.45 69.27 0 . 0 0 0.57 3.71
guinea pig 3 91.09 6.90 1.13 0.25 0.63
guinea pig 4 63.29 36.71 0 . 0 0 0 . 0 0 0 . 0 0
mouse 1 29.18 39.15 3.80 22.45 5.42
mouse 2 13.40 59.00 2.74 21.15 3.71
mouse 3 7.90 65.54 5.91 18.84 1.87
mouse 4 53.65 14.12 2.76 22.48 6.98
mouse 5 26.94 42.92 0 . 0 0 27.85 2.28
mouse 6 50.78 23.35 2.65 19.82 3.39
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Appendix 19
19.1 Individual mg quantities correct for molecular weight of paracetamol 
and its  metabolites after repeated dosing with paracetamol lOOmg/kg twice 
daily in guinea pigs
P PG PS PC PM
0-24h G1 65.18 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
G2 52.97 13.54 0 . 0 0 1.38 0 . 0 0
G3 22.59 36.80 0 . 0 0 1.91 0 . 0 0
G4 30.12 59.42 0 . 0 0 0 . 0 0 0 . 0 0
24-72h G1 82.56 0 . 0 0 0 . 0 0 2.93 0 . 0 0
G2 68.25 0 . 0 0 0 . 0 0 6.71 0 . 0 0
G3 116.43 0 . 0 0 0 . 0 0 5.05 0 . 0 0
G4 20.43 4.76 0 . 0 0 0 . 0 0 0 . 0 0
72-120h G1 38.13 0 . 0 0 0 . 0 0 38.13 0 . 0 0
G2 41.04 0 . 0 0 0 . 0 0 41.04 0 . 0 0
G3 43.90 0 . 0 0 0 . 0 0 43.90 0 . 0 0
G4 15.33 0 . 0 0 0 . 0 0 15.33 0.47
120-168h G1 45.88 13.80 0 . 0 0 0.06 0 . 0 0
G2 135.20 0 . 0 0 0 . 0 0 8.65 0 . 0 0
G3 1 1 2 . 2 0 0 . 0 0 0 . 0 0 4.99 0 . 0 0
G4 19.48 0.23 0 . 0 0 . 2.30 0 . 0 0
168-216h G1 77.18 7.98 0 . 0 0 3.18 0 . 0 0
G2 253.47 0 . 0 0 0 . 0 0 16.20 0 . 0 0
G3 214.20 0 . 0 0 0 . 0 0 14.97 0 . 0 0
G4 45.06 0 . 0 0 0 . 0 0 1.50 0 . 0 0
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Appendix 19 cont'd
19.2 Individual percentage recoveries o f paracetamol and i t s  metabolites
a fte r repeated dosing with paracetamol IQOmg/kg twice da ily  in  guinea pigs
P PG PS PC PM
0-24h G1 1 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
G2 78.02 19.94 0 . 0 0 2.03 0 . 0 0
G3 36.85 60.03 0 . 0 0 3.12 0 . 0 0
G4 33.64 66.36 0 . 0 0 0 . 0 0 0 . 0 0
24-72h G1 96.57 0 . 0 0 0 . 0 0 3.43 0 . 0 0
G2 91.05 0 . 0 0 0 . 0 0 8.95 0 . 0 0
G3 95.84 0 . 0 0 0 . 0 0 4.16 0 . 0 0
G4 81.07 18.93 0 . 0 0 0 . 0 0 0 . 0 0
72-120h G1 1 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
G2 1 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
G3 1 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
G4 97.02 0 . 0 0 0 . 0 0 0 . 0 0 2.97
120-168h G1 76.80 23.10 0 . 0 0 0 . 1 0 0 . 0 0
G2 93.99 0 . 0 0 0 . 0 0 6 . 0 1 0 . 0 0
G3 95.94 0 . 0 0 0 . 0 0 4.26 0 . 0 0
G4 88.50 1.04 0 . 0 0 10.45 0 . 0 0
168-216h G1 87.37 9.03 0 . 0 0 3.60 0 . 0 0
G2 93.99 0 . 0 0 0 . 0 0 6 . 0 1 0 . 0 0
G3 93.47 0 . 0 0 0 . 0 0 6.53 0 . 0 0
G4 96.78 0 . 0 0 0 . 0 0 3.22 0 . 0 0
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Appendix 20
20.1 Individual mg quantities corrected for molecular weight of 
paracetamol and its  metabolites after repeated dosing with paracetamol 




P PG PS PC PM
Ml 0.03 6.77 0 . 0 0 3.59 0.71
M2 0.47 3.88 0 . 0 0 1.70 0.14
M3 0 . 0 0 4.43 0 . 0 0 2.17 0.18
M4 0.03 7.16 0 . 0 0 2.82 0 . 2 1
M5 0 . 0 0 8.83 0 . 0 0 3.53 0.56
M6 0.28 10.93 0 . 0 3.83 0 . 2 1
Ml 20.65 0 . 0 0 0 . 0 0 5.12 1.47
M2 2.62 10.59 0 . 0 0 5.05 0 . 6 6
M3 22.72 0.23 0 . 0 0 8.80 0.99
M4 14.17 2 . 1 0 0 . 0 0 4.34 0.56
M5 3.96 12.19 0 . 0 0 5.96 0.82
M6 6 . 6 8 0 . 0 0 0 . 0 0 1.87 0.33
Ml 9.41 0 . 0 0 0 . 0 0 2.18 1.18
M2 1 . 1 0 0 . 0 0 0 . 0 0 0.32 0.03
M3 13.50 0 . 0 0 0 . 0 0 3.66 0.65
M4 7.77 0 . 0 0 0 . 0 0 2.25 0.15
M5 0.60 3.10 0 . 0 0 1.44 0.28
M6 8.51 0 . 0 0 0 . 0 0 2 . 6 8 0.28
Ml 6.82 0 . 0 0 0 . 0 0 1 . 2 1 0.80
M2 2.18 0 . 0 0 0 . 0 0 0.80 0.07
M3 10.64 0 . 0 0 0 . 0 0 1.82 0.32
M4 15.56 0 . 0 0 0 . 0 0 4.12 0.59
M5 0.55 0.58 0 . 0 0 0.56 0.06
M6 0.85 0 . 0 0 0 . 0 0 0.24 0.04
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Appendix 20
20.1 Individual mg quantities corrected for molecular weight of 
paracetamol and its  metabolites after repeated dosing with paracetamol 
lOOmg/kg in mice Cont'd
168-216h
216-264h
P PG PS PC PM
Ml 13.82 0 . 0 0 0 . 0 0 5.79 1.49
M2 5.02 13.65 0 . 0 0 8.74 1.09
M3 19.40 0 . 0 0 0 . 0 0 9.64 0.50
M4 2.24 12.56 0 . 0 0 6.03 0.38
M5 2.39 16.00 0 . 0 0 10.34 0.83
M6 17.90 0 . 0 0 0 . 0 0 7.58 1.42
Ml 11.58 0 . 0 0 0 . 0 0 5.89 1.09
M2 15.31 0 . 0 0 0 . 0 0 8.17 0.48
M3 1 1 . 0 1 0 . 0 0 0 . 0 0 5.77 0.23
M4 1.41 7.67 0 . 0 0 4.87 0.18
M5 1.48 11.64 0 . 0 0 7.00 0.52
M6 12.33 0 . 0 0 0 . 0 0 5.02 0 . 2 2
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Appendix 20 Cont'd
20.2 Ind iv idua l percentage recoveries o f paracetamol and i t s  metabolites





P PG PS PC PM
Ml 0.27 60.99 0 . 0 0 32.34 6.40
M2 7.59 62.68 0 . 0 0 27.46 2.26
MS 0 . 0 0 65.34 0 . 0 0 32.00 2.65
M4 0.29 70.06 0 . 0 0 27.59 2.05
M5 0 . 0 0 68.34 0 . 0 0 27.32 4.33
M6 1.84 71.67 0 . 0 0 25.11 1.38
Ml 75.81 0 . 0 0 0 . 0 0 18.80 5.40
M2 13.85 55.97 0 . 0 0 26.69 3.49
M3 69.40 0.70 0 . 0 0 26.88 3.02
M4 66.93 9.92 0 . 0 0 20.50 2.64
M5 17.27 53.16 0 . 0 0 25.99 3.58
M6 74.80 0 . 0 0 0 . 0 0 20.94 4.26
Ml 73.69 0 . 0 0 0 . 0 0 17.07 9.24
M2 75.86 0 . 0 0 0 . 0 0 220.7 2.07
M3 75.80 0 . 0 0 0 . 0 0 20.55 3.65
M4 76.40 0 . 0 0 0 . 0 0 2 2 . 1 2 1.47
M5 11.07 57.20 0 . 0 0 26.57 5.17
M6 74.19 0 . 0 0 0 . 0 0 23.36 2.44
Ml 77.24 0 . 0 0 0 . 0 0 13.70 9.06
M2 71.48 0 . 0 0 0 . 0 0 26.23 2.30
M3 83.26 0 . 0 0 0 . 0 0 14.24 2.50
M4 76.76 0 . 0 0 0 . 0 0 20.32 2.91
M5 31.43 33.14 0 . 0 0 32.00 3.43
M6 75.22 0 . 0 0 0 . 0 0 21.24 3.54
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Appendix 20 Cont'd
20.2 Ind iv idual percentage recoveries o f paracetamol and i t s  metabolites
a fte r repeated dosing w ith paracetamol lOOmg/kg twice d a ily  in  mice con t'd
168-216h
216-264h
P PG PS PC PM
Ml 05.50 0 . 0 0 0 . 0 0 27.44 7.06
M2 17.61 47.89 0 . 0 0 30.67 3.82
M3 65.67 0 . 0 0 0 . 0 0 32.63 1.69
M4 10.56 59.22 0 . 0 0 28.43 1.79
M5 8.08 54.13 0 . 0 0 34.98 2.81
M6 66.54 0 . 0 0 0 . 0 0 28.18 5.28
Ml 62.39 0 . 0 0 0 . 0 0 31.73 5.87
M2 63.90 0 . 0 0 0 . 0 0 34.10 2 . 0 0
M3 64.73 0 . 0 0 0 . 0 0 33.92 1.35
M4 9.98 54.28 0 . 0 0 34.46 1.27
M5 7.17 56.40 0 . 0 0 33.91 2.52
M6 70.18 0 . 0 0 0 . 0 0 28.57 1.25
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Appendix 21
21.1 Individual mg quantities (corrected for molecular weight) of 
paracetamol and its  metabolites after concurrent administration of 
metabolic competing agents to guinea pigs
P PG PS PC PM
paracetamol lOOmg/kg G1 2.56 6.95 0 . 0 0 0.07 0.19
G2 2.78 7.28 0 . 0 0 0.06 0.39
G3 7.26 0.55 0.09 0 . 0 2 0.05
G4 0.50 0.29 0 . 0 0 0 . 0 0 0 . 0 0
paracetamol lOOmg/kg + G1 0.85 13.62 0 . 0 0 0 . 0 0 0 . 0 0
salicylamide lOOmg/kg G2 0.75 9.73 0 . 0 0 0 . 0 0 0 . 0 0
G3 0.76 14.36 0 . 0 0 0 . 0 0 0.31
G4 0.47 6 . 6 6 0 . 0 0 0 . 0 0 0.27
paracetamol lOOmg/kg + G1 2.03 16.93 0.85 0 . 0 0 0 . 0 0
L-ascorbic acid 1 0 0 mg/kg G2 0 . 8 6 13.09 0 . 0 0 0 . 0 0 0 . 0 0
G3 1.64 32.81 0.85 0 . 0 0 0 . 0 0
G4 1.40 11.90 0 . 0 0 0 . 0 0 0 . 0 0
paracetamol lOOmg/kg + G1 0.14 5.94 0 . 0 0 0 . 0 0 0 . 0 0
a-tocopherol lOOmg/kg G2 0.19 44.61 3.62 0 . 0 0 1.32
G3 0.47 35.42 0.53 0 . 0 0 0 . 0 0
G4 0.49 16.16 0 . 0 0 0 . 0 0 0 . 0 0
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21.2 Individual percentage recoveries of paracetamol and its  metabolites 
after concurrent administration of metabolic competing agents to guinea 
pigs
P PG PS PC PM
paracetamol lOOmg/kg G1 26.20 71.14 0 . 0 0 0.72 1.94
G2 26.45 69.27 0 . 0 0 0.57 3.71
G3 91.09 6.90 1.13 0.25 0.63
G4 63.29 36.71 0 . 0 0 0 . 0 0 0 . 0 0
paracetamol lOOmg/kg + G1 5.87 94.12 0 . 0 0 0 . 0 0 0 . 0 0
salicylamide 1 0 0 mg/kg G2 7.16 92.84 0 . 0 0 0 . 0 0 0 . 0 0
G3 4.92 93.06 0 . 0 0 0 . 0 0 2 . 0 1
G4 6.35 90.00 0 . 0 0 0 . 0 0 3.65
paracetamol lOOmg/kg + G1 10.25 85.46 4.29 0 . 0 0 0 . 0 0
L-ascorbic acid lOOmg/kg G2 6.16 93.84 0 . 0 0 0 . 0 0 0 . 0 0
G3 4.64 92.95 2.41 0 . 0 0 0 . 0 0
G4 10.53 89.47 0 . 0 0 0 . 0 0 0 . 0 0
paracetamol lOOmg/kg + G1 2.30 97.70 0 . 0 0 0 . 0 0 0 . 0 0
a-tocopherol lOOmg/kg G2 0.38 89.69 7.28 0 . 0 0 2.65
G3 1.29 97.25 1.46 0 . 0 0 0 . 0 0
G4 2.94 97.06 0 . 0 0 0 . 0 0 0 . 0 0
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Appendix 22
22.1 Individual mg quantities (corrected for molecular weight) of 
paracetamol and its  metabolites after concurrent administration of 
metabolic competing agents to mice
P PG PS PC PM
paracetamol lOOmg/kg Ml 2.69 3.61 0.35 2.07 0.50
M2 1 . 6 6 7.31 0.34 2.62 0.46
M3 1.35 1 1 . 2 0 1 . 0 1 3.22 0.31
M4 6.61 1.74 0.34 2.77 0 . 8 6
MS 0.59 0.94 0 . 0 0 0.61 0.005
M6 7.48 3.44 0.39 2.92 0.50
paracetamol lOOmg/kg + Ml 0.74 1.85 0 . 0 0 1.45 0.27
salicylami de lOOmg/kg M2 1 . 1 2 0.37 0 . 0 0 1 . 0 2 0.19
M3 2.37 9.55 0.30 3.88 0.33
M4 2.99 6 . 0 0 0.24 3.20 0.45
MS 3.10 10.05 0.08 3.41 0.54
MS 4.51 5.98 0.37 4.34 0.79
paracetamol lOOmg/kg + Ml 0.56 5.97 1 . 2 0 1 . 6 6 0.46
L-ascorbic acid lOOmg/kg M2 0.93 3.01 0.48 1.05 0.17
M3 1.75 3.83 0.94 1.98 0.35
M4 0.77 3.96 0.90 2.18 0.18
MS 1.16 4.06 0.94 1.70 0.18
MS 0.61 1.30 0.18 0.64 0.08
paracetamol lOOmg/kg + Ml 0 . 2 1 3.83 0.08 1.53 0.18
a-tocopherol lOOmg/kg M2 0.81 8.04 0.30 3.93 0.63
M3 0.19 1.47 0.04 0.52 0.08
M4 0.35 4.56 0 . 0 2 2.15 0.37
MS 0.58 5.28 0 . 0 2 2.26 0.28
MS 0.82 11.30 0 . 8 6 4.86 0.70
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22.2 Individual percentage recoveries of paracetamol and its  metabolites 
after concurrent administration of metabolic competing agents to mice
P PG PS PC PM
paracetamol lOOmg/kg Ml 29.18 39.15 3.80 22.45 5.42
M2 13.40 59.0 2.74 21.15 3.71
MS 7.90 65.54 5.91 18.84 1.81
M4 53.65 14.12 2.76 22.48 6.98
M5 26.94 42.92 0 . 0 0 17.85 2.28
M6 50.78 23.35 2.65 19.82 3.39
paracetamol lOOmg/kg + Ml 17.17 42.92 0 . 0 0 33.64 6.26
salicylami de lOOmg/kg M2 41.48 13.70 0 . 0 0 37.78 7.04
M3 14.42 58.12 1.82 23.62 2 . 0 1
M4 23.21 46.58 1 . 8 6 24.84 3.49
MS 18.04 58.50 0.46 19.85 3.14
M6 28.20 37.40 2.31 27.14 4.94
paracetamol lOOmg/kg + Ml 5.68 60.61 12.18 16.85 4.67
L-ascorbic acid lOOmg/kg M2 16.49 53.37 8.51 18.62 3.01
M3 19.77 43.28 10.62 22.37 3.95
M4 9.64 49.56 11.26 27.28 2.25
MS 14.43 50.50 11.69 21.14 2.24
M6 21.71 46.26 6.40 22.78 2.85
paracetamol lOOmg/kg + Ml 3.60 65.69 1.37 26.24 3.09
a-tocopherol lOOmg/kg M2 5.91 58.64 2.19 28.66 4.60
M3 8.26 63.91 1.74 22.61 3.48
M4 4.70 61.21 0.27 28.86 4.97
MS 6.89 62.71 0.24 26.84 3.32
M6 4.42 60.95 4.64 26.21 3.78
307
Appendix 23
Details of volunteers including smoking and drinking habits, other drugs being 
taken concurrently with aspirin during the control study, and date of birth of 
each volunteer.
Subject No. 1 took 900mg aspirin but a ll other volunteers took 600mg aspirin.
Sex Date of birth
Yolunteer 
No.






























Paracetamol Ig 24 - 36 
prior to aspirin M
None M
None F





















































Drugs and cigarettes 
taken concurrently 
with asprin
Sex Date of b ir
27 None F 132/9/30
28 Cigarette smoker F 31/1/40
29 Cigarette smoker F 25/6/43
30 None F 3/12/21
31 anti hi staminé M 10/9/40
32 None F 11/7/02
33 None M 4/5/08
34 None M 13/3/06
35 None M 13/12/35
36 None M 6/1/18
37 None F 10/1/04
38 None M 31/3/03
39 danthron F 16/1/97
40 danthron F 1/5/03
41 None F 16/7/96
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Amount of aspirin 
taken over 24h of 
the study (mg)
Times at which 
additional aspirin
was taken Other drugs




2 F 63 1 2 0 0 mg 21.30 diazepam, indo­
methacin, 
bendrofluazide
3 F 45 ISOOmg 1 2 . 0 0 , 2 2 . 0 0 phenylbutazone,
prednisolone,
penicillamine
4 F 71 1 2 0 0 mg 2 2 . 0 0 diazepam
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